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Summary 
 
Malaria is a global public health issue responsible for an estimated 219 million cases and 
435’000 deaths in 2017. Although malaria control interventions have led to a significant de-
crease in mortality over the past decade, no further progress in reducing global malaria bur-
den was achieved since 2016. Novel malaria control approaches, such as highly effective 
vaccines and improved diagnostic tools are needed to prevent a resurgence of malaria as has 
been seen in the 1970s. 
The overall goal of this PhD thesis is to contribute to the development, validation and imple-
mentation of novel molecular diagnostic tools in malaria endemic countries targeting all hu-
man infective malaria species. This thesis was conducted within the framework of six clinical 
trials evaluating the PfSPZ Vaccine, an experimental malaria vaccine based on the immuniza-
tion with radiation-attenuated whole, purified, cryopreserved, metabolically active sporozo-
ites in Tanzania and Equatorial Guinea. We used controlled human malaria infection (CHMI) 
to assess vaccine efficacy in these cohorts. Compared to large field studies, CHMI studies 
allow to test various vaccine regimen and dosing in smaller, well defined cohorts in a short 
time period. 
In part one, we aimed to closely monitor malaria parasites at the individual level by establish-
ing a robust laboratory qPCR-platform for molecular monitoring of asexual blood stage para-
sitaemia. This platform was used to evaluate the efficacy of PfSPZ Vaccine by homologous 
CHMI in Tanzanian and Equatorial Guinean adults. Part one was structured around four 
manuscripts: 
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Manuscript 1-3: Safety, immunogenicity and efficacy of attenuated whole sporozoite 
vaccines in Tanzanian and Equatorial Guinean volunteers. 
In clinical trials conducted in malaria pre-exposed volunteers from Tanzania and Equatorial 
Guinea, the PfSPZ Vaccine was found to be well tolerated and safe, even in high-risk popula-
tions such as infants and HIV+ volunteers. The use of CHMI in malaria pre-exposed adults 
has been proven to be highly effective. These trials revealed that the degree of immune re-
sponse and high level of protection seen in previous studies in malaria-naïve volunteers, was 
not reproducible to the same level in Tanzanian and Equato-Guinean populations. 
Manuscript 4: Controlled Human Malaria Infections in Tanzania and Equatorial Guin-
ea: The impact of malaria pre-exposure on diagnosis and multiplication rate of P. falci-
parum parasites 
We used the parasite multiplication rate (PMR), the fold change in number of parasites in 
peripheral blood over one life cycle, to characterize the impact of malaria pre-exposure on the 
outcome of CHMI. Compared to malaria-naïve German volunteers, the parasite’s ability to 
replicate was significantly reduced in Tanzanian and Equato-Guinean volunteers when chal-
lenged with the identical dose, strain and route of cryopreserved, purified P. falciparum spo-
rozoites. We used two different approaches to demonstrate the impact of malaria pre-
exposure on the multiplication rate of P. falciparum parasites. First, we showed that recently 
drug-cleared parasitaemia from an ongoing P. falciparum field infection or P. falciparum and 
P. malariae co-infection leads to a significantly reduced PMR. Second, PMR is significantly 
reduced after two consecutive homologous CHMI conducted in the same volunteer at 7 
months interval. This data indicates the rapid acquisition or recall of parasite growth reducing 
immune effector mechanisms limiting the growth of asexual blood stages in vivo. 
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In part two, we aimed to adapt and extend molecular diagnostic tools for improvement of 
malaria surveillance at the population level by developing novel high-throughput, field-
deployable and highly sensitive tools and approaches. Part two was structured around five 
manuscripts: 
Manuscript 5: A multiplex qPCR approach for detection of pfhrp2 and pfhrp3 gene de-
letions in multiple strain infections of Plasmodium falciparum 
In response to the emerging threat of P. falciparum strains lacking pfhrp2 and/or pfhrp3 
genes and therefore evading detection by PfHRP2-based RDTs, we developed a qPCR-based 
assay well suited for high-throughput identification of pfhrp2 and pfhrp3 gene deletions in P. 
falciparum isolates. The ability to detect “masked” pfhrp2/3 deletions is probably the most 
interesting feature of our approach, because it will allow to study the epidemiology of 
pfhrp2/3 deletions in malaria endemic regions where a high proportion of the population car-
ries multiple strain P. falciparum co-infections. 
Manuscript 6: High Throughput Extraction and Analysis of Nucleic Acids from Rapid 
Diagnostic Tests for Molecular Surveillance of Malaria 
This manuscript describes our attempt to improve extraction of nucleic acids from used ma-
laria RDTs. We used an approach which enabled us to extract total nucleic acids, including 
DNA and RNA from these RDT strips. This approach increased the overall sensitivity for the 
detection of Plasmodium spp. parasites in the small volume of blood which is available on an 
RDT stored at room temperature. We used samples collected during CHMI as a platform to 
evaluate and compare the ability of our protocol to detect and quantify P. falciparum para-
sites with microscopy and qPCR. 
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Manuscript 7: ELIMU-MDx: A Web-Based, Open-Source Platform for Storage, Man-
agement and Analysis of Diagnostic qPCR Data 
We developed a web-based and open-source software for storage, management and analysis 
of diagnostic qPCR data. In response to the vast amount of qPCR data generated during a 
series of CHMIs and other epidemiological studies conducted in Tanzania and Equatorial 
Guinea, we decided to design and build this platform which facilities the larger scale analysis 
and interpretation of diagnostic qPCR data. 
Manuscript 8: Molecular monitoring of the diversity of human pathogenic malaria spe-
cies in blood donations on Bioko Island, Equatorial Guinea 
In collaboration with the central blood bank in Malabo, Equatorial Guinea we analysed 200 
blood donations for the presence of Plasmodium spp. parasites by a novel, multiplex qPCR 
monitoring all human infective malaria species in a single reaction. We found that more than 
one quarter of the blood donations contained malaria parasites and that 75% of P. falciparum 
and 100% of P. malariae and P. ovale spp. infections were missed by routinely performed 
RDT and microscopy.  
Manuscript 9: Two cases of long-lasting, sub-microscopic Plasmodium malariae infec-
tions in adults from Coastal Tanzania 
In this report we describe two cases of P. malariae infections that were identified during a 
study evaluating the safety, tolerability and efficacy of the PfSPZ Vaccine in Bagamoyo, 
Tanzania. Since these two adult participants were enrolled into a clinical trial, we were pro-
vided with a unique opportunity to study clinical manifestations of P. malariae over a follow 
up period of four months.   
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1.1 Malaria – An overview 
 
1.1.1 Plasmodium spp. life cycle 
 
Six species of the genus Plasmodium are known to infect humans, namely Plasmodium falci-
parum, P. vivax, P. malariae, P. ovale curtisi, P. ovale wallikeri and P. knowlesi [1]. The 
description of the life cycle of these parasites is crucial for our understanding of malaria and 
how intervention tools can break the transmission cycle. The basic principles are known for 
more than 100 years, when Ronald Ross discovered that malaria is transmitted by mosquitoes 
and Charles Laveran linked the Plasmodium parasites to malaria disease. Both of these im-
portant milestones were later awarded with the Nobel Prize [2, 3].  
Malaria is a vector-borne disease that is transmitted to humans by Plasmodium-infected fe-
male Anopheles mosquitoes during a blood meal. Successful malaria transmission relies on 
an interaction between parasite, mosquito and human host (Figure 1). The transmission cycle 
starts with the inoculation of an estimated 1-100 sporozoites by a mosquito into the human 
host [4]. The sporozoites migrate through the skin, where they spend the majority of their 
extracellular time, and use the bloodstream to reach liver, where they infect hepatocytes with-
in minutes [5]. The asymptomatic liver stage lasts one to two weeks, depending on species, 
strain and the hosts’ immunity [1]. After asexual replication inside hepatocytes, ten thousands 
of merozoites are released into the bloodstream [6]. P. vivax and P. ovale spp. are able to 
form dormant liver-stages, named hypnozoites, which can be reactivated and cause malaria 
relapse [7]. After entering the bloodstream, the parasites enter the erythrocytes within sec-
onds to minutes. This quick disappearance from the circulation reduces the risk of being ex-
posed to the host immune system [8]. Once the merozoites have invaded erythrocytes, the 
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asexual blood-stage cycle starts with the ring stage that evolves into a trophozoite and finally 
into a schizont. As for P. falciparum, during one cycle, each merozoite passing through the 
ring, trophozoite, and schizont stages, grows and divides into 8–32 fresh merozoites until the 
erythrocyte ruptures and merozoites are released [9]. This cycle is repeated over many times 
and leads to clinical symptoms like fever each time parasites break free from the schizont 
stages to invade new erythrocytes [10]. One asexual blood-stage cycle takes roughly 48 hours 
for P. falciparum, P. vivax and P. ovale spp., while it takes 72 hours for P. malariae and 24 
hours for P. knowlesi [11]. A small proportion of blood-stage parasites develop into gameto-
cytes, the sexual stage of Plasmodium spp., which is transmitted to mosquitoes. Inside the 
mosquito gut, sexual reproduction takes place, when the gametocytes form an ookinete which 
develops into an oocyst. The oocyst bursts and liberates sporozoites, which migrate to the 
salivary glands to re-start the transmission cycle with the next blood meal. The entire cycle, 
including the mosquito, liver and blood stage, takes on average one month [11]. 
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Figure 1. The life cycle of Plasmodium spp. parasites. The life cycle can be divided into 
three stages, the mosquito, the liver and the blood-stage. (A) The cycle starts with the inocu-
lation of sporozoites by female Anopheles mosquitoes. (B) The sporozoites invade hepato-
cytes where they develop into merozoites. (C) The merozoites are then released into the 
blood where they invade erythrocytes. The asexual blood-stage cycle consists of an exponen-
tial parasite replication phase causing malaria-related symptoms. (D) A proportion of blood-
stage parasites develop into gametocytes, which are then transmitted to mosquitoes. Inside 
the mosquito the gametes fuse to zygotes and develop step-by-step into transmissible sporo-
zoites. Figure adapted from White et al. [11] 
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1.1.2 Epidemiology and burden of malaria 
 
Malaria is a global public health issue with an estimated 219 million cases resulting in 435 
000 deaths in 2017. More than 90% of these malaria cases and deaths occurred in Sub-
Saharan Africa with Nigeria (25%), Democratic Republic of the Congo (11%), Mozambique 
(5%) and Uganda (4%) carrying almost half of the global burden. P. falciparum is the most 
pathogenic malaria species accounting for the vast majority of malaria cases and deaths [12]. 
Malaria endemicity is restricted to geographical areas where Anopheles mosquitoes can be 
found (Figure 2). The P. falciparum parasite rate, the proportion of the population found to 
carry asexual blood-stage parasites in their peripheral blood, is used to characterize the malar-
ia risk and transmission intensity [13, 14].  
 
Figure 2. P. falciparum endemicity in 2017. The Malaria Atlas Project (MAP, 
https://map.ox.ac.uk/) was used to map the P. falciparum parasite rate, in 2-10 year old chil-
dren with data collected in 2017.  
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Clinically, malaria can present as uncomplicated or severe malaria. Symptoms of uncompli-
cated malaria are usually unspecific which makes clinical diagnosis unreliable [1]. The mani-
festations of severe malaria often include severe anaemia and/or coma in case of cerebral 
malaria [11]. Other common manifestations of severe malaria include acute lung injuries, 
which can progress to acute respiratory distress syndrome and acute kidney injuries [1]. The 
case fatality rate of treated cerebral malaria is usually 10 - 20% [1], while when treated, un-
complicated malaria has a mortality of roughly 0.1% [11]. In 2017, there were estimated 
435’000 deaths from malaria globally with children under five years as the most vulnerable 
group affected by malaria. They accounted for 61% of all malaria deaths worldwide [12]. 
Women pregnant for the first time are at great risk too. These women have higher risks of 
severe malaria and death than their nonpregnant counterparts [15]. It is estimated that twenty-
five million pregnant women are currently at risk for malaria, which accounts for over 10,000 
maternal and 200,000 neonatal deaths per year [16]. Beside children under the age of five and 
pregnant women during their first pregnancy, other high-risk populations include persons 
with human immunodeficiency virus (HIV) infection and nonimmune travellers [10]. These 
vulnerable groups have in common that their immune system lacks the ability to control para-
sitaemia during a malaria infection. Through repeated exposure to malaria parasites, individ-
uals living in malaria endemic regions develop naturally-acquired immunity (NAI) resulting 
in the ability to control blood-stage parasite multiplication [17]. These asymptomatic individ-
uals can account for the majority of infections in the population [18, 19]. Beside these fatal 
outcomes, malaria has also severe socio-economic consequences. Countries with intensive 
malaria transmission have significantly reduced economic growth, 10% reduction in malaria 
is projected with 0.3% higher economic growth [20]. Malaria has a negative impact on devel-
opment, investment, worker productivity, absenteeism, premature mortality and medical costs 
[21]. 
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1.1.3 Plasmodium malariae and ovale spp. - the neglected malaria parasites 
 
P. malariae is widespread throughout all major malaria-endemic regions worldwide [22], 
while P. ovale spp. is found mainly in Africa and southeast Asia [23]. The prevalence of P. 
malariae and P. ovale spp. in the affected population is thought to be underestimated due to 
the difficulties in detection. Microscopic diagnosis of P. malariae asexual blood-stage para-
sites is hampered by the usually low parasitaemia and morphological similarities to P. falci-
parum [24], and P. ovale spp. has the ability to form hypnozoites and therefore is not detect-
able in peripheral blood [25]. Lack of sensitive P. malariae and P. ovale spp. diagnosis 
methods applicable in the field and the research focus on P. falciparum has resulted in signif-
icant knowledge gaps regarding the potential spectrum of clinical manifestations and burden 
of P. malariae and P. ovale spp. infections [23].  
Clinical episodes of P. malariae infections are characterized by a mild illness caused by low 
numbers of parasites which can persist for extremely long periods, often for years [22]. There 
are reports of cases of P. malariae caused illness decades after malaria eradication from these 
regions [26, 27]. Incidences of P. ovale spp. episodes are low [23] but relapse can occur up to 
4 years after infection [25]. Using whole genome sequencing, it was demonstrated that P. 
ovale spp. essentially consists of two distinct species termed P. ovale curtisi and P. ovale 
wallikeri [28]. Recently, a study conducted in Gabon described different infection dynamics 
of P. ovale curtisi compared to P. ovale wallikeri [29]. Despite the relatively mild disease 
caused by P. malariae and P. ovale spp. compared to P. falciparum, both species should be 
included in future research agendas. The health burden of such chronic or re-occurring infec-
tions in an endemic context is not clear and little is known about the potential interactions 
caused by co-infections with different Plasmodium spp. species [23]. 
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1.1.4 Malaria control methods 
 
Current strategies to fight malaria include vector control using insecticide-treated mosquito 
nets (ITNs) and indoor residual spraying with insecticides (IRS), as well as access to diagnos-
tic testing and antimalarial treatment. The combination of these tools has contributed to a 
reduction of 20 million malaria cases globally since 2010 [12]. Exemplary for this trend, the 
P. falciparum parasite rate in Tanzanian children obtained from 2000 to 2017 is shown (Fig-
ure 3). 
 
Figure 3. P. falciparum parasite rate in Tanzania from 2000-2017. The Malaria Atlas Pro-
ject (MAP, https://map.ox.ac.uk/) was used to plot the P. falciparum parasite rate, in 2-10 
years old children based on data collected between 2000 and 2017.  
 
The first pillar of successful malaria control programs is an effective case management of 
patients with malaria, which includes rapid diagnosis and prompt treatment. Rapid diagnostic 
tests (RDTs) provide test results within 20 minutes [30] and in Sub-Saharan Africa, RDTs 
have almost completely replaced light microscopy for malaria diagnosis [12]. The treatment 
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of malaria was revolutionised by the introduction of the artemisinin derivatives and their drug 
combinations, which are rapidly effective, safe, and well tolerated [31]. With the widespread 
resistance to chloroquine and sulfadoxine–pyrimethamine, artemisinin-based combination 
treatments (ACTs) are now the recommended first line treatment for malaria [1].  
The second pillar is vector control, ITNs [32] have contributed substantially to the recent 
reduction in malaria morbidity and mortality [33]. Additionally, IRS with insecticides that 
persist and kill mosquitoes has also proven to be an important component of malaria control 
[34]. 
Alarmingly, for the second year since 2016, there is a flat-lining of what had been a steady 
decline in the global malaria epidemic [12, 35]. Figure 3 demonstrates this trend in the epi-
demiological context of Tanzania. The global malaria control efforts, especially among high-
burden countries, are under attack by reduced international funding. According to the WHO, 
the average level of funding per person at risk declined between 2015–2017 compared to 
2012–2014 by 20% [12]. Additionally, there is an increased emergence of drug and insecti-
cide resistance of the parasite and vector, respectively, observed. An additional 116,000 ma-
laria deaths annually is predicted under the scenario of widespread artemisinin resistance 
[36]. The extensive use of insecticides for ITNs and IRS resulted in a dramatic increase of 
resistant mosquito populations in Africa, presumably reflecting the increased selection pres-
sure [37]. Still, ITNs continue to be an effective tool for malaria prevention, even in areas 
where mosquitoes have developed resistance to pyrethroids, the only insecticide class cur-
rently used in ITNs [12]. Facing these challenges, besides an increase in funding for malaria 
control programs, the implementation of alternative intervention tools would ensure the sus-
tainability of malaria control.  
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1.1.5 Malaria diagnosis 
 
The rapid and accurate diagnosis of malaria cases is an essential factor in the control of ma-
laria. Diagnosis of malaria is performed in blood collected from potentially infected humans. 
Currently, three different major diagnostic approaches are used for malaria diagnosis, includ-
ing the direct visualization of blood-stage parasites by microscopy, detection of parasite-
derived antigens using RDTs and amplification of parasite-specific nucleic acids by nucleic 
amplification techniques (NATs). 
The gold standard for malaria diagnosis remains light microscopy of Giemsa stained blood 
smears. Thick blood smears (TBS) provide sensitivity and allow quantitation of infection. 
Thin blood smears allow the identification of different malaria species [38], which can be 
difficult for some species based on the similar morphology of the trophozoite stage [24]. 
Identification of blood stage parasites is time consuming and labour intensive and the lack of 
skilled technologists leads to poor quality [39]. A study which assessed the performance of 
malaria microscopy in the context of a clinical trial concluded that diagnostic errors occur 
with microscopy, including false positive findings, and that these errors can affect clinical 
trial results [40]. 
RDTs are nowadays widely used since they offer less dependence on the availability of la-
boratory infrastructure, and can be employed by inexperienced health care workers in re-
source limited settings where electricity might be a shortage [30]. Malaria RDTs are an im-
mune-chromatographic assay based on a lateral-flow device. They detect circulating malaria 
antigens in small amounts of capillary blood, usually 5 to 15 μL, using antigen specific anti-
bodies [24]. The majority of antibodies in use recognise the P. falciparum-derived histidine-
rich protein 2 (PfHRP2) [39]. The low costs, rapid testing, wide availability and simplicity in 
use and interpretation makes RDTs highly valuable to national malaria control programs. 
Chapter I – Introduction  11 
This is reflected in 245 million RDTs distributed worldwide and an estimated 75% of malaria 
tests conducted in Sub-Saharan Africa being based on RDTs in 2017 [12]. However, RDTs 
have several inherent limitations that reduce their usefulness for epidemiological studies of 
malaria. Since PfHRP2 is only expressed by P. falciparum, the other human infective malaria 
species will be missed by these RDTs. Alternative antibodies targeting Pan-Plasmodium anti-
gens such as lactate dehydrogenase (pLDH) or aldolase, are on the market. However, these 
RDTs have a ten-fold lower sensitivity compared to PfHRP2-based RDTs [38, 39]. P. malar-
iae and P. ovale spp. infections, which are often found to occur co-endemic in areas together 
with P. falciparum are usually characterized by very low parasitaemia in peripheral blood 
[23]. These non-falciparum Plasmodium species will hardly be detected by malaria surveil-
lance programs depending on RDTs only.  
An increasing number of reports are raising the issue of pfhrp2/pfhrp3 gene deletion in circu-
lating P. falciparum populations resulting in false negative PfHRP2-based RDTs - even at 
high parasite densities. These deletions are found around the world, with different proportions 
of the local parasite population affected. Among the areas with the highest proportions of 
reported pfhrp2 deletions are South America followed by Sub-Saharan Africa [41]. Since 
malaria control programmes depend on reliable diagnosis of malaria cases using RDTs, para-
sites lacking pfhrp2/3 genes pose a threat to malaria control programs [42].  
NATs are more expensive and require advanced laboratory infrastructure but provide much 
better sensitivity and broader diagnostic capabilities. NATs, such as polymerase chain reac-
tion (PCR), use amplified parasite-specific nucleic acids as a biomarker for infection with P. 
falciparum parasites [43]. These techniques are also easily expandable to non-falciparum 
Plasmodium species [44]. Therefore, NAT-based assays for detection, quantification and 
identification of malaria parasites add substantially more information to malaria surveillance 
programs [45].  
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The distribution and detection of the P. falciparum infection reservoir found in populations 
living in endemic regions is illustrated in Figure 4. Clinical symptoms are strongly associated 
with high parasite density and usually parasitaemia levels below 100 parasites/µL are asymp-
tomatic, particularly in semi-immune populations [1, 46].  
Microscopy and RDTs are critical diagnostic tools for identifying symptomatic malaria infec-
tions enabling appropriate treatment. However, due to the reduced performance in infections 
with low parasite density, their use for diagnosis of infection in asymptomatic individuals is 
rather limited [17]. It is a well-established fact that the limit of detection (LOD) of microsco-
py conducted by an expert reader is 20 – 50 parasites/µL, but for non-experienced microsco-
pists, it is up to ten-fold higher [38]. LOD of standard PfHRP2-based RDTs is about 100 par-
asites/µL, while LDH-based RDTs detect Plasmodium spp. infections with a LOD of about 
1000 parasites/µL [47–49]. Novel “ultra-sensitive” RDTs were recently introduced, which 
have a slightly better sensitivity for P. falciparum, but still fail to detect a substantial propor-
tion of parasite carriers [50] and there is probably no advantage over conventional RDTs for 
diagnosis of febrile patients [51]. 
As already mentioned above, for the detection of Plasmodium spp. parasites, NATs have 
proven to perform better than microscopy or RDTs. The parasites’ multi-copy 18S small sub-
unit ribosomal deoxyribonucleic acid (rDNA) and/or its highly expressed ribonucleic acid 
(rRNA) is the most frequently used biomarker for NATs [52] and recently received qualifica-
tion through the US Food and Drug Administration as a malaria biomarker for use in CHMI 
studies at non-endemic sites [53]. Different methods for 18S rDNA/rRNA detection are cur-
rently in use with a great variation in sensitivity. Qualitative methods targeting 18S rDNA, 
such as nested PCR [54] or LAMP [55], reach LODs of 0.1-10 parasites/µL. The use of quan-
titative PCR (qPCR) [56], does not only allow absolute quantification of infections but also 
lowers the LOD to less than 1 parasite/µL. The use of reverse transcription qPCR (RT-
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qPCR), amplifying total nucleic acids (RNA and DNA) of the 18S genes [57–59], is further 
increasing sensitivities of NATs. Alternatively, qPCR assays targeting multi-copy genomic 
sequences are able to achieve sensitivities close to 18S rRNA-based RT-qPCR assays [60]. 
 
 
Figure 4. P. falciparum infection reservoir in endemic populations. Typical parasite 
infection densities for asymptomatic and symptomatic populations living in endemic regions 
are shown. The dynamic ranges of different diagnostic tools are indicated. The creation of 
this figure was inspired by Manning et al. [61] 
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1.2 Host immune response and development of vaccines 
 
1.2.1 Naturally acquired immunity to malaria  
 
In malaria endemic regions, severe disease and the resulting deaths are mostly found among 
in children below the age of five years [1]. This vulnerable population lacks NAI, which is 
thought to develop during repetitive exposure to malaria parasites [17, 62]. NAI mediates 
protection against clinical disease but not re-infection, resulting in a high proportion of the 
population carrying asymptomatic infections at low parasite density [18, 19]. The mechanism 
is thought to be mediated by a broad range of antibodies directed against blood-stage antigens 
and therefore limiting parasite replication [46, 63]. These antibodies are involved in blocking 
merozoite invasion of erythrocytes, opsonize merozoites and infected erythrocytes for phago-
cytosis or fix and activate complement on the merozoite surface resulting in parasite lysis 
[64]. Although the mechanisms of NAI are poorly understood, it had been shown that it is 
highly effective. Cohen et al showed 1961 in a proof of concept study that transfer of immu-
noglobulins from malaria immune adults to children with clinical malaria reduced parasite 
density and subsequently also clinical symptoms [65]. NAI provides solid protection against 
severe malaria and death reflected in the fact that most malaria episodes are reported in popu-
lations lacking NAI. Older children and adults constantly exposed to malaria rarely experi-
ence life threatening complications caused by malaria [46].  
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1.2.2 Immunological correlates of vaccine efficacy  
 
Understanding immunity to malaria becomes increasingly important in development of ma-
laria vaccines. The identification of immunological correlates of protection could possibly 
lead to improved vaccine designs or immunization regimens. Immunological correlates could 
also reduce costs and complexity of clinical trials, especially when exposure to malaria is 
low, if used as a surrogate marker for protection [63]. Given the complexity of the interaction 
between the malaria parasite and the host, it is not surprising that no clear immunological 
correlates of malaria protection have been identified so far [10]. Complexity of the parasite, 
including its life cycle, strain diversity and antigenic variation, as well as host-derived factors 
such as different levels of pre-existing immunity, genetics and co-infections with other path-
ogens may hamper the identification of immunological markers associated with malaria in 
field trials. Therefore, CHMI studies might provide an promising alternative platform to iden-
tify correlates of protection [63, 66]. 
 
1.2.3 Malaria vaccines 
 
The introduction of an effective malaria vaccine, complementary to existing intervention 
tools, would be a game-changing milestone on the road towards malaria elimination. There 
are numerous potential malaria vaccine candidates under evaluation in clinical trials. Current-
ly investigated vaccine candidates, their efficacy and mode-of-action are illustrated in Figure 
5 and have been extensively reviewed recently [10, 63, 67–69]. 
Depending on which stage of the parasite’s life cycle is being targeted, these vaccine candi-
dates can be divided into pre-erythrocytic, blood-stage and transmission-blocking vaccines. 
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Successful pre-erythrocytic vaccines would lead to a sterile immunity by preventing the de-
velopment of blood-stage parasitaemia with the consequence of obviating clinical symptoms 
and blocking transmission. Pre-erythrocytic immunity could be achieved by preventing 
hepatocyte invasion via antibodies that target sporozoites or P. falciparum-specific CD8 T-
cells that target infected hepatocytes [10]. The two most advanced pre-erythrocytic vaccine 
candidates, RTS,S/A01 and PfSPZ Vaccine are discussed throughout this thesis extensively. 
On the contrary, blood-stage vaccines mimic NAI, by inducing a strong humoral immune 
response against target proteins expressed on the surface of infected erythrocytes or involved 
in merozoite invasion or egress [10]. A blood-stage vaccine, targeting the apical membrane 
antigen 1 (AMA1), showed high immunogenicity in malaria-exposed adults [70], but failed to 
provide significant protection against clinical malaria in a field trial in Mali [71]. Different 
subunit vaccines based on three merozoite surface proteins (MSP1, MSP2 and MSP3) were 
tested in different malaria pre-exposed populations [72, 73]. GMZ2 is a fusion protein of 
fragments of glutamate-rich protein (GLURP) and MSP3, which showed 14% vaccine effica-
cy against clinical malaria in a phase 2 trial in children from Burkina Faso, Gabon, Ghana 
and Uganda [74]. Among candidates earlier in the clinical evaluation phase are P27A and 
RH5. The candidate vaccine P27A has been considered safe and induced a particularly robust 
immunogenic response in combination with GLA-SE adjuvant in Swiss and Tanzanian vol-
unteers [75]. Currently, the safety and immunogenicity of ChAd63 RH5 and MVA RH5 in 
adults, children and infants is tested in Bagamoyo, Tanzania (Ally Olotu, personal communi-
cation, Clinical trial registration: NCT03435874).  
A third group of vaccine candidates aim to prevent transmission by targeting the development 
of gametocytes or inhibiting parasite development in mosquitoes. Transmission-blocking 
vaccines do not provide an direct benefit to the vaccinated individual but would contribute to 
a reduction of malaria infections in the population [76]. In a Malian field trial, the safety and 
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functional immunogenicity of Pfs25H-EPA/Alhydrogel was assessed. Although, Pfs25H-
EPA/Alhydrogel was well tolerated, the number of volunteers who infected at least one mos-
quito by direct skin feeds did not differ between recipients of this transmission blocking vac-
cine after the fourth dose and a comparator vaccine (Euvax B, recombinant hepatitis B vac-
cine) [77]. 
 
Figure 5. Vaccine candidates targeting different stages of the P. falciparum life cycle. 
Pre-erythrocytic vaccines inhibit sporozoite infection or kill infected hepatocytes. Blood-
stage vaccines target blood-stage antigens and induce humoral immune response to inhibit 
merozoite invasion or parasite replication. Transmission-blocking vaccines inhibit sexual-
stage development. Figure adapted from Draper et al [67].  
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Despite the need for a vaccine and decades spend on research and development, no vaccine 
against malaria has been licensed until today. Several obstacles to malaria vaccines have been 
identified. The complex life cycle, genetic diversity and antigenic variation are among the 
parasite-derived challenges [78]. Additional impediments are found in the human host. The 
required immune responsiveness of the target population can be compromised by nutritional 
status, different levels of malaria pre-exposure or co-infections [63]. 
Nevertheless, promising advances have been made in the past decade. The large-scale pilot 
implementation program of the currently most advanced malaria vaccine candidate -
RTS,S/AS01- in three African countries has started in April 2019 [79]. This hybrid recombi-
nant subunit vaccine, consisting of the central tandem repeat and carboxyl terminal portion of 
P. falciparum circumsporozoite protein (PfCSP) fused to the hepatitis B surface antigen, acts 
as a pre-erythrocytic stage vaccine. The antigen is administered with AS01, a liposome-based 
vaccine adjuvant system containing two immune-stimulants: 3-O-desacyl-4'-monophosphoryl 
lipid A and the saponin QS-21 [80]. In a large phase 3 clinical trial conducted from 2009 to 
2012 and including more than 15’000 infants and children from seven Sub-Saharan African 
countries, RTS,S/AS01 vaccine efficacy (VE) against clinical malaria was found to be 36.3% 
for children aged 5-17 months and 25.9% for infants aged 6-12 weeks at first vaccination 
during a follow up period of 12 months after the last dose [81]. A declining VE over time was 
described by Olotu et al.; over a 4-year period VE was only 16.8% in Tanzanian and Kenyan 
children aged 5-17 months [82]. However, the RTS,S vaccine has set the benchmark against 
which other vaccination approaches will be compared in future studies. 
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1.2.4 Whole sporozoite vaccines 
 
An alternative approach to subunit vaccines is the immunization with live, attenuated whole 
P. falciparum sporozoites. This idea is not novel as first experiments were conducted in the 
1970s. Clyde and colleagues demonstrated that vaccination with radiation-attenuated sporo-
zoites (RAS) could protect one out of three malaria-naïve volunteers from infection with P. 
falciparum through mosquito bites [83]. A milestone in the development of a whole sporozo-
ite based vaccine was achieved when the US biotech company Sanaria Inc. managed to de-
velop GMP-compliant methods to isolate, purify and cryopreserve P. falciparum sporozoites 
from infected mosquitoes. The direct inoculation by needle and syringe of their standardized 
manufactured product, named PfSPZ Vaccine, allows to move away from immunization via 
mosquito bite and to test the vaccine in the population most in need [84]. In order to elicit a 
strong immune response, most likely localized in the liver [85], PfSPZ Vaccine needs to be 
administered by direct venous inoculation (DVI) [86, 87]. While the clinical development of 
immunization with PfSPZ Vaccine is ongoing in the different age groups, alternative ap-
proaches of parasite attenuation are pursued. Immunization with fully infectious sporozoites 
under chloroquine coverage, an approach named PfSPZ-CVac, has shown promising results 
in malaria naïve volunteers [88]. Another approach uses genetically attenuated parasites 
(GAP), which leads to an arrest of parasite development in hepatocytes due to the deletion of 
three genes expressed during the pre-erythrocytic stage [89]. The current rational of vaccinat-
ing with attenuated whole sporozoites is that the sporozoites will infect hepatocytes without 
being able to develop into merozoites that would induce asexual blood stage infection. Para-
site attenuated by irradiation will stop early after hepatocyte infection since they cannot repli-
cate their DNA strands. Parasites attenuated by chloroquine (prevention of blood stage infec-
tion) or genetically modified to knock-out essential genes, will develop within hepatocytes 
Chapter I – Introduction  20 
until later stages. Therefore, the immune system might be exposed to a broader repertoire of 
antigens which could be beneficial for inducing effective and long-term immune responses 
using fewer sporozoites [67]. 
The identification of immunological mechanisms mediating protection is still ongoing. Im-
munization with PfSPZ Vaccine induces both, antibodies against PfCSP [90, 91] as well as 
liver-resident P. falciparum specific CD8 T-cells in monkeys [85, 90]. Liver-resident cells 
which are involved in inducing cellular-mediated immunity upon vaccination with PfSPZ 
Vaccine are difficult to access in peripheral blood in human subjects and therefore no clear 
correlate of protection has been found so far [67]. The humoral part of the immune response 
is better accessible. Serum from Tanzanian PfSPZ Vaccine-immunized volunteers was used 
to demonstrate that IgM antibodies can inhibit P. falciparum sporozoite invasion into hepato-
cytes in vitro and fix complement on sporozoites [92]. Furthermore, purified IgG from malar-
ia-naïve PfSPZ vaccinated volunteers reduced liver infection significantly in humanized liv-
er-chimeric mouse models [90].  
While a high protective efficacy of PfSPZ Vaccine in malaria-naïve volunteers assessed by 
homologous CHMI was observed [93], clinical trials conducted in malaria pre-exposed popu-
lations resulted in reduced vaccine efficacy [94]. The outcomes of additional trials, evaluating 
PfSPZ Vaccine, conducted in Tanzania and Equatorial Guinea are discussed in Chapter 2. 
Currently, the planning for an already financed phase 3 clinical trial on Bioko Island, Equato-
rial Guinea is undergoing. The first of a total 2100 volunteers is planned to be immunized 
with PfSPZ Vaccine in the first quarter of 2020 [95].  
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1.3 Controlled Human Malaria Infections (CHMI) 
 
1.3.1 CHMI: One hundred years of experience 
 
Controlled Human Malaria Infection, the deliberate inoculation of infective sporozoites or 
merozoites into human volunteers, has been practiced since the early 20th century. Before the 
introduction of penicillin, the induction of fever caused by artificial infection with Plasmodi-
um spp. parasites was the most effective treatment for neurosyphilis [96]. Only a few years 
after the first trials the so-called malariotherapy was fully accepted by the scientific commu-
nity and in 1927 even awarded with the Nobel Prize [97]. Clinical and parasitological data 
obtained from the era of malariotherapy has provided invaluable insight into the human im-
mune response and parasite growth dynamics, which remains informative a century later [98]. 
The first use of CHMI to assess vaccine efficacy was published in 1973 by David Clyde [83].  
Today, variations of several CHMI models using different stages of the parasite are used to 
infect humans with the aim to evaluate the efficacy of different types of vaccines. Infection 
with sporozoites is mediated by bites of infected mosquitoes [99] or by injection of purified, 
cryopreserved live sporozoites [86]. Alternatively, blood-stage parasites can be used for 
CHMI by intravenous inoculation with infected erythrocytes [100]. 
For obvious reasons, most CHMI studies are focusing on P. falciparum, but non-falciparum 
malaria CHMI models are also being developed. Different clinical trial sites have successful-
ly established P. vivax CHMI models [101]. Recently, it was demonstrated that the controlled 
infection of two volunteers with cryopreserved P. malariae-infected erythrocytes was well 
tolerated and led to stable parasitaemia [102]. No modern CHMI platform for infecting hu-
mans with P. ovale spp. and P. knowlesi has been established so far to our knowledge. 
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1.3.2 An accelerator for vaccine and drug development? 
 
CHMI is increasingly being used to assess the efficacy of malaria vaccines and therefore con-
tributes to acceleration in malaria vaccine development [103]. Based on the data from small 
CHMI trials an iterative process of vaccine and immunisation regimen optimization can be 
followed, which reduces the chance of late failures of candidates pushed into large and ex-
pensive phase 2 and 3 field vaccine trials [104]. Additionally, CHMI studies also offer a well-
controlled environment to rapidly assess the efficacy of antimalarial drugs [105]. Using 
qPCR assays for asexual blood stage parasite quantification failing drugs can be identified 
immediately which increases patients safety [106]. 
There are also challenges and limitations when it comes to conducting CHMI studies that can 
only be performed in adults. Further standardization of CHMI protocols is needed to allow 
comparison across different studies and clinical trial sites which has improved by using the 
PfSPZ Challenge at a fixed dose of 3200 sporozoites inoculated intravenously. To cover the 
genetic diversity of P. falciparum in the field, it is important to have several strains from dif-
ferent malaria endemic regions which could be used for CHMI [66, 107]. Currently, for spo-
rozoite-based CHMI studies only a limited number of P. falciparum strains are available. P. 
falciparum strains of West-African origin (PfNF54 [108] and PfNF166.C8 [109]), of Brazili-
an (Pf7G8 [110]) and Cambodian origin (PfNF135.C10 [111]) were tested in humans. De-
pending on the availability of cultured parasites more strains for CHMI might become availa-
ble in future. 
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1.3.3 CHMI as a tool to study host and parasite immunobiology 
 
The African continent carries the highest burden of malaria and its population is most in need 
for effective malaria control measures. Conducting CHMIs in malaria endemic population 
would allow earlier assessment of vaccine efficacy in target populations and provide insight 
into the immunological responses associated with NAI [112]. Although there are reports from 
Kenya, Nigeria and Liberia where controlled malaria infections were conducted between 
1954 and 1962 [113], most CHMI studies have been performed so far in malaria-naïve popu-
lations [112]. In the past, the challenge to conduct CHMIs in Africa was attributed to the lack 
of high security facilities able to rear P. falciparum-infected Anopheles mosquitoes [114]. 
This obstacle had been overcome by PfSPZ Challenge [115]. In 2012, we showed for the first 
time that inoculation of malaria pre-exposed Tanzanians with PfSPZ Challenge is safe, well 
tolerated and infective [114]. These findings were later confirmed in studies conducted in 
Kenya [113] and Gabon [116, 117] where volunteers from malaria endemic regions were 
successfully infected with PfSPZ Challenge. Two additional, so far unpublished clinical trials 
used CHMI in Mali (clinicaltrials.gov: NCT02996695 and NCT02627456). 
Given the logistical and financial expenditure of conducting CHMI studies, the use of this 
platform should be extended to more basic research questions beyond the evaluation of vac-
cine and drug candidates. The implementation of research projects on host and parasite im-
mune-biology embedded within CHMI studies should be encouraged. Data obtained from 
CHMI is not only critical for the evaluation of vaccine candidates but also provides an oppor-
tunity to study immunological responses to infection in a controlled setting. Furthermore, 
data on parasite growth dynamics allows analysing parasite-host interaction in the most rele-
vant populations. CHMIs also offer a convenient platform to evaluate novel diagnostic ap-
proaches for malaria as shown in Chapter 3 of this thesis. 
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1.3.4 Monitoring of parasitaemia during CHMI 
 
Post CHMI, volunteers are closely monitored for signs and symptoms of malaria. Parasi-
taemia in whole blood is rigorously monitored and volunteers are treated before they develop 
high parasitaemia levels and severe symptoms. Historically, the appearance of blood-stage 
parasitaemia was diagnosed using TBS microscopy while recently the more sensitive qPCR 
method is used as the diagnostic test in CHMI for the primary study endpoint. Several CHMI 
conducting research sites have discussed the use and in particular the advantages of qPCR-
based monitoring of parasitaemia during CHMI studies in malaria-naïve [118–122] and pre-
exposed individuals [113, 121, 123]. In summary, the implementation of qPCR improves 
safety while reducing the clinical burden and costs without compromising the evaluation of 
protective efficacy of pre-erythrocytic vaccine candidates in malaria-naïve volunteers [118] 
and might be the only solution to identify all infected volunteers in malaria pre-exposed pop-
ulations with varying levels of NAI [124]. Special attention needs to be paid to performance 
evaluation, quality control and external quality assessment of any diagnostic tool used in di-
agnosis of malaria during clinical trials and in particular during CHMI studies [125]. 
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1.4 Aims of this thesis 
 
Malaria control interventions, such as distribution of ITNs and wide-spread IRS, have led to a 
significant decrease in prevalence and mortality from 2010 to 2015. Alarmingly, since the 
year 2016 no further progress in reducing global malaria cases and deaths could be achieved. 
This is most likely the result of reduced public funding for malaria control and the appear-
ance of insecticide resistant vectors and drug resistant parasites. Novel malaria control ap-
proaches, such as highly effective vaccines and improved diagnostic tools are needed to pre-
vent a resurgence of malaria as has been seen in the 1970s.  
The overall goal of this PhD thesis is to contribute to the development, validation and imple-
mentation of novel molecular diagnostic tools in malaria endemic countries targeting all hu-
man infective malaria species.  
In part one, we aimed to closely monitor asexual blood stage parasites at the individual level 
including the following three objectives: 
i) To establish a robust laboratory-based qPCR-platform for molecular monitoring of asexual 
blood stage parasitaemia in volunteers residing in Tanzania and Equatorial Guinea. 
ii) To evaluate the efficacy of attenuated whole sporozoite vaccines (PfSPZ Vaccine and 
PfSPZ-CVac) by homologous CHMI in Tanzanian and Equatorial Guinean adults.  
iii) To study the impact of malaria pre-exposure on multiplication rates of P. falciparum par-
asites during CHMI.  
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In part two, we aimed to adapt and extend molecular diagnostic tools for improvement of 
malaria diagnosis for surveillance at the population level. The following objectives were de-
fined: 
i) To develop novel high-throughput, field-deployable and highly sensitive tools and ap-
proaches for molecular malaria surveillance.  
ii) To include qPCR-based detection of P. malariae and P. ovale spp. parasites in active ma-
laria surveillance in Tanzania and Equatorial Guinea. 
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Molecular monitoring of asexual blood stage parasites 
at the individual level 
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2.1 PfSPZ Vaccine safety, immunogenicity and efficacy against CHMI in Tanzanian and 
Equato-Guinean volunteers 
 
A short review of all six clinical trials, which were the backbone of this PhD thesis is follow-
ing below. The outcomes of the BSPZV3, EGSPZV2 and EGSPZV3 trials are not published 
yet.  
 
BSPZV1 – Safety, immunogenicity and protective efficacy of PfSPZ Vaccine in Tanza-
nian adults 
The BSPZV1 study [124], with the identical vaccination schedule as studies in the USA [126] 
and Mali [94], showed that two different doses of PfSPZ Vaccine, five immunizations with 
1.35 × 105 or 2.7 × 105 RAS, were safe and well tolerated in Tanzanian men. A dose-effect 
was observed. In the group receiving the lower dose, VE against homologous CHMI was 
5.6% (1/18 volunteers protected), while in the higher dose group the VE was 20% (4/20 vol-
unteers were protected). The five immunizations with 2.7 × 105 RAS were less protective in 
Tanzanians than in Americans who received the same dosage and regimen of PfSPZ Vaccine 
[126]. VE was similar as seen in intense field exposure to heterogeneous P. falciparum para-
sites in Mali [94], suggesting that CHMI is a valuable tool to assess and predict vaccine effi-
cacy in malaria pre-exposed populations. Antibody responses to PfCSP in Tanzanians were 
lower than in malaria-naïve Americans, but significantly higher than in Malians. Further-
more, all four volunteers from the high dose group which were protected against CHMI 3 
weeks after the last vaccination, were still protected against a second CHMI 24 weeks post 
vaccination. Notably, the prepatent period assessed by qPCR of unprotected vaccinated vol-
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unteers was significantly longer than the prepatent period in placebo controls, indicating a 
vaccine-induced reduction of sporozoites in the liver. 
 
BSPZV2 – Safety and immunogenicity of PfSPZ Vaccine in Tanzanian adults, adoles-
cents, children, and infants 
A total of 93 volunteer were enrolled into the BSPZV2 study [127]. Using an age-de-
escalation study design, vaccinations started in adults, followed by adolescents, children and 
finally infants. PfSPZ Vaccine was safe and well tolerated in all age groups, including the 
infants. Immunogenicity was assessed in all age groups receiving three doses of 9.0 × 105 
RAS. Humoral immune responses against PfCSP were highest in infants and lowest in adults. 
T-cell responses were higher in children than in adults and completely absent in infants, sug-
gesting that PfSPZ Vaccine may be more protective in children than in adults and infants. 
Vaccine efficacy against CHMI was only assessed in adults. Two different doses, three im-
munizations with 9.0 × 105 and 1.8 × 106 RAS were tested against CHMI. Unexpected, high-
er VE (100%, 5/5 protected) was observed in the lower dose group compared to the group 
which received higher dose (33%, 2/6 protected). Humoral and cellular immune responses 
were higher in the high dose group which was less protective against CHMI. After a second 
CHMI, 37-40 weeks after last vaccination, only one volunteer from the high dose group re-
mained protected. 
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BSPZV3 – Safety, immunogenicity and efficacy of PfSPZ Vaccine in HIV+ Tanzanian 
adults 
There is a significant geographic overlap between HIV and malaria in Sub-Saharan Africa 
[128]. Therefore, safety of malaria vaccine needs to be assessed in people living with HIV. 
We evaluated the safety, immunogenicity and protective efficacy in HIV+ Tanzanian volun-
teers. Four doses of 9.0 × 105 RAS within one week followed by a booster vaccination at day 
28 were tested in two groups, consisting of 12 HIV+ and 9 HIV- volunteers. The HIV+ vol-
unteers were enrolled based on documented HIV infection at WHO clinical stage 1. They 
were all on stable anti-retroviral therapy for at least 3 months and had CD4 counts above 500 
cells/μL at screening. CD4 counts and HIV-1 viral loads were monitored closely throughout 
the entire trial. The outcomes of this trials are not published yet but based on a pre-liminary 
analysis of the data it can be concluded that the PfSPZ Vaccine was safe and well tolerated in 
HIV+ individuals. Antibody responses to PfCSP were significantly lower in HIV+ volunteers 
(S. L. Hofmann, personal communication). None of the HIV+ volunteers were protected up-
on CHMI, while the VE in the HIV- group was 83.3% (5/6). Although, the HIV+ volunteers 
were on anti-retroviral therapy with stable CD4 counts and HIV-1 viral loads, this result sug-
gests that their immune system is still compromised to a certain degree which impairs im-
mune responses induced by PfSPZ Vaccine. 
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EGSPZV1 - Safety and immunogenicity of PfSPZ Vaccine in Equatorial Guineas first 
clinical trial 
In the first clinical trial ever conducted in Equatorial Guinea, the safety and immunogenicity 
of three doses of 2.7 × 105 RAS was tested in 20 adult male volunteers [129]. The vaccine 
was well tolerated, but antibody responses to PfCSP were significantly lower than responses 
in US or Tanzanian adults who received the same dosage regimen. Although, it was a small 
trial its importance for Equatorial Guinea’s malaria research efforts should not be underesti-
mated. This trial is the foundation for development of a robust research and development 
program to eliminate malaria on Bioko Island using a malaria vaccine as a complimentary 
tool to already ongoing malaria control efforts. 
 
EGSPZV2 - Safety and immunogenicity of PfSPZ Vaccine in Equato-Guinean adults, 
adolescents, children, and infants and comparison between PfSPZ Vaccine and PfSPZ-
CVac for efficacy against CHMI 
Compared to the BSPZV2 study, higher doses of PfSPZ Vaccine were tested. Adults received 
three doses of 2.7 × 106 RAS, while younger children (1-5 years old) and infants received 
three doses of 1.8 × 106 RAS. These increased PfSPZ Vaccine doses were safe and well tol-
erated in all age groups. The approach of using three doses of 100’000 non-attenuated sporo-
zoites administered under chloroquine prophylaxis, resulted in transient parasitaemia (ranging 
100-1000 parasites/mL) in whole blood 7 – 9 days post vaccination similar to what had been 
observed in malaria naïve German volunteers [88]. The direct, side-by-side comparison of 
vaccination with RAS and PfSPZ-CVac in Equato-Guinean volunteers revealed higher pro-
tective efficacy among volunteers who received PfSPZ-CVac, with VE of 33% (6/18) for 
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RAS versus 57% (8/14) for PfSPZ-CVac. The analysis of immunological correlates of pro-
tection is still ongoing. 
 
EGSPZV3 – Optimization of PfSPZ Vaccine dosage regimen in Equato-Guinean adults 
The EGSPZV3 study was designed to compare the administration of four different regimens 
of PfSPZ Vaccine for vaccine efficacy against homologous CHMI eight weeks after last vac-
cination. The focus was to establish which of the condensed regimens, completing all re-
quired immunizations within four weeks or less is optimal to be used during the upcoming 
phase 3 clinical trial planned for 2020 on Bioko Island. This trial is not unblinded yet, there-
fore no conclusion about the different vaccination schedules can be made at this time. How-
ever, indications are that the vaccination dose of 9 x 105 RAS applied at days 1, 8 and 28 is 
superior to the other regimen tested. 
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Abstract. Weareusingcontrolled humanmalaria infection (CHMI) bydirect venous inoculation (DVI) of cryopreserved,
infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time and costs of developing
PfSPZ Vaccine to preventmalaria in Africa. Immunizationwith ﬁve doses at 0, 4, 8, 12, and 20weeks of 2.7 × 105 PfSPZ of
PfSPZ Vaccine gave 65% vaccine efﬁcacy (VE) at 24 weeks against mosquito bite CHMI in U.S. adults and 52% (time to
event) or 29% (proportional) VE over 24weeks against naturally transmitted Pf inMalian adults.We assessed the identical
regimen in Tanzanians for VE against PfSPZ Challenge. Twenty- to thirty-year-old men were randomized to receive ﬁve
dosesnormal salineorPfSPZVaccine in adouble-blind trial. Vaccineefﬁcacywasassessed3and24weeks later. Adverse
eventswere similar in vaccinees and controls. Antibody responses toPf circumsporozoite proteinwere signiﬁcantly lower
than in malaria-naı¨ve Americans, but signiﬁcantly higher than in Malians. All 18 controls developed Pf parasitemia after
CHMI. Four of 20 (20%) vaccinees remained uninfected after 3 week CHMI (P = 0.015 by time to event, P = 0.543 by
proportional analysis) and all four (100%)were uninfected after repeat 24weekCHMI (P=0.005by proportional,P=0.004
by time to event analysis). Plasmodium falciparum SPZ Vaccine was safe, well tolerated, and induced durable VE in four
subjects. Controlled human malaria infection by DVI of PfSPZ Challenge appeared more stringent over 24 weeks than
mosquito bite CHMI in United States or natural exposure inMalian adults, thereby providing a rigorous test of VE in Africa.
INTRODUCTION
In2015 and in 2016, therewere an estimated429,000–730,500
deaths caused by malaria.1–3 Plasmodium falciparum (Pf) is
the cause of > 98% of malaria deaths and > 80% of malaria
cases in sub-Saharan Africa. Our goal is to ﬁeld a vaccine that
will prevent infection with Pf and thereby prevent all mani-
festations of Pf malaria and parasite transmission from
humans to mosquitoes.4
Plasmodium falciparum sporozoites (SPZ) are the only im-
munogens that have ever prevented Pf infection in > 90% of
subjects.5–7 Sanaria® PfSPZ Vaccine (Sanaria Inc., Rockville,
MD) is composed of radiation-attenuated, aseptic, puriﬁed,
cryopreserved PfSPZ.8,9 When administered by rapid in-
travenous injection, PfSPZ Vaccine protected 100% (6/6) of
malaria-naı¨ve subjects in the United States against mosquito
bite–controlled human malaria infection (CHMI) with Pf para-
sites similar to those in the vaccine (homologous) 3 weeks after
the last immunization,10 and 65% at 24 weeks.11 Protection
was durable against homologous mosquito bite CHMI for at
least 59 weeks12 and heterologous (parasites different than in
vaccine) mosquito bite CHMI for at least 33 weeks.13 PfSPZ
Vaccine also prevented naturally transmitted heterogeneous
Pf in adults in Mali for at least 24 weeks (vaccine efﬁcacy [VE]
52% by time to event and 29% by proportional analysis).14
We used the same dosage regimen as in the United States
and Mali to evaluate the tolerability, safety, immunogenicity,
and VE of PfSPZ Vaccine in young adult male Tanzanians.
Previously, we had conducted the ﬁrst modern CHMI in Africa
and showed that injection of aseptic, puriﬁed, cryopreserved
PfSPZ, Sanaria® PfSPZ Challenge, consistently infected
Tanzanian volunteers and subsequently repeated in multiple
other countries.15–21 In this study, we took advantage of this
capability to assess VE of PfSPZVaccine byCHMIwith PfSPZ
Challenge (NF54). The same PfSPZ Vaccine dosage regimen
was less immunogenic and protective in Tanzanians than in
Americans,11 and VE against homologous CHMI in Tanzania
was lower (or similar) to VE against intense ﬁeld exposure to
heterogeneous Pf parasites in Mali.14
MATERIAL AND METHODS
Study design and population. This double-blind, ran-
domized, controlled trial was conducted in Bagamoyo, Tan-
zania, between April 2014 and August 2015. Sixty-seven
healthy male volunteers of 18–35 years of age were recruited
from higher learning institutions in Dar es Salaam. After initial
screening, prospective volunteers were invited to the Bag-
amoyo Clinical Trial Unit of the Ifakara Health Institute (IHI) to
complete informed consent and screening.
All had to complete a 20-question assessment of trial un-
derstanding with a 100% correct response rate on the ﬁrst or
second attempt (Supplemental Table 1) to be eligible. Volun-
teers were screened using predetermined inclusion and ex-
clusion criteria (Supplemental Tables 2 and 3). History of
malaria in the previous 5 years or antibodies to Pf exported
protein 1 (PfEXP1) byanenzyme-linked immunosorbent assay
(ELISA) above a level associated with a single, recent Pf in-
fection by CHMI19 (see the Antibody assays section) were the
exclusion criteria. Hematology, biochemistry, and parasitol-
ogy testing, including malaria thick blood smear (TBS), stool,
* Address correspondence to Stephen L. Hoffman, Sanaria Inc., 9800
Medical Center Dr., Suite A209, Rockville, MD 20850. E-mail:
slhoffman@sanaria.com
†These authors contributed equally to this study.
338
and urine by microscopy was carried out. Tests for human
immunodeﬁciency virus andhepatitis B andCwereperformed
after counseling; volunteers were excluded if positive and
referred for evaluation and management by appropriate local
physicians. Volunteers were excluded if they had signiﬁcant
abnormalities on electrocardiograms.
The trial was performed in accordance with Good Clinical
Practices. The protocol was approved by institutional review
boards (IRBs) of the IHI (Ref. No. IHI/IRB/No:02-2014), the Na-
tional Institute for Medical Research Tanzania (NIMR/HQ/R.8a/
Vol.IX/1691), the Ethikkommission Nordwest-und Zentral-
schweiz, Basel, Switzerland (reference number 261/13), and by
the Tanzania Food and Drug Authority (Ref. No. TFDA 13/CTR/
0003); registered at Clinical Trials.gov (NCT02132299); and
conducted under U.S. FDA IND application.
Investigational products (IPs). The IPs were Sanaria®
PfSPZ Vaccine8–14 and Sanaria® PfSPZChallenge.15–20 PfSPZ
Vaccine consists of aseptic, puriﬁed, vialed, metabolically ac-
tive, nonreplicating (radiation attenuated), cryopreserved
PfSPZ (NF54 strain). It was stored, thawed, diluted, and ad-
ministered by direct venous inoculation (DVI) in 0.5 mL through
a 25-gauge needle.11,14,18,20 PfSPZ Challenge is identical to
PfSPZ Vaccine except it is not radiation attenuated. It was
handled and administered like PfSPZ Vaccine. Preparation of
IPs was supervised by the study pharmacist. After labeling the
syringe, the pharmacist handed it to the clinical team through a
window.
Allocation and randomization. Volunteers were allocated
to ﬁve groups (Table 1; Figure 1). Forty-nine received PfSPZ
Vaccine and eight normal saline (NS). Ten were additional in-
fectivity controls. The clinical team and volunteers were blin-
ded to assignment to vaccine or NS until study end.
Group 1. Three volunteers received consecutive doses of
3 × 104, 1.35× 105, and 2.7 × 105PfSPZofPfSPZVaccine at 4-
week intervals to assess safety (Group 1).
Groups 2 and 3. Volunteers were randomized to receive
1.35 × 105 PfSPZ of PfSPZ Vaccine (N = 20) or NS (N = 4)
(Group 2), or 2.7 × 105 PfSPZ of PfSPZ Vaccine (N = 20) or NS
(N = 4) (Group 3) at 0, 4, 8, 12, and 20 weeks.
Group 4. Six volunteers were immunized with 2.7 × 105
PfSPZ of PfSPZ Vaccine on the same schedule as Group 3.
Group 5. Ten volunteers served as unblinded infectivity
controls during CHMIs (see in the following paragraph): two
with CHMI #1, two with CHMI #2, and six with CHMI #3.
Vaccine efﬁcacy. Controlled human malaria infection.
Vaccine efﬁcacy was assessed by CHMI by DVI of 3.2 × 103
PfSPZ of PfSPZ Challenge. Controlled human malaria in-
fection #1 was 3 weeks after the last immunization in Group 2.
Controlled human malaria infection #2 was 3 weeks after the
last immunization in Group 3. Controlled human malaria in-
fection #3was 24weeks after the last immunization in Groups
3 and 4 and included the four volunteers in Group 3 who did
not develop parasitemia after CHMI #2 and the six Group 4
volunteers. Volunteers were inpatients from day 9 after PfSPZ
Challenge injection for observation until diagnosed and
treated for malaria or until day 21; daily outpatient monitoring
for TBS-negative volunteers continued until day 28. Thick
bloodsmearswereobtainedevery12hours ondays9–14after
CHMI and daily on days 15–21 until positive or until day 21.
Thick blood smears could be performed more frequently, if
volunteers had symptoms/signs consistent withmalaria. After
initiation of treatment, TBSs were assessed until two con-
secutive daily TBSs were negative and on day 28.
Detection of Pf parasites and parasite DNA. Slide prepara-
tion and reading for TBSs were performed as described.19
Sensitivity was 2 parasites/μL blood unless the volunteer was
symptomatic, in which case four times as many ﬁelds were
read. Parasitemia was also determined by quantitative poly-
merase chain reaction (qPCR) with sensitivity of 0.1 parasites/
μL blood based on a multiplex assay detecting Plasmodium
spp. 18S genes and the human RNaseP gene as endogenous
control.22 A second, more sensitive qPCR assay with a sen-
sitivity of 0.05 parasites/μL blood and targeting the Pf-speciﬁc
telomere-associated repetitive element 223 was used to
reanalyze all samples thatwere negative by 18S-based qPCR.
After the start of CHMI, the time of ﬁrst blood sample positivity
by qPCR was used to determine infection status and for the
calculation of prepatent period. Volunteers were continuously
monitored by qPCR until malaria treatment based on TBS
positivity. The World Health Organization International Stan-
dard for Pf DNA Nucleic Acid Ampliﬁcation Techniques
(NIBSC, Hertfordshire, United Kingdom) was used as stan-
dard for calculation of parasite densities. DNA was extracted
from 100 μL whole blood and eluted with 50 μL Elution Buffer
using Quick-gDNA Blood MicroPrep Kit (Zymo Research,
Irvine, CA). Blood samples were analyzed retrospectively by
qPCR after storing at −80Cafter the conclusion of CHMIs. To
exclude ﬁeld strain infections, parasite genotyping was per-
formed on samples randomly chosen as described.24 In all
cases in which TBS was negative and qPCR was considered
positive, two consecutive samples were positive by qPCR.
Adverse events (AEs). Volunteers were observed as in-
patients for 48 hours after administration of IP and discharged
with diaries and thermometers for recording AEs and tem-
peratures and followed with daily telephone calls. Symptoms
and signs (solicited and unsolicited) were recorded and
graded by physicians: mild (easily tolerated), moderate
(interfere with normal activity), severe (prevents normal activity),
TABLE 1
Demographic characteristics of volunteers
Vaccinees Normal saline controls Infectivity controls
Number of volunteers 49 8 10
Percentage males 100% 100% 100%
Mean age in years (range) 24 (20, 30) 23 (20, 28) 25 (21, 28)
Percentage Africans 100% 100% 100%
Mean body mass index (range) 22.33 (18.00, 29.70) 21.91 (19.00, 24.20) 21.68 (18.40, 24.30)
Number (%) heterozygous for alpha thalassemia 22 (44.9%) 4 (50%) 5 (50%)
Number (%) with LTBI* (QuantiFERON positive) 17 (34.7%) 3 (36.5%) 1 (10%)
Number (%) positive on screeningof urine or stool for parasitic infection 0 (0%) 1 (12.5%) 0 (0%)
Number (%) students 49 (100%) 8 (100%) 10 (100%)
* Latent tuberculosis infection.
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or life threatening. Axillary temperature was grade 1 (> 37.5–
38.0C), grade 2 (> 38.0–39.0C), grade 3 (> 39.0–40.0C), or
grade 4 (> 40.0C). Hematological and biochemical abnormali-
ties were also assessed using standard clinical assays.
During the ﬁrst 7 days after injection of IPs, prespeciﬁed
local (site of injection) and systemic AEswere solicited. Open-
ended questioning was used to identify unsolicited AEs
through day 28 (Supplemental Table 4). All AEswere assessed
for severity and relatedness to IP administration. Adverse
events were classiﬁed as deﬁnitely related, probably related,
possibly related, unlikely to be related, and not related. Deﬁ-
nitely, probably, and possibly were considered to be related.
Unlikely to be related and not related were considered to be
unrelated.ForCHMIs, volunteers returnedonday9 foradmission
to theward for diagnosis and treatment ofmalaria. Events during
the8–28dayperiodwereassessed for relationship toPf infection
and considered related if the event waswithin 3 days before and
7 days after TBS was ﬁrst positive.
Antibody assays. Sera were assessed for antibodies
by ELISA, immunoﬂuorescence assay (aIFA), and inhibition
of sporozoite invasion (ISI) assay as described (seeSupplemental
Table 5).25 For ELISAs, the results are reported as the serum di-
lution at which the optical density (OD) was 1.0. Enzyme-linked
immunosorbent assay forPfEXP1wasused toscreen volunteers
for possible malaria exposure (Supplemental Table 6). Any
subject with an OD 1.0 of ³ 600 was excluded. This was be-
cause we had previously determined in Tanzanians who un-
derwent CHMI19 that antibodies to PfEXP1 at this level were a
sensitive indicator of recent Pf infection (unpublished).
T-cell assays.T-cell responses in cryopreservedperipheral
blood mononuclear cells (PBMC) were measured by ﬂow
cytometry in a single batch after the study as described.12
After stimulation, cells were stained as described.26 The
staining panels are in Supplemental Table 7 and antibody
clones and manufacturers are in Supplemental Table 8. All
antigen-speciﬁc frequencies are reported after background
FIGURE 1. Volunteer participation (CONSORT 2010 diagram). This ﬁgure appears in color at www.ajtmh.org.
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subtractionof identical gates from the samesample incubated
with control antigen. Data were analyzed with FlowJo v9.9.3
(TreeStar, Ashland, OR) and graphed in Prism v7.0a (Graph-
Pad, San Diego, CA).
Statistical analysis. Comparisons of categorical variables
between groups were analyzed using 2-tailed Fisher’s exact
test. Comparisons of continuous variables between groups
were analyzed by 2-tailed nonparametric tests. For multiple
group comparisons, theKruskal–Wallis testwas used. Time to
event was assessed by the Kaplan–Meier curves and log-rank
test. Vaccine efﬁcacy by time to event was quantiﬁed using
Cox proportional hazards ratios. Time to event data were
analyzed from CHMI injection until positive TBS result or
positive qPCR result. Controlled human malaria infection
follow-up period lasted until day 28 after CHMI injection.
Analyses of immunological data are described with the data.
Role of the funding source. The funders were involved in
study design, study management, data collection, data anal-
ysis, data interpretation, and writing the report. Salim Abdulla
and Stephen L. Hoffman had full access to all data in the study
and ﬁnal responsibility for decision to submit for publication.
RESULTS
Study population and experience with DVI. Fifty-seven
Tanzanianmen (Table 1; Figure 1)met the criteria (Supplemental
Tables 2 and 3) and received PfSPZ Vaccine (N = 49) or NS
(N = 8). All volunteers had AA hemoglobin and normal G6PD
activity. Thirty-one volunteers (46%) were heterozygous for
α-thalassemia; 21 had evidence of latent tuberculosis in-
fection by Quantiferon testing, but showed no evidence of
active tuberculosis. One volunteer (group 2, NS) had
Strongyloides stercoralis on screening and was success-
fully treated before vaccination (Table 1).
Of 237 immunizations with PfSPZ Vaccine, 234 were com-
pleted with a single injection (98.7%). Two hundred and thirty
injections (97.0%) were considered painless by the volunteer.
For NS subjects, 39 of 40 immunizations (97.5%) were com-
pleted in a single injection and 39 of 40 (97.5%) considered
painless by the volunteer. The nurse performing immuniza-
tions considered the procedure to be simple in 265 of 273
single injections (97.1%).
One subject in Group 2 received four immunizations. The
third immunization was withheld while the subject was evalu-
ated forwhatwasdiagnosedasbenign ethnic neutropenia.27,28
One subject in Group 4missed his second immunization when
he left town. All other subjects (other than Group 1 and added
infectivity controls) received ﬁve immunizations.
Safety. Among 49 volunteers who received 237 doses of
PfSPZVaccine, therewere 17 solicited AEs possibly related to
IP (17/237 = 7.2%) in 10 of the 49 vaccinees (20.4%) (Table 2).
Among eight volunteers who received 40 doses of NS, there
were two solicited AEs possibly related to IP (2/40 = 5.0%) in
one of the eight controls (12.5%) (Table 2). There were no AEs
consideredby theclinicians tobeprobably or deﬁnitely related
to IP. There were no local or serious AEs. One episode each of
headache and fever were grade 2; all other solicited AEs were
grade 1. None of the comparisons of AEs between vaccinees
and controls or between Group 2 (1.35 × 105 PfSPZ) and
Groups 3 and 4 (2.7 × 105 PfSPZ) showed statistically signif-
icant differences (Table2). Twenty-six of 49vaccinees (53.1%)
experienced 43unsolicitedAEs (0.88/individual) in the 28days
following injections #1–#4 and the 21 days before CHMI after
injection #5. Seven of eight controls (87.5%) experienced 14
unsolicited AEs (2/individual) during this period. None of these
unsolicited AEs recorded within 28 days of an immunization
was considered related to IP.
Laboratory abnormalities occurred at roughly equal rates
comparing PfSPZ Vaccine recipients and controls, except for
leukocytosis and eosinophilia, which were more frequent in
controls (Table 3). There was no apparent explanation for
these differences. A cyclic variation in total bilirubin following
TABLE 2
Solicited AEs by group considered possibly* related to administration of the investigational product during the ﬁrst 7 days post immunization
Group 1 (dose escalation) Group 2 (1.35 × 105 PfSPZ) Group 3 (2.7 × 105 PfSPZ) Group 4 (2.7 × 105 PfSPZ) Total PfSPZ vaccine NS controls
Number of volunteers 3 20 20 6 49 8
Total number of injections 9 99 100 29 237 40
Number of local AEs 0 0 0 0 0 0
Numbers of systemic AEs (% of total immunizations)
All 1 (11%) 10 (10.1%) 6 (6%) 0 17 (7.2%) 2 (5.0%)
Headache* 1 (11%) 7 (7%)† 2 (2%) 0 10 (4.2%) 1 (2.5%)
Abdominal pain 0 2 (2%) 1 (1%) 0 3 (1.3%) 0
Chills 0 0 1 (1%) 0 1 (0.4%) 0
Fever 0 0 2 (2%) 0 2 (0.8%) 0
Diarrhea 0 0 0 0 0 1 (2.5%)
Chest pain 0 1 (1%) 0 0 1 (0.4%) 0
Other 0 0 0 0 0 0
Systemic AEs - no. volunteers with ³ 1 event (% of volunteers)
Any 1 (33%) 7 (35%) 2 (10%) 0 10 (20.4%) 1 (13%)
Headache 1 (33%) 6 (30%) 2 (10%) 0 9 (18.4%) 1 (13%)
Abdominal pain 0 2 (10%) 1 (5%) 0 3 (6.1%) 0
Chills 0 0 1 (5%) 0 1 (2.0%) 0
Fever 0 0 2 (10%) 0 2 (4.1%) 0
Diarrhea 0 0 0 0 0 1 (13%)
Chest pain 0 1 (5%) 0 0 1 (2.0%) 0
All other 0 0 0 0 0 0
AEs = adverse events; PfSPZ =Plasmodium falciparum sporozoites. There were no signiﬁcant differences between vaccinees as compared with normal saline (NS) controls for any or all AEs. All
AEswere grade 1, except one headache and one fever. Local solicited AEs: injection site pain, tenderness, erythema, swelling, or induration. Systemic solicited AEs: allergic reaction (rash, pruritus,
wheezing, shortness of breath, bronchospasm, allergy-related edema/angioedema, hypotension, and anaphylaxis), abdominal pain, arthralgia, chest pain/discomfort, chills, diarrhea, fatigue, fever,
headache, malaise, myalgia, nausea, pain (other), palpitations, shortness of breath, and vomiting.
* All AEs were considered possibly related. None were considered probably or deﬁnitely related.
† 4/7 episodes of headache occurred after the third vaccine dose and did not recur with fourth or ﬁfth doses. No factor was identiﬁed to account for this apparent clustering of headache.
PFSPZ VACCINE SAFETY, IMMUNOGENICITY, EFFICACY IN TANZANIA 341
each immunization was observed equally in volunteers re-
ceiving vaccine or NS that was attributed to enriched diet, as
the volunteers were transported to Bagamoyo from Dar es
Salaam during the periods of immunization and CHMI and
were amply fed (see Supplemental Figure 1). In Dar esSalaam,
malaria transmission is low. No volunteer had malaria during
screening or during the trial other than from CHMI.
Tolerability, safety, and VE during CHMI. Forty-six vac-
cinees, eight NS controls, and 10 added infectivity controls
underwent homologous CHMI. All subjects were negative by
TBS and qPCR for Pf infection on the day of CHMI. Two vol-
unteers were excluded from primary analysis—a Group 2
volunteer who left the area 2 days after administration of
PfSPZ Challenge and a Group 4 volunteer who left 9 days
after. Both volunteers were located and treated preemptively.
Tolerability and safety of administration of PfSPZ challenge.
Controlled humanmalaria infection was well tolerated with no
local solicited AEs and three systemic solicited AEs (grade 1
headache inGroup 3, grade 2 headache inGroup 4, and grade
1 arthralgia in an infectivity control) in the 7 days post-
administration of PfSPZ Challenge.
Parasitemia. Controls. The 18 NS and infectivity controls
developed Pf infection after CHMI (16 TBS and qPCR positive
and two TBS negative and qPCR positive) (Figure 2A–D and
Supplemental Table 9). These included four NS and two in-
fectivity controls in CHMI #1, the same in CHMI #2, and six
infectivity controls in CHMI #3. All received the same lot of
PfSPZChallenge. One isolate of those positive fromCHMI #1,
one fromCHMI #2, and four fromCHMI #3 were genotyped,24
and all parasites tested were PfNF54. Vaccine efﬁcacy was
calculated based on the results of qPCR assays from the six
controls in CHMI #1, CHMI #2, and CHMI #3 individually
(Figure 2D).
Group2 (1.35×105PfSPZ). Seventeenof 18 volunteerswho
received ﬁvedoses and1/1 volunteerwho received four doses
developed parasitemia (Figure 2A), 15 positive by TBS and
qPCR, and 3 by qPCR only (CHMI #1) (Supplemental
Table 10). One volunteer was negative through day 28 by
TBS and qPCR. Vaccine efﬁcacy by proportional analysis
was 5.56% (95% conﬁdence interval [CI]: 3.61%, 14.73%;
P>0.99, Fisher’s exact test, 2-tailed). Therewas no signiﬁcant
delay in parasitemia by qPCR in the vaccinees as compared
with controls (P = 0.4481 by log rank).
Group 3 (2.7 × 105 PfSPZ). First CHMI at 3weeks (CHMI #2):
16/20 volunteers who received ﬁve doses developed para-
sitemia (Figure 2B), all positive by TBS and qPCR; four vol-
unteers were negative through day 28 by TBS and qPCR.
Vaccine efﬁcacy by proportional analysis was 20% (95% CI:
4.62%, 35.38%; P = 0.543). There was a delay in the onset of
parasitemia in vaccinees as comparedwith controls (P=0.015
by log rank).
Second CHMI at 24 weeks (CHMI #3): The four uninfected
volunteers from the ﬁrst CHMI underwent a second CHMI
24 weeks after the last vaccine dose (Figure 2C). Three were
negative by TBS and qPCR through day 28 day. The fourth
volunteer, who was asymptomatic, was reported to have a
positive TBS on day 12 and treated. The sample with positive
TBSwas negative by retrospective qPCR. Reevaluation of the
TBS indicated anerror in slide reading (false-positive). Vaccine
efﬁcacy by proportional analysis at this time point was 100%
(for 3/3 and 4/4 protected: 95%CI: 43.8%, 100%, and 51.01%,
100%; P = 0.012 and 0.005, respectively). However, given the
20% VE at 3 weeks by proportional analysis, overall VE by pro-
portional analysis was considered to be 20%.
Group 4 (2.7 × 105 PfSPZ). First CHMI at 24 weeks after the
last vaccine dose (CHMI #3): 4/5 vaccinees developed para-
sitemia by TBS and qPCR. The ﬁfth was negative by TBS, but
positive by qPCR (see Supplemental Table 10). Therewas one
excluded volunteer (see the previous paragraph). Vaccine ef-
ﬁcacybyproportional analysiswas0%(P>0.99%). Therewas
a signiﬁcant delay in the onset of parasitemia by qPCR in
vaccinees as compared with controls (P = 0.001 by log rank).
α-thalassemia. Volunteers heterozygous for α-thalassemia
were no more likely to be TBS negative and qPCR positive
than volunteers without α-thalassemia (three of 27 versus
three of 34, P = 1.0). Protection from CHMI did not correlate
with α-thalassemia status; 3/37 with normal hemoglobin and
2/29 heterozygous for α-thalassemia were protected.
TABLE 3
Summary of abnormal laboratory values and severity grades
Vaccinees in Group 2
(1.35 × 105 PfSPZ)
(N = 20)
Vaccinees in groups 3
and 4 (2.7 × 105 PfSPZ)
(N = 26) NS controls (N = 8) P values: vaccinees
(N = 46) vs.
controls (N = 8)Laboratory parameter No. % No. % No. %
Leukocytosis 1 5 2 7.7 3 37.5 0.0358
Leukopenia 6 30 7 27 1 12.5 > 0.05
Neutropenia 6 30 5 19 2 25 > 0.05
Lymphopenia 3 15 3 11.5 2 25 > 0.05
Eosinophilia 0 0 2 7.7 3 37.5 0.0194
Decreased hemoglobin 1 5 0 0 0 0 > 0.05
Thrombocytopenia 1 5 0 0 0 0 > 0.05
Elevated creatinine 2 10 4 15.4 2 25 > 0.05
Low total bilirubin 4 20 7 27 1 12.5 > 0.05
Elevated total bilirubin 2 10 2 7.7 2 25 > 0.05
Elevated alkaline phosphatase 1 5 2 7.7 0 0 > 0.05
Elevated alanine aminotransferase 3 15 5 19 2 25 > 0.05
Elevated aspartate aminotransferase 0 0 3 11.5 0 0 > 0.05
PfSPZ=Plasmodium falciparumsporozoites.P valuescalculatedusingFisher’sexact test (2-tailed).Onevolunteerwho receivedsalinedevelopedGrade3eosinophilia attributed toStrongyloides
stercoralis infection, which improved with anthelminthic therapy. This volunteer had a baseline of mild eosinophilia, which persisted throughout the clinical trial. All other laboratory abnormalities
were Grade 2 or less. There was no association between laboratory abnormalities and time after a dose or increasing number of doses. Three abnormalities during immunization were deemed
clinically signiﬁcant or Grade 3. One was diagnosed as benign ethnic neutropenia, one was lymphopenia associated with an infected foot laceration, and one was eosinophilia associated with
Fasciolopsis buskiandS. stercoralis infection. Lymphopenia andeosinophilia resolvedwith treatment. TwoGroup4 volunteers hadasymptomatic hookworm infectionsdiagnosedbefore controlled
human malaria infection; one was coinfected with Enterobius vermicularis.
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Prepatent periods and parasite densities. Although the
median prepatent periods by TBS in controls in each CHMI
group (12.5, 13.0, and 12.0, respectively) were shorter than in
the vaccinees in Groups 2–4 (14.0, 14.0, and 15.3 days, re-
spectively), these differences did not reach the level of sta-
tistical signiﬁcance (P = 0.486, P = 0.491, and P = 0.333,
respectively) (Supplemental Table 9). The prepatent periods
by qPCR in vaccineees in Group 3 (3 and 24week CHMIs) and
Group 4 (24 week CHMI) were signiﬁcantly longer than in the
respective controls (Figure 2D). The parasite densities by
qPCR and TBS at the time of diagnosis for each individual are
in Supplemental Table 10. The median parasite density in
controls versus vaccinees at the timeof ﬁrst positivitywere 0.5
versus 0.4 parasites/μL for qPCR (P = 0.5714) and 11.2 versus
15.0 parasites/μL for TBS (P = 0.1492).
Tolerability and safety of parasitemiaduringCHMI.Controls.
Sixteen controls developed parasitemia by TBS; 9 (56%)
never had symptoms (Supplemental Table 11). Headache
occurred in 7/7 symptomatic individuals. One of two control
volunteers only positive by qPCRdid not have any symptoms;
the second had headache 8 days after qPCR spontaneously
reverted to negative. No volunteer had symptoms at the time
of ﬁrst positive qPCR.
Vaccinees. Thirty-ﬁve immunized volunteers developed
parasitemia by TBS; 20 (57%) never had symptoms. Three
volunteers had temperature > 39.0C; all other clinical mani-
festations were grade 1 or 2. Fever (28.6%) and headache
(31.4%) were most common. Compared with controls, ele-
vated temperature was more common in vaccinees with
positive TBSs (9/35 versus 0/16, P = 0.043). There was no
signiﬁcant difference in the frequency of headache between
controls and vaccinees. In the three volunteers inGroup 2who
were qPCR positive and TBS negative, one developed head-
ache 3 days after qPCR positivity. No volunteer had symp-
toms at the time of ﬁrst positive qPCR.
Clinical laboratories. No unexpected changes were ob-
served following CHMI. Declines in lymphocyte counts were
observed in TBS positive controls and vaccinees (mean de-
cline 1,110 ± 720 cells/μL and 1,180 ± 680 cells/μL, re-
spectively) on day of ﬁrst positive TBS. Absolute lymphocyte
FIGURE 2. Kaplan–Meier survival curves in immunized volunteers vs. controls as assessed by quantitative polymerase chain reaction (qPCR).
Kaplan–Meier curves in volunteers undergoing controlled humanmalaria infection (CHMI) 3weeks after the last of ﬁve doseswith 1.35 × 105 (Group
2) (A) or 2.7 × 105 (Group 3) (B)Plasmodium falciparumSporozoites (PfSPZ) of PfSPZVaccine. Panel (C) volunteers undergoing either ﬁrst (Group 4)
or second (Group 3) CHMI 24 weeks after the ﬁfth immunization with 2.7 × 105 PfSPZ of PfSPZ Vaccine. (D) Vaccine efﬁcacy and prepatent period
results. *This was the second CHMI for the 4 volunteers in Group 3 who were protected after the ﬁrst CHMI at 3 weeks. **One volunteer was
inappropriately treated on day 13 for a false positive TBS. Without this volunteer, 3/3 protected. With this volunteer 4/4 were protected. ***Conﬁ-
dence intervalswere calculatedusingWilson’s score interval. ****Volunteers inCHMI #1and#2 (3weekCHMI inGroups2and3) hadspecimens ﬁrst
acquired on day9. Volunteers in CHMI #3 (24 week CHMI in Groups 3 and 4) had specimens ﬁrst acquired on day 8. This ﬁgure appears in color at
www.ajtmh.org.
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counts less than 1,000 cells/μL were observed in 8/16 and
16/35 TBS positive controls and vaccinees. All lymphocyte
counts returned to the baseline by day 28. There were mild
decreases in platelet counts in TBS positive subjects, but all
platelet counts were > 100 × 103 cells/μL.
Treatment. Volunteers with positive TBSs were treated with
either atovaquone/proguanil (N = 43) or artemether/lumefantrine
(N = 8) within 24 hours of ﬁrst positive TBS. Normal saline and
infectivity controlswhowereTBSnegative (N=2)were treatedat
day 28.
Immunogenicity. Antibody responses. Pf circumsporo-
zoite protein (PfCSP) andPfSPZ. Antibodies against PfCSPby
ELISA 1), PfSPZ by aIFA 2), and PfSPZ by ISI 3) in sera taken
2 weeks after the last vaccine dose and just before CHMI
(20–23 days after the last dose) for Groups 2 (CHMI #1) and 3
(CHMI #2) are in Figure 3A–C. The median responses and
those uninfected and infected by qPCR are shown.
For all three assays,median antibody responses before ﬁrst
CHMI were higher in uninfected than in infected vaccinees.
There was a signiﬁcant difference in median net aIFA
FIGURE 3. Antibody responses toPlasmodium falciparumSporozoites (PfSPZ) andPfCSPbefore controlled humanmalaria infection (CHMI). For
all assays, uninfected subjects are shown as ﬁlled (black) circles and infected subjects are open circles. For each of the deﬁned subject groups, the
interquartile ranges and themedian values of response of subjects in each group are shown. Assessment of antibodies was performed in sera from
subjects before immunization andbeforeCHMI#1 (∼2weeks after the last doseof PfSPZVaccineor normal saline [NS]) and/orCHMI#2 (∼24weeks
after last dose of PfSPZ or NS) (A,D). Antibodies to PfCSP by ELISA are reported as net optical density (OD) 1.0 (the difference in OD 1.0 between
pre-CHMI and preimmunization sera). (B,E) Antibodies to PfSPZ by aIFA are reported as net AFU 2 × 105, the reciprocal serumdilution at which the
ﬂuorescent unitswere2×105 (AFU2×105) in pre-CHMIminuspreimmunization sera. (C,F) Results of inhibitionof sporozoite invasion (ISI) assayare
reported as serumdilution at which therewas 80% reduction of the number of PfSPZ that invaded a human hepatocyte line (HC-04) in the presence
of pre-CHMI as comparedwith preimmunization sera from the same subject. PanelsA–C showgroups 2 (ﬁve doses of 1.35 × 105 PfSPZ) and 3 (ﬁve
doses of 2.7 × 105 PfSPZ) before short-term CHMI (2 weeks after the last dose of PfSPZ or NS) and panelsD–F show those volunteers in Groups 3
(ﬁve dosesof 2.7 × 105 PfSPZ) and 4 (ﬁvedoses of 2.7 × 105 PfSPZ)whounderwent long-termCHMI (24weeks after the last dose of PfSPZ). PanelG
shows net optical density (OD) 1.0 anti-PfCSP antibodies by an enzyme-linked immunosorbent assay (ELISA) comparing vaccinated Tanzanian
volunteers to volunteers in other trials receiving the same regimen. After ﬁve doses of 2.70 × 105 PfSPZ/dose, volunteers in bagamoyo sporozoite
vaccine1 (BSPZV1) (N=25) had a 4.3-fold lowermedian netOD1.0 than those in theU.S.-basedclinical trialWalter ReedArmy Institute ofResearch
(WRAIR) 2080 (N = 26) but a 6.6-fold higher medianOD 1.0 than volunteers in 14-I-N010 in Bamako,Mali (N = 42), wheremalaria transmission rates
are higher. Therewas a signiﬁcant difference between the results forWRAIR2080 vs. BSPZV1 (P= 0.0012),WRAIR2080 vs. 14-I-N010 (P< 0.0001),
and even 14-I-N010 vs. BSPZV1 (P= 0.002) (two-tailed t-test). AFU= arbitrary ﬂuorescence units; aIFA= antibodies by immunoﬂuorescence assay.
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responses between infected and uninfected volunteers in
Group 3 before CHMI #1 (P = 0.0499, Wilcoxon Rank-Sum
Test), but not PfCSP (P = 0.290) or for ISI (P = 0.249).
In sera collected before CHMI #3 (170–171 days after the
last vaccine dose), antibodies by the three assays for Group 4
and for the four volunteers in Group 3 uninfected in CHMI #1
who underwent CHMI #2 are in Figure 3D–F. All data appear in
Supplemental Table 12.
After the ﬁfth dose, in the PfCSP ELISA, volunteers were
considered to have seroconverted if their net OD 1.0 and OD
1.0 ratio calculated, respectively, by subtracting or dividing by
the prevaccination antibody OD 1.0, were ³ 50 and ³ 3.0. By
these criteria, 15/18 volunteers (83%) in Group 2, 20/20
(100%) in Group 3, and 5/5 (100%) in Group 4 seroconverted,
median net OD 1.0 of positives of 1,189, 2,685, and 961, and
median OD 1.0 ratio of positives of 11.50, 21.15, and 37.83,
respectively (Supplemental Table 13). In the aIFA, volunteers
with a net arbitrary ﬂuorescence unit (AFU) 2 ×105 of³ 150 and
a ratio of post- to pre-AFU 2 × 105 of ³ 3.0 were considered
positive (Supplemental Table 13). By these criteria, 17/18
volunteers (94%) in Group 2, 18/20 (90%) in Group 3, and 5/5
(100%) in Group 4 seroconverted, median net OD 1.0 of
positives of 2,844, 1,165, and 1,820, and median OD 1.0 ratio
of positives of 1,193.00, 552.88, and 224.86, respectively
(Supplemental Table 13). For the ISI, volunteers with a net ISI
activity of ³ 10% and a ratio of post- to pre-ISI activity of ³ 3.0
were considered positive. By these criteria, 3/18 volunteers
(17%) in Group 2, 8/20 (40%) in Group 3, and 3/5 (60%) in
Group 4 were positive, median net OD 1.0 of positives of
22.05, 38.92, and 12.44, and median OD 1.0 ratio of posi-
tives of 19.79, 12.53, and 13.44, respectively (Supplemental
Table 13).
Other antigens. Two weeks after the ﬁfth dose in Group 2
(1.35 × 105 PfSPZ) and groups 3 and 4 (2.7 × 105 PfSPZ), there
were antibodies to PfCSP in 15/18 and 25/25 subjects, re-
spectively. Ten of 25 volunteers immunized with 2.7 × 105
PfSPZ made antibodies to Pf apical membrane antigen 1 and
4–16% responded to PfCelTOS, PfMSP5, PfMSP1, or Pf
erythrocyte binding antigen 175 (PfEBA175) (Supplemental
Table 14). The presence of antibodies, albeit at low incidence,
against proteins ﬁrst expressed in late liver stages (PfMSP1
and PfEBA175) was unexpected; results were conﬁrmed by
repeating the assays.No antibody responseswere associated
with protection.
T-cell responses. T cells against liver-stage malaria para-
sites in mice and nonhuman primates immunized with
FIGURE 3. (Continued)
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radiation-attenuated SPZ mediate protection9,29–31 and it is
likely this is the case in humans.12 CD8 and CD4 T-cell re-
sponses generally peak after the ﬁrst vaccination with PfSPZ
Vaccine.13 In this trial, T-cell responsesweremeasured before
immunization, 2weeks after the ﬁrst and 2weeks after the ﬁnal
immunization in Group 2 (1.35 × 105 PfSPZ). For technical
reasons (loss of viability), the other groups could not be
studied.
After the ﬁrst vaccination, the percent of Pf red blood cell
(PfRBC)-speciﬁc and PfSPZ-speciﬁc cytokine-producing
memory CD4 T-cell responses increased by 0.25 ± 0.06
(mean ± SEM) and 0.24 ± 0.04, respectively (Figure 4A, B).
Throughout, “naı¨ve T cell” refers to cells that co-express
CCR7 and CD45RA, and “memory T cell” refers to all other
T cells. After the ﬁnal vaccination, at week 22, the CD4 T-cell
responses were above prevaccine responses by 0.17 ± 0.05
and 0.18 ± 0.05%points, respectively. These responses were
lower than after the same immunization regimen in malaria-
naı¨ve U.S. adults.10
PfRBC-speciﬁcCD8 T cells were not signiﬁcantly above the
prevaccine levels, and PfSPZ-speciﬁc CD8 T cells were
slightly above background (Figure 4C, D); responses were
lower than in U.S. adults.10,12
In contrast to other PfSPZ Vaccine trials,10,12–14 there was
negligible change in the frequency of circulating γδ T cells
(Figure 4E) or activation asmeasured by change in expression
of the activation markers HLA-DR and CD38 following immuni-
zation (Figure 4F). To identify potential explanations for lower
cellular immune responses in Tanzanians, we examined fre-
quency of T regulatory (Treg) cells (CD4+Foxp3+CD25+CD127−)
expressing theactivationmarkerCD137 (alsoknownas4-1BB)32
after stimulation with PfRBC. There was no difference in pre-
vaccine frequency of PfRBC-speciﬁc Tregs in the Tanzanians
ascomparedwithAmericans10 (Figure4G).ConsistentwithCD4
and CD8 T-cell responses, PfRBC-speciﬁc Tregs were highest
after ﬁrst immunization (Figure 4H). Last, the prevaccine fre-
quency of totalmemory T cells relative to total naı¨ve T cells was
signiﬁcantly higher than in Americans (Figure 4I).
DISCUSSION
To our knowledge, this was the ﬁrst assessment of the VE of a
malaria vaccine in Africa against CHMI. Plasmodium falciparum
SPZ Vaccine was well tolerated and safe but less immunogenic
and protective in Tanzanian men than in U.S. volunteers.
In our studies, all 18 controls became infected. Four of 20
(20%) recipients of ﬁve doses of 2.7 × 105 PfSPZ did not be-
come infected after homologous CHMI by DVI 3 weeks after
the last immunization. By contrast, 12/13 (92.3%) volunteers
in the United States who received ﬁve doses of 2.7 × 105
PfSPZ were protected after homologous CHMI by mosquito
bite 3 weeks after the last vaccine dose.11 When the four un-
infected Tanzanian volunteers underwent repeat homologous
CHMI at 24 weeks after the last dose, all four (100%) were
protected. In the United States, Seven of 10 previously pro-
tected volunteers were protected when they underwent ho-
mologous CHMI at 24 weeks11 and all ﬁve volunteers in the
United States who were protected at 21 weeks after the last
immunization (four doses of 2.7 × 105 PfSPZ) were protected
against repeat mosquito-administered CHMI at 59 weeks.12
This could be due to boosting by the small numbers of PfSPZ
administered during the CHMI, or is more likely due to the fact
that in these protected individuals, the protective immune
responses induced by immunization were sustained.
The same exact immunization regimenwas assessed for VE
against intense ﬁeld transmission of heterogeneous Pf inMali.
Vaccine efﬁcacy against infection with Pf on TBSwas 52%by
time to event and 29% by proportional analysis during
24 weeks after the last vaccine dose.14 This was higher than
the VE by proportional analysis against homologous CHMI in
Tanzania. In Tanzania, there was a signiﬁcant delay in the
onset of parasitemia after CHMI at 3 and 24 weeks in subjects
who received ﬁve doses of 2.7 × 105 PfSPZ and were not fully
protected (Figure 2B–D). Nonetheless, the proportional anal-
ysis suggests that homologous CHMI by DVI of a 100% in-
fectious dose of homologous PfSPZ Challenge is at least as
rigorous as a test of VE and potentially more rigorous than
intense ﬁeld transmission of heterogeneous Pf.
Vaccine-induced antibody and T-cell responses in the
Tanzanians were lower than in malaria-naı¨ve Americans who
received the exact samedosage regimen. Twoweeks after the
last dose, themedian antibody responses to PfCSP, themajor
protein on the surface of PfSPZ, were 4.3 times lower in the
Tanzanians than those in Americans (P = 0.0012, Student’s
t-test, 2-tailed),11 but signiﬁcantly higher than in Malians who
received the same immunization regimen (P = 0.002)14
(Figure 3G).
The T-cell responseswere also lower than inAmericans10,12
(Figure 4), but this could only be assessed in PBMCs from
individuals who received the lower dose (ﬁve doses of 1.35 ×
105PfSPZ), not in the individualswho received thehigher dose
(ﬁve doses of 2.7 × 105 PfSPZ), the group that had sustained
protection for 24 weeks. Thus, it is possible that had PBMCs
from the higher dose group been assessed, responses would
have been comparable to the responses in nonimmune
Americans. The Tanzanians who were assessed had a sig-
niﬁcantly higher proportion of total memory T cells compared
with total naı¨ve T cells at the baseline than did the Americans.
This higher frequency of memory cells compared with naı¨ve
cells may explain the lower immunogenicity due to less
available naı¨ve cells for expansion during the vaccinations.
Moreover, the greater frequency of non-Pf–speciﬁc memory
T cells may compete for infected cell contacts during patho-
gen surveillance.33 These data suggest that PfSPZ Vaccine
immunogenicitymaybedependent oncumulative history ofPf
exposure. Another explanation is that an activated immune
microenvironment in the Tanzanians as compared with the
Americans reduced immune responses.34 Helminth infections
have been associated with reduced immune responses to
malaria35; however, the paucity of helminth infections in this
population does not support helminth infection as a cause of
the reduced immune responses.
Therewerenodifferencesbetween vaccineandNSplacebo
recipients in regard to vaccine tolerability or AEs; 97.1%of the
DVI administrations were rated painless and no volunteer
experienced any local AE. Systemic AEs, most commonly
headache, were mild, infrequent, and of short duration, with a
similar frequency in NS controls as in vaccinees (no statisti-
cally signiﬁcant differences in rates).
Among the controls, 16 of 18were positive for Pf by TBS after
CHMI. However, all 18were positive by qPCR. This is consistent
with ﬁndings in Gabon after CHMI.21 It is likely that preexisting
asexual blood stage immunity limits Pf replication in some indi-
viduals. Thus, they never reach the threshold for detection by
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FIGURE 4. Plasmodium falciparumSporozoites (PfSPZ)–speciﬁc T-cell responses in vaccine recipients receiving 1.35 × 105 PfSPZ. (A–D) PfSPZ-
speciﬁc T-cell responses. Frequency of cytokine-producing memory CD4 T cells responding to (A) PfRBC or (B) PfSPZ. Throughout, “naı¨ve T cell”
refers to cells that co-express CCR7 and CD45RA, and “memory T cell” refers to all other T cells. Frequency of cytokine-producing memory CD8
T cells responding to (C) PfRBCor (D) PfSPZ.Results are the percentage ofmemory T cells producing interferon gamma, interleukin 2, and/or tumor
necrosis factor alpha following stimulation minus the percentage of cells following control stimulation. (E) Frequency of the Vδ2+ subfamily of γδ
T cells of total lymphocytes. Results are expressed as fold-change from the prevaccine frequency. (F) γδ T-cell activation in vivo. Data are the
percentage of memory γδ T cells expressing HLA-DR and CD38 as measured on PBMCs following incubation with control stimulation (vaccine
diluent). (G) Prevaccine frequency of PfRBC-speciﬁc Tregs in Tanzania compared with malaria-naı¨ve U.S. subjects from the Vaccine Research
Center (VRC) 314 study. (H) Frequencyof PfRBC-speciﬁc Treg.Results are thepercentage ofCD4+Foxp3+CD25+CD127−Tcells expressingCD137
(also known as 4-1BB) after stimulation with Pf red blood cell (PfRBC) minus the percentage of cells following stimulation with uninfected RBC. (I)
Percentage of total CD4 (left) or CD8 (right) T cells that are naı¨ve (gray bar; CCR7+CD45RA+) or memory (blue bar; not CCR7+CD45RA+) phenotype
assessed prevaccination in all 48 subjects vaccinated in Tanzania or in 14 healthy U.S. subjects from the VRC 314 study.13 For A–F andH,N = 24,
and statistical difference wasmeasured by using theWilcoxonmatched-pairs signed rank test. ForG and I, statistical difference wasmeasured by
using theMann–WhitneyU test.P values are reported as not signiﬁcant (ns), < 0.05 (*), < 0.01 (**), or < 0.001 (***). Data aremean ± SEM. Time points
are prevaccine, 2 weeks after the ﬁrst vaccination, and 2 weeks after the ﬁnal vaccination. Black arrowhead designates PfSPZ Vaccine adminis-
tration. This ﬁgure appears in color at www.ajtmh.org.
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TBS. In our CHMI studies in Bagamoyo, we now use qPCR to
conﬁrm positive TBS, and retrospectively or in real time, assess
parasitemia in all volunteers by qPCR.
We propose that increasing the numbers of PfSPZ per dose
and altering intervals between doses will lead to overcoming
the downregulation of humoral and cell-mediated immunity
most likely because of previous exposure to Pf and thereby
increase immune responses to PfSPZ Vaccine and VE. We
also hypothesize that immune responses in younger, less
malaria-exposed individuals will be of greater magnitude than
those in adults.
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Abstract. Equatorial Guinea (EG) has implemented a successful malaria control program on Bioko Island. A highly
effective vaccine would be an ideal complement to this effort and could lead to halting transmission and eliminating
malaria. Sanaria® PfSPZ Vaccine (Plasmodium falciparum sporozoite Vaccine) is being developed for this purpose. To
begin the process of establishing the efﬁcacy of and implementing a PfSPZ Vaccinemass vaccination program in EG, we
decided to conduct a series of clinical trials of PfSPZ Vaccine on Bioko Island. Because no clinical trial had ever been
conducted in EG, we ﬁrst successfully established the ethical, regulatory, quality, and clinical foundation for conducting
trials.Wenow report the safety, tolerability, and immunogenicity results of the ﬁrst clinical trial in the history of the country.
Thirty adult males were randomized in the ratio 2:1 to receive three doses of 2.7 × 105 PfSPZ of PfSPZ Vaccine (N = 20) or
normal saline placebo (N = 10) by direct venous inoculation at 8-week intervals. The vaccine was safe and well tolerated.
Seventy percent, 65%, and 45% of vaccinees developed antibodies to Plasmodium falciparum (Pf ) circumsporozoite
protein (PfCSP) by enzyme-linked immunosorbent assay, PfSPZ by automated immunoﬂuorescence assay, and PfSPZ
by inhibition of sporozoite invasion assay, respectively. Antibody responses were signiﬁcantly lower than responses in
U.S. adults who received the same dosage regimen, but not signiﬁcantly different than responses in young adult Malians.
Basedon these results, a clinical trial enrolling 135 subjects aged 6months to 65 years has been initiated in EG; it includes
PfSPZ Vaccine and ﬁrst assessment in Africa of PfSPZ-CVac. ClinicalTrials.gov identiﬁer: NCT02418962.
INTRODUCTION
Malaria hasmajor public health signiﬁcance in sub-Saharan
Africa.1 World Health Organization-Global Technical Strategy
has set a goal of eliminating malaria from at least 10 malaria-
endemic countries by the year 2020.2 Development and de-
ployment of new tools such as highly efﬁcacious malaria
vaccines that can interrupt malaria transmission will be es-
sential to achieve this goal. The RTS,S/AS01 candidate
malaria vaccine has shown moderate efﬁcacy against clinical
disease in young children,3 but its limited efﬁcacy against in-
fection and signiﬁcant adverse events (AEs) restrict its use-
fulness for malaria elimination.4,5
Sanaria® PfSPZ Vaccine is a live attenuated Plasmodium
falciparum (Pf ) whole sporozoite (SPZ) vaccine that is cur-
rently being assessed in clinical trials in the United States,
Europe, and Africa. PfSPZ Vaccine has been well tolerated,
safe, and protective against controlled human malaria in-
fection (CHMI) in the United States and against natural ex-
posure to malaria in Mali.6,7 Protection durable for at least
6–14 months has been demonstrated.7–10
A robust malaria control program has been in place on Bioko
Island, Equatorial Guinea (EG) since 2004.11 Using insecticide-
treated bed nets, indoor residual spraying and early diagnosis
and treatment with artemisinin combination therapy,11 the Bioko
Island Malaria Control Program has reduced the average prev-
alence of malaria parasitaemia in the island’s children from 45%
in 2000 to 11.1% in 2016. To capitalize on this success, the EG
Malaria Vaccine Initiative (EGMVI) was established in 2014 to as-
sess the utility of PfSPZ Vaccine to eliminate malaria. EGMVI is
funded by the Government of EG and three U.S. energy compa-
nies, Marathon EG Production Limited, Noble Energy, Atlantic
Methanol Production Company, and EG LNG, and aims to cul-
minate itsactivitieswithan island-widemassvaccinationprogram.
Here we report the ﬁndings from the ﬁrst clinical trial in the
history of EG. This was a phase 1 clinical trial to evaluate the
safety, tolerability, and immunogenicity of three doses of 2.7 ×
105 PfSPZ of PfSPZ Vaccine administered by direct venous
inoculation (DVI) to healthy, malaria-exposed semi-immune
young Equatoguinean men living in a malaria-endemic region
of Bioko Island, EG.
MATERIALS AND METHODS
Clinical trial design. The primary objective of this study
was to assess the safety, tolerability and immunogenicity of
three doses of 2.7 × 105PfSPZof PfSPZVaccine as compared
with normal saline (NS) placeboadministered to healthy young
EquatoguineanmenbyDVI at 8-week intervals. The studywas
conducted at La Paz Medical Center, Malabo, EG. A Safety
Monitoring Committee (SMC) was appointed by the study
sponsor and consisted of three external experts and the local
* Address correspondence to Stephen L. Hoffman, Sanaria Inc., 9800
Medical Center Drive, Rockville, MD 20850. E-mail: slhoffman@
sanaria.com
†These authors contributed equally to this study.
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safety monitor, who was an independent Equatoguinean
physician based in Malabo and accessible during the entire
study period.
The study had three groups with a total of 33 volunteers.
Group 1, the sentinel safety group, included three volunteers
who received 1.35 × 105 PfSPZ followed by 2.7 × 105 PfSPZ of
PfSPZ Vaccine 2 weeks later. The SMC reviewed the data
from Group 1 and then recommended proceeding with vac-
cination of the rest of the volunteers.
For Groups 2 and 3, the study was a phase 1 randomized,
double-blind, placebo-controlled clinical trial. Twenty volun-
teers in Group 2 received three doses of 2.7 × 105 PfSPZ of
PfSPZ Vaccine and 10 volunteers in Group 3 received three
doses of NS at 8-week intervals.
Ethical considerations. Ethical approval was obtained
from the National Ethics Committee of EG, the Ifakara Health
Institute Institutional Review Board, Dar es Salaam, Tanzania,
the MaGil Institutional Review Board in Maryland, USA, and
the Ethical Review Committee of Northwestern and Central
Switzerland. The study was registered at ClinicalTrials.gov
(ClinicalTrials.gov registration number: NCT02418962). The
volunteers were briefed on the speciﬁcs of the planned study,
and then were assessed for their understanding of study
procedures using amultiple-choice questionnaire. Only those
who correctly answered all 10 questions proceeded with the
consenting procedure. All volunteers gave a written informed
consent before any study procedure was done. As EG is a
Spanish-speaking country, approved Spanish-translated in-
formed consent forms were used during the consenting pro-
cess, which was conducted by investigators who were ﬂuent
in Spanish.
Vaccine. PfSPZ Vaccine is composed of aseptic, puriﬁed,
metabolically active, nonreplicating (live, radiation attenu-
ated) cryopreserved PfSPZ.12,13 The vaccine is stored in liq-
uid nitrogen vapor phase at −150C to −196C. Before
administration, PfSPZ Vaccine is thawed and then diluted in
phosphate-buffered saline (PBS) with human serum albumin
to achieve the correct dose.
Study population and enrollment criteria. Volunteers
were healthy male adults between 18 and 35 years of age
recruited from the towns of Baney and Rebola located in
Baney District, Bioko Island. The study area has low malaria
endemicity with estimated prevalence in 2016 of less than 1%
in children aged 2 to 14 years. Volunteers were excluded from
enrollment if they were taking immunosuppressive drugs,
or had 1) clinically signiﬁcant acute or chronic diseases,
2) clinically signiﬁcant abnormalities in electrocardiogram at
screening, 3) plans to travel outside Bioko Island, EG, in the
ﬁrst 9 months of the study, 4) immunosuppressive disorders,
5) a positive blood test for hepatitis B surface antigen
(HBSAg), hepatitis C virus, or human immunodeﬁciency virus
(HIV )-1, or 6) clinically signiﬁcant abnormalities on basic
hematology, hepatic and renal function laboratory tests.
Volunteers with conﬁrmed malaria parasitemia by micros-
copy of Giemsa-stained thick blood smears (sensitivity of
2–4 parasites/μL blood), intestinal parasites by microscopy
of Lugol-stained fecal material (10× objective for detection
and quantiﬁcation and 40× objective for species identiﬁca-
tion), or urinary tract infections were treated and conﬁrmed
cured before they were enrolled into the study. In addition,
volunteers with risk factors for clinically active tuberculosis
plus a positive tuberculin skin test were excluded.
Randomization and vaccination. No randomization was
performed in Group 1 in which all volunteers received PfSPZ
Vaccine. Participants in Group 2 and 3 were randomized in a
ﬁnal ratio of 2:1 to receive threedosesof either 2.7×105PfSPZ
of PfSPZ Vaccine or NS. Randomization was done using a
computer-generated list of randomnumbersbyan independent
statistician from theSwissTropical andPublicHealth Institute.
At enrollment, volunteers were assigned either PfSPZ Vaccine
or NS as speciﬁed in a master randomization list.
PfSPZ Vaccine and NS were administered as a 0.5 mL
volume by DVI using a 1 mL syringe with a 25-gauge needle.
Syringe preparation was done in a biological safety cabi-
net in a pharmacy out of sight of the study physicians
and nurses who evaluated the study end points and of
the study volunteers. Pharmacy personnel preparing
the doses were aware of the treatment assignments, but
took no other part in study-related procedures and were
instructed not to reveal the assignments to either the vol-
unteers or study investigators. The study clinical team was
blinded to treatment.
Deﬁnitions. An AE was deﬁned as any unfavorable or
unintended change in body structure, body function or
laboratory result associated temporally with the study treat-
ment, whether or not it was considered to be related to
the study treatment. A serious AE (SAE) was deﬁned as any
untoward medical occurrence that resulted in death, was
life threatening, required hospitalization or prolongation of
hospitalization, resulted in disability, or was otherwise con-
sidered serious by the investigators. All AEs were classiﬁed
according to the preferred term in the Medical Dictionary for
Regulatory Activities (MedDRA). When the report ﬁled by the
investigator did not clearly correspond to aMedDRA term, the
most appropriate classiﬁcation was clariﬁed in discussion
between the study sponsor and the investigators before
unblinding.
Outcomemeasures. The primary outcomemeasureswere
the occurrence of solicited and unsolicited AEs during a 7-day
and 28-day surveillance period after each vaccination, re-
spectively. SAEs were collected throughout the study period,
which extended 24weeks after the last dose of study product.
Local solicited AEs included erythema, swelling, induration,
pain, and tenderness at the injection site. Systemic solicited
AEs included malaise, nausea, vomiting, abdominal pain,
diarrhea, fever (axillary temperature ³ 37.5C), arthralgia,
myalgia, fatigue, chills, headache, chest pain/discomfort,
shortness of breath, palpitations, and potential allergic re-
actions (wheezing, urticaria, edema/angioedema, hypoten-
sion, anaphylaxis). All solicited local AEs were considered
deﬁnitely related to the study product and solicited systemic
AEs were considered to be possibly or probably related be-
cause of existence of alternative causes.
Safety monitoring. Before being vaccinated, all volunteers
were trained to measure their body temperature using digital
thermometers. After each vaccination, the volunteers were
evaluated for solicited AEs at 15minutes, 1 hour, and 2 hours.
After 2 hours, the volunteers were transported to their homes
where study personnel collected GPS coordinates of their
houses. These were kept in the volunteers’ ﬁles to facilitate
follow-up in case of a missed scheduled visit. All volunteers
were evaluated clinically at the study center 2, 7, 14, and
28 days after each vaccination, and every 4weeks for 24weeks
after the last vaccination. In addition, study physicians called
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the volunteers by telephone on days 1, 3, 4, 5, and 6 after
each vaccination to solicit local and systemic AEs. All vol-
unteers were provided with mobile phones and encouraged
to come to the study center or call the study physician when
they felt unwell. Study physicians evaluated symptoms
identiﬁed at scheduled visits and appropriate management
was provided. In case further care was required, volunteers
were referred to appropriate services at La Paz Medical
Center where high-quality inpatient and outpatient care was
available 24 hours a day, 7 days a week. Clinical evaluations
consisted ofmeasurement of vital signs and assessment for
local injection site and general solicited signs or symptoms.
Blood for safety analyses was collected at screening, be-
fore each vaccination and on days 2, 7, 14, and 28 after
each vaccination, and every 4 weeks for 24 weeks after the
last vaccination. At screening, a complete blood count and
serum biochemistry (alanine aminotransferase [ALT ] and
aspartate aminotransferase [AST ], creatinine, bilirubin,
potassium, sodium, and alkaline phosphatase) were assessed.
At subsequent scheduled visits, a complete blood count
and limited biochemistry (ALT, AST, and creatinine) were
assessed. Biochemistry testswere performed using a Pentra
60C+ and hematological tests were done with a Roche
Cobas Integra 400 Plus.
Solicited local AEswere assessed asmild,moderate, severe,
or life threatening (grades1,2, 3, and4, respectively).Painat the
injectionsitewascategorizedasgrade1:doesnot interferewith
activity, grade2: interfereswith activity or requires repeateduse
of non-narcotic pain reliever > 24 hour, grade 3: prevents daily
activity or requires any use of narcotic pain reliever, or grade 4:
requires hospitalization. Tenderness was graded as grade 1:
mild discomfort to touch, grade 2: discomfort with movement,
grade 3: signiﬁcant discomfort at rest, or grade 4: discomfort
that requires hospitalization. Erythema, swelling, or induration
at the injection site measured at greatest single diameter were
grade 1: > 2.5–5 cm, grade 2: 5.1–10 cm, grade 3: > 10 cm, or
grade 4: presence of necrosis. Solicited systemic AEs were
assessed as mild, moderate, severe, or life threatening (grades
1, 2, 3, and 4 respectively), deﬁned as grade 1: AEs that were
easily tolerated; grade 2: AEs that interfered with daily activity,
grade 3: AEs that prevented daily activity, or grade 4: AEs that
required hospitalization.
The degree to which an AE could be attributed to vaccina-
tion was determined by the principal investigator (PI) with
advice from the rest of the clinical team and categorized as
not, unlikely, possibly, probably, or deﬁnitely related. For the
ﬁnal analysis categories, “not related” and “unlikely related”
were combined into “unrelated.” “Possibly related,” “probably
related,” and “deﬁnitely related”were combined into “related.”
Abnormal laboratory ﬁndings were graded using an FDA-
recommended14 grading scheme adapted to be consistent
with normal ranges in EG, Mali, and Tanzania. Abnormal lab-
oratory tests were assessed as clinically signiﬁcant if they
were associated with clinical symptoms or required medical
intervention or clinically nonsigniﬁcant if there were no asso-
ciated symptoms, and they required no treatment. Information
on any other symptoms, the use of any medications (pre-
scription and/or over the counter), unscheduled medical
consultations, and hospitalizations were also collected. All
aspects of the trial were assessed by a sponsor-appointed
clinical trial monitor, who also reviewed established safety
stopping criteria together with the PI.
Immunogenicity assessment. Antibody responses were
measured on sera obtained from participants before the ﬁrst
vaccination and 2 weeks after the last vaccination.
IgG antibodies to P. falciparum circumsporozoite protein
(PfCSP) by enzyme-linked immunosorbent assay (ELISA).
Antibodies against PfCSP were measured by ELISA at
Sanaria Inc. Brieﬂy, 96-well plates (Thermo Fisher Scientiﬁc,
Rochester, NY) were coated overnight at 4Cwith 2.0 μg/mL
per well of recombinant PfCSP in 50 μL coating buffer (KPL -
Sera Care, Milford,MA). Plateswere washed three times with
2 mM imidazole, 160 mM NaCl, 0.02% Tween 20, 0.5 mM
EDTA, and then blocked with 1% bovine serum albumin
(BSA), blocking buffer (KPL - Sera Care, Milford, MA) con-
taining 1%nonfat dry milk for 1 hour at 37C. The plates were
washed three times and serially diluted serum samples (in
triplicates) were added and incubated at 37C for 1 hour.
After three washes, peroxidase-labeled goat antihuman IgG
(KPL - Sera Care, Milford, MA) was added at a dilution of
0.1 μg/mL and incubated at 37C for 1 hour. Plates were
washed three times, ABTS peroxidase substrate was added
for plate development, and the plates were incubated for
75 minutes at 22C. The plates were read with a Spectramax
Plus384 microplate reader (Molecular Devices, Sunnyvale,
CA) at 405 nm. The data were collected using Softmax Pro
GXPv5 and ﬁt to a 4-parameter logistic curve, to calculate the
serum dilution at OD 1.0. A negative control (pooled serum
from non-immune individuals from a malaria free area) was
included in all assays. The positive control was pooled hu-
man sera taken 2 weeks after the last immunization from 12
volunteers immunized four or ﬁve times with PfSPZ Vaccine
in the VRC 312 clinical trial, who did not develop parasitemia
after CHMI.6 Samples were considered positive if the differ-
ence between the post-immunization OD 1.0 and the pre-
immunization OD 1.0 (net OD 1.0) was ³ 50, and the ratio of
post-immunization OD 1.0 to pre-immunization OD 1.0
was ³ 3.
IgG antibodies to PfSPZ by automated immunoﬂuores-
cence assay (aIFA). In the PfSPZ aIFA, the serum dilution at
which the arbitrary ﬂuorescence units (AFU) was 2 × 105 was
determined at Sanaria. Puriﬁed PfSPZ (NF54 strain) from
aseptic Anopheles stephensi mosquitoes produced by
Sanaria were resuspended in PBS (pH 7.4). Forty microliters
containing 0.5 × 104 PfSPZwere added to eachwell of Greiner
cellstar clear bottom black 96-well plates (Greiner Bio-One
GmbH, Frickenhausen, Germany), the plates were then left at
ambient temperature for 12–18 hour to air-dry. Two-fold serial
dilutions (50 μL/well) of sera, starting at 1:50, diluted in PBS
with 2% BSA were added to each well of the 96-well plate
containing air-dried PfSPZ and incubated at 37C for 1 hour.
The plateswerewashed in PBS three times using anAquamax
Microplate washer. Alexa Fluor 488–conjugated goat antihu-
man IgG (Life Technologies Corporation, Eugene, OR) was
diluted 1:250 in PBS with 2% BSA, and 40 μL were added to
each well. The plates were then incubated for 1 hour at 37C,
washed three times with PBS, and then 100 μL PBS was
added to eachwell. Theplateswere sealedusing aplate sealer
and stored in the dark at 4C until data acquisition. Samples
were assessed by scanning the plates using an Acumen eX3
laser scanning imaging cytometer. The positive control was
the same pooled human sera used for ELISA. The Acumen
image cytometer scans the entire surface area of eachwell in a
96-well plate, and the ﬂuorescence intensity values (arbitrary
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units) therefore represent the signal from all 0.5 × 104 PfSPZ
that were seeded in each well.
Data were plotted to ﬁt a 4-parameter sigmoid curve
in GraphPad Prism software using serum dilution (log trans-
formed) as the xaxis variable andAFUon the yaxis.Overmany
iterations during development of this assay, we have de-
termined that sera from naı¨ve volunteers in the United States
and Europe, including pre-immune sera, always register an
arbitrary ﬂuorescence value less than 2.0 × 105 even at
the highest concentration (1:50 dilution) used in this assay.
Moreover, sera that do react toPfSPZ, 2.0 ×105AFU, fall in the
exponential portion of their sigmoidal curves. Therefore, 2.0 ×
105 has been chosen as a threshold in the aIFA assay, and the
results for each volunteer for antibodies to PfSPZ are reported
as the reciprocal serum dilution at which ﬂuorescence in-
tensity was equal to 2.0 × 105 AFU. For this study, the AFU
values were calculated for sera collected before immunization
and after immunization because individuals pre-exposed to
malaria in EG were expected to harbor antibodies to PfSPZs
before immunization with PfSPZ Vaccine. Sera were consid-
ered positive for seroconversion if their net AFU 2 × 105 and
AFU 2 × 105 ratio, calculated respectively by subtracting the
pre-vaccination from the post-vaccination AFU 2 × 105 and
dividing the post-vaccination by the pre-vaccination AFU 2 ×
105 were ³ 150 and ³ 3.0, respectively.
Functional antibodies to PfSPZ by inhibition of sporozoite
invasion (ISI) assay. HC-04 (1F9) cells (hepatocytes) were
cultured in complete medium (10% FBS in DMEM/F12 with
100 units/mLpenicillin and 100 μg/mL streptomycin; Gibco by
Life Technologies, Grand Island, NY) in (Entactin-Collagen
IV-Laminin) ECL-coated96-well clear bottomblackwell plates
(Greiner Bio-One GmbH, Frickenhausen, Germany) at a den-
sity of 2.5 × 104 cells per well, and incubated for 24 hours at
37C, 5%CO2 with 85% relative humidity. Twenty-four hours
later, cells were infected with 104 aseptic, puriﬁed, cry-
opreserved PfSPZ per well, without or with sera diluted in an
11-point dilution series from subjects immunized with PfSPZ
Vaccine. The assay control included PfSPZ added with media
alone. Sera were assessed at pre-immunization (baseline)
and predetermined time points after immunization. PfSPZ
that had not invaded the HC-04 cells were removed 3 hours
later by washing three times with Dulbecco’s phosphate-
buffered saline, and the cultures were ﬁxed using 4%
paraformaldehyde for 15 minutes at room temperature.
Differential immunostaining was performed to distinguish
between PfSPZ inside the hepatocytes versus PfSPZ out-
side the hepatocytes. PfSPZ outside the hepatocytes were
stained with an anti-PfCSP mAb (2A10, 6.86 μg/mL) (Protein
Potential LLC, with permission from New York University
School ofMedicine) conjugatedwith Alexa Fluor 633 (far-red)
(1 μg/mL; custom-conjugated at GenScript® USA Inc., Pis-
cataway, NJ), a 1:500 dilution. The hepatocytes were then
permeabilizedwith 0.1%Triton X-100 for 15minutes at room
temperature, and the PfSPZ inside the hepatocytes were
stained with the anti-PfCSP mAb (2A10, 6.86 μg/mL) con-
jugated with Alexa Fluor 488 (green; 1 μg/mL, conjugated
from Genscript USA Inc., Piscataway, NJ), a 1:500 dilution.
The numbers and intensity of infected hepatocytes (green
only) were counted by scanning the plates using an Acumen
eX3 laser scanning imaging cytometer. Inhibitory activity at
each serum dilution sera was calculated using the following
formula:
FIGURE 1. Consort diagram for EGSPZV1 clinical trial.
Percent inhibition¼ 100

Fluorescence values of invadedPfSPZ in presence of serum*100
Fluorescence values of invadedPfSPZ inmedia control

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The number of invaded PfSPZ scored in this assay in the ab-
sence of serum was 400–600, giving an intensity of 1–3 × 106
ﬂuorescence units. Data were plotted to ﬁt a 4-parameter sig-
moidcurve inGraphPadPrismsoftware using serumdilution (log
transformed) as the x axis variable and percent inhibition on the
y axis. Eighty percent inhibition was interpolated from the sig-
moidal curves as the reciprocal serum dilution at which the
ﬂuorescence intensity of infected wells with serumwas 20%of
the negative control without serum. The serumdilution atwhich
inhibition of PfSPZ invasion into hepatocytes was 80% as
compared with a negative control without serum was desig-
nated as ISI activity. Sera with a net ISI activity of ³ 10% be-
tween post- and pre-immunization sera and a ratio of post- to
pre-vaccination ISI activity of ³ 3.0 were considered positive.
Statistical analysis. This was a phase 1 clinical trial with no
formal sample size calculation. We compared the proportion
of subjects with AEs as well as frequencies of individual AEs
between vaccination groups recorded from the ﬁrst vaccina-
tion through study conclusion (24 weeks post last vaccination).
The data for local and systemic AEs were grouped by vac-
cination groups and summarized by frequency and severity
of AEs using descriptive statistics. A two-sided Fisher’s exact
test was used to compare the frequency of AEs between
vaccinees and controls. For the immunogenicity analysis,
change from thebaselineof anti-PfCSPantibodieswasplotted
by vaccine group and time points together with the median
and interquartile ranges. Nonparametric statistics (Wilcoxon–
Mann–Whitney test) were used to compare the change of
PfSPZantibody from thebaseline betweenPfSPZVaccine and
NS groups. The Spearman correlation coefﬁcient was used to
assess the association between the results of the different
antibody assays. Fixed effect regression model was used to
TABLE 1
Demographic and baseline characteristics by group of study population
Group 1 PfSPZ Vaccine Group 2 PfSPZ Vaccine Group 3 normal saline
Number of volunteers 3 20 10
Mean age (range) 19.7 (19–20) 20.0 (17–26) 22.9 (18–33)
Mean body mass index (range) 22.5 (20.6–24.8) 23.0 (18.8–28.6) 22.1 (19.5–24.0)
PfSPZ = Plasmodium falciparum sporozoites.
FIGURE 2. Comparison of adverse events (AEs) in volunteers receiving normal saline (NS) and PfSPZ Vaccine. The percent of volunteers with a
speciﬁc AE is depicted. Only a single volunteer had any individual AE after each immunization (maximum of 1/10 [10%] for NS and 1/20 [5%] for
PfSPZ Vaccine). U, V, £, β are individual volunteers. This ﬁgure appears in color at www.ajtmh.org.
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evaluate the effect of PfSPZ Vaccine on hematology (white
blood cells [WBCs], neutrophils, and eosinophils) parameters
taking into account the repeated measurements in each vol-
unteer over time. Data were analyzed using STATA 13.0. Anti-
PfCSP antibody activities were compared between different
clinical trials using a Kruskal–Wallis test followed by a Dunn’s
multiple comparisons test for signiﬁcance between pairs.
These data were analyzed using GraphPad Prism 7.
Genotyping of parasites. One volunteer developed
asymptomatic Pf infection 5 months after the third dose of
PfSPZ Vaccine. The Pf parasites from this volunteer were
assessed by microsatellite analysis15 to determine if the
parasites were derived from PfSPZ Vaccine (PfNF54) or
from a naturally acquired infection. The DNA was isolated
from a blood specimen using Quick-gDNA Blood MiniPrep
Kit (Zymo Research, Irvine, CA). Unlinked microsatellite
markers Poly alpha, PfPK2, TA81, ARA2, TA87, and TA40
were ampliﬁed using heminested PCR.15 Capillary elec-
trophoresis was performed using an Applied Biosystems
3730XL 96-capillary DNA sequencer and software. Capil-
lary electrophoresis output ﬁles were analyzed using
Geneious 8.1.8 software. The detailed protocol is avail-
able on the University of Maryland website (http://www.
medschool.umaryland.edu/malaria/Protocols/). Genomic con-
trol strains NF54, 3D7, 7G8, HB3, and V1S (ATCC-MR4, Man-
assas, VA) were included to determine characteristic peak
morphology for each microsatellite locus and control for slight
variations among runs. Peak sizes were determined bymanual
inspection of each electropherogram and then normalized
against the Genescan™ 600 Liz® size standard (Applied Bio-
systems, Foster City, CA). Normalized peak sizes were com-
pared with those observed for PfNF54.
RESULTS
Study population. Between March and April 2015, 57
adults were screened and of the 40 who met the eligibility
criteria, 33 were enrolled into the study (Figure 1). Three vol-
unteers were enrolled into Group 1, and 30 volunteers were
randomized into Groups 2 (N = 20) and 3 (N = 10). The most
common reasons for exclusion were positive HBSAg and/or
positive HIV tests. Of 57 volunteers screened, helminth in-
fections were diagnosed in 31 (54%). The mean age at en-
rollment was 20 (17–26) years in the PfSPZ Vaccine group and
23 (18–33) years in the control group. All the groups were
generally similar at enrollment with regard to age and body
mass index (Table 1). Of the 33 volunteers, all received all
scheduled immunizations, and 31 (94%) completed all follow-
up visits. Two volunteers failed to complete their follow-up;
one vaccinee traveled abroad for further studies 2 months
after the last vaccination, and one control was lost to follow up
at 5months after the last vaccination. The two volunteerswere
healthy at their last scheduled visits.
Vaccine administration. Vaccinations took place over a
4-month period from March through August 2015. Study
nurses administered the vaccine by DVI. Injection by DVI was
completed in one attempt in 88 of 96 (92%) administrations.
The other eight administrations were completed in two at-
tempts. The nurse performing the injection judged the pro-
cedure as simple in 87 of the 88 (99%) single-attempt
injections. Of 96 administrations, 91 (95%) were judged to be
painless by the volunteers, and ﬁve (5%) were judged to be
associated with mild pain. The entire DVI procedure from the
time of syringe handover to completion of injection took a
mean of 3.80 (1–8) minutes, 2.19 (1–5) minutes, and 2.40 (1–5)
minutes in the safety sentinel, PfSPZ Vaccine, andNS groups,
respectively.
Solicited and unsolicited AEs. No volunteer developed
local or systemic solicited AEs in the sentinel group of three
volunteers who received two vaccinations with PfSPZ Vac-
cine. No local solicited AEs were reported after administration
of any of the three doses of PfSPZ Vaccine and NS in themain
groups. Overall, three of 20 (15%) and one of 10 (10%) vol-
unteers reported a systemic solicited AE after any of the three
doses in the PfSPZ Vaccine and NS groups, respectively
(Figure 2). Of the 11 reported systemic AEs, nine (82%) were
grade 1, and 2 (18%) were grade 2 (one in the PfSPZ Vaccine
and one in the NS group) (Figure 2). All solicited AEs resolved
without sequelaewithin 7days after vaccination. Therewasno
TABLE 2
Number of solicited AEs after an injection in recipients of NS and
PfSPZ Vaccine
AE NS N (%)*
PfSPZ Vaccine
N (%)*
Local (site of injection)
Any AE 0 0
Systemic
Headache 1 (3%) 2 (3%)
Abdominal pain 0 2 (3%)
Chills 0 1 (2%)
Diarrhea 0 1 (2%)
Vomiting 0 1 (2%)
Arthralgia 1 (3%) 0
Fever 1 (3%) 1 (2%)
Myalgia 0 0
Allergic reactions 0 0
Chest pain/palpitations/shortness of
breath
0 0
TOTAL 3 (10%) 8 (13%)
AE = adverse event; N = number of AEs; NS = normal saline; PfSPZ = Plasmodium
falciparum sporozoites.
% = Percentage of injections which gave rise to the AE using number of injections (60
injections for vaccine group, 30 injections for NS group) as denominator. There were no
signiﬁcant differences in the incidence of solicited AEs between recipients of NS and PfSPZ
Vaccine.
* The P value for the Fisher exact test (2-sided) comparing the two groups for each AE and
overall AE rate was > 0.05 for all comparisons.
TABLE 3
Number of unsolicited AEs in recipients of NS and PfSPZ Vaccine
Unsolicited AEs (MedRA term) NS N (%)*
PfSPZ Vaccine
N (%)*
Dental and periodontal infections 1 (6.3%) 3 (18.8%)
Ear and labyrinth disorders 0 (0.0%) 1 (6.3%)
Gastrointestinal disorders 0 (0.0%) 1 (6.3%)
General disorders 3 (18.8%) 1 (6.3%)
Infections and infestations 6 (37.5%) 8 (50.0%)
Injury and procedural complications 2 (12.5%) 0 (0.0%)
Musculoskeletal and connective tissue
disorders
3 (18.8%) 1 (6.3%)
Nervous system disorders 0 (0.0%) 1 (6.3%)
Skin and subcutaneous tissue disorders 1 (6.3%) 0 (0.0%)
Total number of unsolicited AEs 16 16
AE = adverse event; NS = normal saline; PfSPZ = Plasmodium falciparum sporozoites.
There were no signiﬁcant differences in the incidence of unsolicited AEs between recipients
of NS andPfSPZ Vaccine. TheP valueswere calculated on a per volunteer basis (e.g. 3/20 vs.
1/10 for dental and periodontal infections) in a two-sided Fisher’s exact test. All P values
were ³ 0.1.
* The numbers in brackets are calculated as the proportion of the total unsolicited AEs
reported.
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evidence of increasing frequency or severity of reported local
and/or systemic solicited AEs with subsequent doses of
vaccine nor were there reports of anaphylaxis or any other
serious allergic reactions. There was no signiﬁcant difference
in the frequency of solicited AEs between PfSPZ Vaccine and
NS groups (Table 2).
There were 32 unsolicited AEs reported during the study, of
which 27 (84.4%) were mild (grade 1), three (9.4%) were
moderate (grade 2), and two (6.2%) were of severe (grade 3)
severity (Table 3). The two severe unsolicited AEs were perio-
dontitis and toothache. One volunteer completed treatment
of periodontitis and recovered within 16 days. The other vol-
unteer’s severe toothache resolved after 2 days. Subsequent
evaluation revealed that he had pre-existing dental caries.
None of the unsolicited AEs were considered related to the
Investigational Product. All other unsolicited AEs resolved
without sequelae. There was no statistically signiﬁcant dif-
ference in frequency of unsolicited AEs between volunteers
receiving PfSPZ Vaccine and those receiving NS (P = 0.319,
Fisher’s exact test, 2-tailed) (Table 3).
One volunteer developed asymptomatic Pf infection
5 months after the third dose of PfSPZ Vaccine. The volun-
teer was treated with artesunate–amodiaquine, and a repeat
blood smear 7 days later conﬁrmed clearance of para-
sitemia. The microsatellite patterns of the DNA from the
parasites from this individual indicated that the volunteer
was not infected with PfNF54, the Pf strain used to make
PfSPZ Vaccine. The microsatellite analysis indicated that
the volunteer was infected with multiple other strains of Pf.
Overall, no unexpected or SAEs occurred. Furthermore, no
volunteers were withdrawn because of AEs.
Laboratory safety tests. Most of the abnormal hematol-
ogy (WBC and differentials) and biochemistry (serum creati-
nine, ALT and AST) laboratory abnormalities were grade
1 and 2 (Table 4). Eosinophilia was a common laboratory
abnormality, occurring at some point in most volunteers
and often associated with the presence of helminth infec-
tions, which includedAscaris lumbricoides, Trichuris trichiura,
and Schistosoma haematobium. The only grade 3 laboratory
abnormality identiﬁed after vaccination in the main study
groups, an elevated eosinophil count in a PfSPZ Vaccine re-
cipient, was associated with infection with S. haematobium,
and fell to grade 1 after treatment. Transient, grade 1–2 de-
creases in neutrophil counts were also common, but showed
no relationship to administration of PfSPZ Vaccine, occurring
more frequently in control volunteers than vaccine recipients.
Eosinophils and WBCs had a minimal, but signiﬁcant down-
ward trend during the study period in the PfSPZ Vaccine
group, but not in NS controls (data not shown). Elevated ALT
and AST levels, which could theoretically be expected after
the administration of a live PfSPZ vaccine, occurred with
similar frequency in vaccine and control volunteers. In sum-
mary, there were no signiﬁcant trends or group differences in
laboratory parameters indicating a vaccine effect.
Immunogenicity. In the PfCSP ELISA, 14/20 (70%) of
vaccinated subjects and 0/10 (0%) of control subjects
were considered to have become positive as compared
with before immunization (P = 0.0003, Fisher’s exact test,
2-tailed) with a median net OD 1.0 of positives of 890 and
the median OD 1.0 ratio of positives of 9.50 (Table 5).
Among positives, the net OD 1.0 ranged from 136 to 2,414,
and the OD 1.0 ratio ranged from 3.10 to 23.66 (Figure 3A)
( Table 5).
In the aIFA, 13/20 (65%) of vaccinated subjects and 3/10
(30%) of control subjects were considered to have become
positive as compared with before immunization (Figure 3B)
(Table 5) (P=0.12). Amongpositive vaccinees, the net AFU2×
105 ranged from 150 to 647, and the AFU 2 × 105 ratio ranged
from 3.10 to 270 (Table 5). Of the 14 vaccinees who sero-
converted by PfCSP ELISA, only one did not seroconvert by
PfSPZ aIFA (Table 5).
In the ISI, 9/20 vaccinees and 1/10 control subjects were
considered to have become positive as compared with before
immunization (Figure 3C) (Table 5) (P=0.10). All ninewere also
positive by PfCSP ELISA, and 8/9 were positive by the aIFA.
Among positives, the net ISI activity ranged from 11.42 to
63.23 and the ISI activity ratio ranged from 3.14 to 25.63
(Table 5).
TABLE 4
Laboratory abnormalities
Laboratory parameter* Grade abnormality Pilot N (%) PfSPZ Vaccine N (%) Normal saline N (%)
Decreased hemoglobin 1 0 (0%) 0 (0%) 1 (10%)
Decreased platelets 1 0 (0%) 4 (20%) 0 (0%)
Increased WBC count 1 0 (0%) 5 (25%) 2 (20%)
2 – – 1 (5%) – –
Decreased WBC count 1 1 (33%) 5 (25%) 5 (50%
Decreased neutrophils 1 1 (33%) 17 (85%) 8 (80%)
2 – – 1 (5%) 2 (20%)
Decreased lymphocytes 1 1 (33%) 0 (0%) 1 (10%)
Increased eosinophils 1 0 (0%) 14 (70%) 10 (100%)
2 – – 11 (55%) 3 (30%)
3 – – 1 (5%) – –
Elevated ALT 1 1 (33%) 8 (40%) 4 (40%)
Elevated AST 1 0 (0%) 6 (30%) 3 (30%)
2 – – 2 (10%) – –
Elevated total bilirubin 1 0 (0%) 0 (0%) 0 (0%)
Elevated creatinine 1 1 (33%) 0 (0%) 2 (20%)
Hypoglycemia 1 0 (0%) 2 (10%) 0 (0%)
Hyperglycemia 1 1 (33%) 2 (10%) 1 (10%)
2 1 (33%) – – 1 (10%)
ALT=alanine aminotransferase;AST=aspartate aminotransferase; N=number of volunteers experiencing the abnormality; PfSPZ=Plasmodium falciparum sporozoites;WBC=white bloodcell;
% = proportion of the number of volunteers in the group experiencing the abnormality. Number (percent) of volunteers experiencing laboratory abnormalities after vaccination (excluding
abnormalities identiﬁed at screening or prior to the ﬁrst vaccination).
* Abnormal Laboratory Values are deﬁned as grade 1 or higher per the protocol deﬁned toxicity ranges.
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The antibody responses by ELISA (net OD 1.0) and net
ISI activity (80% inhibition of PfSPZ invasion) were posi-
tively correlated 2 weeks after the third dose (r2 = 0.39, P =
0.0033); the samewas true for correlation betweenPfCSPELISA
and net aIFA (r2 = 0.52, P = 0.0003). There was no signiﬁcant
correlation between net aIFA and net ISI (r2 = 0.11, P = 0.16).
We compared the anti-PfCSP responses by ELISA at
2 weeks (United States, Mali, EG) or 4 weeks (Tanzania)
after administration of three doses at 8-week intervals of
2.7 × 105 PfSPZ to adults in EG, to responses to three doses
of 2.7 × 105 PfSPZ administered to adults at 4-week intervals
in Mali7 and Tanzania (Jongo, unpublished data), and in the
United States at 4-week intervals or over 20 weeks8,9
(Figure 4). Responseswere signiﬁcantly lower inMali and EG
than in the United States, and the responses in EG were
signiﬁcantly lower than in Tanzanian young adults who had
minimal exposure to malaria during the previous 5 years.
There was no difference in responses in sera from Mali
and EG.
DISCUSSION
We have conducted the ﬁrst clinical trial in the history of
EG. There were signiﬁcant regulatory, quality, clinical, and
logistical challenges in conducting this trial fully adhering to
the international standards of Good Clinical Practices. A
detailed report of these developments and capacity build-
ing efforts will be published elsewhere. The trial was suc-
cessful in showing that three doses of 2.7 × 105 PfSPZ of
PfSPZ Vaccine were safe, well tolerated, and moderately
immunogenic in healthy 18–35-year-old male Equatogui-
neans living in an area with low malaria exposure.
Almost all the vaccinees and controls indicated that there
was no pain associated with injection of PfSPZ Vaccine by
DVI. There were no differences in the rate of solicited or un-
solicited AEs between the 20 volunteers who received PfSPZ
Vaccine and the 10 who received NS. There were no local
solicited AEs or severe solicited systemic AEs after vaccina-
tion, and only two grade 3 unsolicited AEs were reported
during the trial, both unrelated to investigational product. We
observed no unexpected trends in hematological (hemoglobin,
hematocrit, WBCs, platelets) or biochemical (creatinine, ALT,
AST) laboratorymarkersexcept that eosinophils andWBCshad
a minimal, but signiﬁcant downward trend during the study
period in the PfSPZ Vaccine group, but not in NS controls. We
havenoexplanation for thisﬁnding. Theexcellent reactogenicity
and safety proﬁle in Equatoguineans immunized with PfSPZ
Vaccine is consistent with ﬁndings from Mali7 and Tanzania
TABLE 5
Immune responses in volunteers receiving NS and PfSPZ Vaccine before the ﬁrst immunization and 2 weeks after the third immunization
Group Volunteer ID
ELISA PfCSP OD 1.0 aIFA AFU 2 × 105 ISI reciprocal serum dilution for 80% inhibition
Pre-immune* Immune† Net‡ Ratio§ Pre-immune* Immune† Net‡ Ratio§ Pre-immune* Immune† Net‡ Ratio§
NS 201 188 342 154 1.82 0 73 73 73.00 4.91 21.33 16.41 4.34
222 192 278 86 1.45 0 71 71 71.00 15.31 16.31 0.99 1.06
225 38 37 −1 0.97 73 345 272 4.73 13.72 2.60 −11.13 0.19
232 102 158 56 1.55 54 81 27 1.50 0.00 8.83 8.83 8.83
235 62 158 96 2.55 127 216 89 1.70 13.76 14.11 0.36 1.03
241 167 133 −34 0.80 0 39 39 39.00 9.36 12.88 3.52 1.38
251 654 481 −173 0.74 138 0 −138 0.00 17.43 3.75 −13.69 0.21
253 45 47 2 1.04 19 104 85 5.47 10.17 21.02 10.84 2.07
256 95 210 115 2.21 0 238 238 238.00 13.15 25.61 12.46 1.95
258 39 40 1 1.03 0 372 372 372.00 7.31 7.55 0.23 1.03
Median 99 158 29 1.25 19 93 79 22.24 11.66 13.50 2.26 1.22
PfSPZ Vaccine 203 46 808 762 17.57 0 270 270 270.00 0.00 9.93 9.93 9.93
204 328 551 223 1.68 134 122 −12 0.91 12.51 28.69 16.18 2.29
206 275 412 137 1.50 212 268 56 1.26 16.05 5.75 −10.29 0.36
212 172 1,472 1,300 8.56 18 252 234 14.00 8.60 67.53 58.93 7.85
215 77 603 526 7.83 88 488 400 5.55 0.00 14.06 14.06 14.06
217 85 938 853 11.04 74 470 396 6.35 4.55 20.71 16.15 4.55
218 89 736 647 8.27 82 254 172 3.10 13.55 31.99 18.44 2.36
226 311 381 70 1.23 259 340 81 1.31 5.65 2.44 −3.22 0.43
227 525 536 11 1.02 417 293 −124 0.70 12.67 27.71 15.04 2.19
229 237 1,314 1,077 5.54 127 538 411 4.24 21.80 33.79 11.99 1.55
231 118 1,547 1,429 13.11 84 404 320 4.81 0.00 39.64 39.64 39.64
233 199 1,472 1,273 7.40 59 706 647 11.97 0.00 20.32 20.32 20.32
236 62 198 136 3.19 299 292 −7 0.98 3.07 20.03 16.96 6.52
242 47 755 708 16.06 16 341 325 21.31 21.38 39.39 18.01 1.84
243 188 1,115 927 5.93 0 329 329 329.00 15.27 5.53 −9.74 0.36
244 23 240 217 10.43 0 151 151 151.00 0.00 11.18 11.18 11.18
249 106 219 113 2.07 71 147 76 2.07 10.95 18.46 7.51 1.69
250 47 1,112 1,065 23.66 3 512 509 170.67 21.35 46.07 24.72 2.16
252 236 2,650 2,414 11.23 44 272 228 6.18 8.13 27.76 19.63 3.41
257 42 90 48 2.14 45 107 62 2.38 22.56 19.12 −3.43 0.85
Median 112 746 678 7.61 72 292 231 5.18 9.77 20.51 15.60 2.33
AFU= arbitrary ﬂuorescence units; aIFA= automated immunoﬂuorescence assay; ELISA =enzyme-linked immunosorbent assay; ISI = inhibition of sporozoite invasion assay;NS= normal saline;
PfCSP=Plasmodium falciparum circumsporozoite protein; PfSPZ =P. falciparum sporozoites; Volunteer ID = volunteer identiﬁcation number. Immune responsesweremeasured in all Group 2 and
Group 3 volunteers using PfCSP ELISA, aIFA, and ISI assays. Those in bold were considered to have developed antibodies after immunization.
* Pre-immune sera taken before the ﬁrst immunization.
† Immune sera taken 2 weeks after the last immunization.
‡Net = immune–pre-immune value.
§Ratio = immune/pre-immune value. All values of 0 were changed to 1 when calculating ratios.
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(Jongo et al., unpublished data) where similar doses of
PfSPZ Vaccine were administered. Higher doses of PfSPZ
Vaccine are currently being assessed in infants, children,
and adults in EG.
The tolerability and safety proﬁles are also consistent with
results of multiple other studies of PfSPZ Vaccine,6–10,13
PfSPZ Challenge (live PfSPZ for infection),16–19 and PfSPZ-
CVac (PfSPZ Challenge with an antimalarial drug).20,21 So far,
no breakthrough malaria infections have been observed with
Sanaria’s radiation-attenuated PfSPZ Vaccine. There was no
evidence for local or severe systemicAEs, thought tobedue to
the quality (e.g., purity and sterility) of PfSPZ Vaccine. This
favorable safety and tolerability proﬁle will facilitate compli-
ance if PfSPZ Vaccine is used, as planned,22,23 in mass vac-
cination programs.
PfSPZ Vaccine induced antibody responses to PfCSP and
PfSPZ.However, induction of functional activity assessed by
ISI was modest. The antibody responses in this EG study
were signiﬁcantly lower than in a U.S. study in which the
same immunization regimen was administered, but similar to
antibody responses in a study in a highly endemic area of
Mali (Figure 4). Interestingly, antibody responses were higher
in young adult Tanzanians who were selected for having
had minimal exposure to malaria during the past 5 years
(Figure 4). We hypothesize that long-term exposure to Pf
infections leads to downregulation of immune responses to
PfSPZ Vaccine. It is also possible that an activated immune
microenvironment, compared with that in Americans, re-
duced the antibody responses. This has been shown for a
yellow fever vaccine study in Entebbe, Uganda.24 Additional
studies will be needed to better explain and overcome this
poor immunogenicity.
The baseline rate of helminth infection (54%) was high. The
most common helminths were A. lumbricoides, T. trichiura
andS. haematobium. Helminth infection can impair responses
to vaccines against various diseases,25–27 and speciﬁcally
impaired antibody responses after vaccination with subunit
malaria vaccines inhumans28andmice.29,30 Incontrast, helminth
infection did not affect the immunogenicity and protection of
radiation-attenuated SPZ vaccine inmice.31 The helminth rate at
enrollment was signiﬁcantly lower in Mali (3/93 (3.2%)7 where
antibody responses were similarly low (Figure 4). Thus, we do
not think that active, ongoing helminth infections alone were
responsible for the poor antibody responses. Nonetheless, we
will continue to study the impact of helminth infections on im-
munogenicity and protective efﬁcacy where possible.
Trained study nurses performed all of the DVI injections of
PfSPZ Vaccine and NS. The procedure took little time to learn
or to perform and was largely painless. At the time of writing
this manuscript, > 4,000 injections by DVI of PfSPZ Vaccine,
PfSPZ-CVac,20,21 PfSPZ Challenge,16–19 or NS placebo have
been administered to > 1,900 individuals worldwide, including
infants and children in Tanzania, Kenya, and EG. It is more
challenging to administer by DVI to children less than 2 years
of age than to older children, adolescents, and adults. How-
ever, experience from studies conducted inMali and Tanzania
shows that injection skills improve signiﬁcantly with practice,
and more than 350 5–12-month-old infants have successfully
received PfSPZ Vaccine or NS placebo by DVI. Data from an
ongoing PfSPZ Vaccine study in Kenya including more than
300 infants will provide even more insight into the operational
requirements for DVI in young children and infants.
In conclusion, PfSPZ Vaccine was safe and well tolerated in
young Equatoguinean adults living in an area of low malaria
transmission, but the vaccine induced lower anti-PfCSP an-
tibody responses compared with those in malaria-naı¨ve
adults. Further studies are ongoing to improve the immuno-
genicity through dose escalation. By successfully conducting
the ﬁrst clinical trial in the country’s history, we have laid
the foundation for development of a robust research and
FIGURE 3. Antibody responses 2 weeks after the last vaccination. Responses in all vaccinees and controls who received three doses of PfSPZ
Vaccineor normal salineweremeasuredby (A)Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) enzyme-linked immunosorbent assay
(ELISA), (B) Automated immunoﬂuorescence assay (aIFA), and (C) Inhibition of sporozoite invasion assay (ISI) assay. In the ELISA, antibody
responses are reportedas thenetOD1.0.OD1.0 is the serumdilutionatwhich theoptical density is 1.0, andnetOD1.0 is the differencebetween the
post- and pre-immunization OD 1.0. In the aIFA assay, antibody responses are reported as the reciprocal serum dilution at which the arbitrary
ﬂuorescence units (AFU) were 2 × 105. In the ISI assay, antibody responses are reported as the reciprocal serumdilution that gave 80% inhibition of
PfSPZ invasion. Medians with interquartile ranges are shown.
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development program in EG that will contribute to future
malaria elimination efforts.
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Abstract. In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine
wouldbean ideal additional tool for reducingmalaria’s impact. Sanaria®PfSPZVaccine, composedof radiation-attenuated,
aseptic, puriﬁed, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria-
naı¨ve andexperiencedadults in theUnitedStatesandMali andprotective against controlledhumanmalaria infectionwithPf
in the United States and ﬁeld transmission of Pf in Mali, but had not been assessed in younger age groups. We, therefore,
evaluatedPfSPZVaccine in93Tanzaniansaged45years to6months ina randomized,double-blind,normal salineplacebo-
controlled trial. Therewere no signiﬁcant differences in adverse events between vaccinees and controls or betweendosage
regimens. Because all age groups received three doses of 9.0 × 105 PfSPZ of PfSPZ Vaccine, immune responses were
compared at this dosage. Median antibody responses against Pf circumsporozoite protein and PfSPZ were highest in
infants and lowest in adults. T-cell responses were highest in 6–10-year olds after one dose and 1–5-year olds after three
doses; infants had no signiﬁcant positive T-cell responses. The safety data were used to support initiation of trials in > 300
infants in Kenya and Equatorial Guinea. Because PfSPZ Vaccine–induced protection is thought to be mediated by T cells,
the T-cell data suggest PfSPZ Vaccine may be more protective in children than in adults, whereas infants may not be
immunologically mature enough to respond to the PfSPZ Vaccine immunization regimen assessed.
INTRODUCTION
Despite an annual investment of more than $2.7 billion in
insecticide-treated bed nets, indoor residual spraying, di-
agnosis, and treatment, in 2015, 2016, and 2017 therewere an
estimated 429,000–730,500 deaths each year caused by
malaria1–3; 90% of the mortality was in children under the age
of 5 years. Plasmodium falciparum (Pf) was the cause of more
than 98%of deaths frommalaria andmore than 80%of cases
of malaria in sub-Saharan Africa. Our goal is to ﬁeld a vaccine
that will prevent infection with Pf and thereby prevent all
clinical and pathological manifestations of malaria and halt
parasite transmission from humans to mosquitoes.4
A number of malaria vaccines are under development, but
none have received marketing authorization (licensing) by a
regulatory authority. RTS,S/AS01 has completed Phase 3
clinical trials,5 received a positive opinion (Article 58) from the
European Medicines Agency6 and in 2019, large-scale pilot
implementation trials will be initiated in Kenya, Malawi, and
Ghana to conﬁrm the level of protective efﬁcacy, demonstrate
that the entire immunization regimen can be successfully ad-
ministered, and assess several safety signals seen in thePhase
3 trial (increased meningitis, febrile seizures, and female mor-
tality in vaccinees as comparedwith controls).7,8 A secondpre-
erthrocytic stage vaccineChAd63 andMVAME-TRAPhas also
been studied in African infants to adults.9–11
Sanaria® PfSPZ Vaccine is composed of radiation-
attenuated, aseptic, puriﬁed, and cryopreserved Plasmo-
dium falciparum (Pf) sporozoites (SPZ).12 The vaccine has been
extremely well tolerated and safe inmultiple clinical trials.13–18 In
Mali, Equatorial Guinea, andTanzania, therewasnodifference in
adverse events (AEs) between the PfSPZ Vaccine and normal
saline (NS)control indouble-blind, placebo-controlled trials.18–20
PfSPZ Vaccine has been reported in malaria-naı¨ve adults to
havea vaccine efﬁcacy (VE) of > 90%against controlled human
malaria infection (CHMI)withhomologousPfparasites (samePf
strain in vaccine and CHMI),14,16 80% against CHMI with het-
erologous Pf parasites (different Pf strain in vaccine and CHMI)
3 weeks after the last vaccine dose,14,16 65%and 55%against
homologous CHMI 24,16 and 5915 weeks and 54% against
heterologous CHMI 33 weeks after the last vaccine dose.17 In
Malian adults, VE against Pf infection during the 24weeks after
last vaccine dose was 52% by time to infection analysis and
29% by proportional analysis.18 Protection by immunization
with sporozoites isdependent onTcells inmice andnonhuman
primates13,21–24 and thought to be T cell–dependent in hu-
mans.13 The durable protection demonstrated in the Mali trial
was associated with elevated gamma delta T-cell frequencies,
providing support for this hypothesis.25
However, in Tanzanian adults, ﬁve doses of 2.7 × 106 PfSPZ
had a VE against 3- and 24-week homologous CHMI of
20%.20 This was the same immunization regimen used in the
Mali trial that gave 52% VE and in a trial in the United States
that gave 92% and 65% VE against 3- and 24-week homol-
ogousCHMI.16 In Tanzania, the antibodyandT-cell responses
to PfSPZ in adults were signiﬁcantly lower than in adults in the
United States20; antibody responses in Mali were even
*Address correspondence to Stephen L. Hoffman, Sanaria, Inc., 9800
Medical Center Dr. Suite A209, Rockville, MD 20850. E-mail:
slhoffman@sanaria.com
†These authors contributed equally to this work.
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lower.18We hypothesized that the lower immune responses in
malaria-exposed African subjects as compared with malaria-
naı¨veU.S. subjectswere due to immunedysregulation caused
by long-term exposure to malaria parasites18,20 and that nat-
urally acquired immunity may have reduced the effective
PfSPZ inoculum.We, therefore, proposed that injecting larger
doses of PfSPZmight partially overcome these effects. This is
in part because when humans are immunized with radiation-
attenuated PfSPZ administered by mosquito bite,26 PfSPZ
Vaccine14,15,17,27 and PfSPZ-CVac27 protection is dose de-
pendent.26 Thus, increasing immune responses by increasing
the dose should increase VE. Thus, in this study, we increased
the dose of PfSPZ Vaccine from 2.7 × 105 PfSPZ to 9.0 × 105
PfSPZ and 1.8 × 106 PfSPZ.
All previous studies of PfSPZVaccine have been conducted
in adults. However, the major burden of malaria is in older
infants and children. The present study was the ﬁrst to assess
the tolerability, safety, and immunogenicity of PfSPZ Vaccine
in adolescents, children, and infants aged 6months and older
and the ﬁrst to compare these results with those of adults.
Furthermore, we hypothesized that infants and young children
with little previous exposure to Pf parasites would have more
robust immune responses to the vaccine than adults, recog-
nizing that the infants’ immunological systems might not be
fully mature, particularly for T-cell responses.28
MATERIAL AND METHODS
Study design and population. This single-center, age de-
escalation, double-blind, randomized, placebo-controlled
trial (ClinicalTrials registration no. NCT02613520) was con-
ducted in Bagamoyo, Tanzania, betweenDecember 2015 and
March 2017. It had two major components, an age de-
escalation, dose escalation component to assess safety, tol-
erability, and immunogenicity of PfSPZ Vaccine (part A), and a
CHMI component to assess VE (part B). Herein, we report the
results of part A.
One hundred seventy-three healthy male and female vol-
unteers aged 6 months to 45 years were recruited from the
Bagamoyo region through locally presented sensitization
meetings. After an initial screening, prospective volunteers
were invited to the Bagamoyo Clinical Trial Unit (BCTU) of the
Ifakara Health Institute (IHI) to complete the informed consent
process and further screening.
Informed consent was obtained from all volunteers or the
parents/legal guardians after the nature and risks of the study
were explained. Following this, the adult volunteers or the
parent/legal guardian of child volunteers were required to
complete a 10-question assessment with a 100% correct
response rate on the ﬁrst or second attempt to demon-
strate understanding of the study procedures (Supplemental
Table 1) to be eligible for enrollment. In addition, all children
and adolescents aged 9–18 years providedwritten assent and
children aged 6–8 years provided oral assent. Volunteerswere
screened using predetermined inclusion and exclusion crite-
ria based on clinical examinations and laboratory tests
(Supplemental Tables 2 and 3). Medical history was analyzed
to exclude any past or presentmedical problem in conjunction
with a detailed clinical examination. Laboratory testing in-
cluded hematology, biochemistry, urinalysis, and parasitol-
ogy testing to include malaria thick blood smear (TBS), stool
for intestinal helminth infections, and urine for Schistosoma
haematobium. Tests for HIV and hepatitis B and C were per-
formedonlyafterpretestcounselingwascarriedout; volunteers
were excluded if positive and referred for further evaluation and
management. Volunteers were excluded if they had signif-
icant abnormalities on electrocardiograms. The complete
eligibility criteria are published at https://clinicaltrials.gov/
show/NCT02613520.
The trial was performed in accordance with good clinical
practices. The protocol was approved by institutional review
boards (IRBs) of the IHI (Ref. No. IHI/IRB/ No: 32-2015), the
National Institute for Medical Research Tanzania (NIMR/HQ/
R.8a/Vol.IX/2049), and the Ethikkommission Nordwest- und
Zentralschweiz, Basel, Switzerland (reference number 15/
104). The protocol was also approved by the Tanzania Food
and Drug Authority (Auth. No. TZ15CT013), registered at
ClinicalTrials.gov (NCT02613520) and conducted under a
U.S. Food and Drug Administration Investigational New Drug
application (FDA IND) application.
Intervention and randomization. Volunteers spanning ﬁve
age groups were sequentially allocated to 11 different dose
groups and randomly assigned to receive PfSPZ Vaccine or
NS in a 2:1 ratio. Twelve additional, age-matched, adult vol-
unteerswere enrolled as nonimmunized infectivity controls for
CHMI studies.
The details of each of ﬁvemain age groups (Groups 1–5) are
outlined in Table 1. Immunizationbeganwith the adults (Group
1a, 9.0 × 105 PfSPZ and Group 1b, 1.8 × 106 PfSPZ) and
continued progressively to teenagers (11–17 years; Group 2a,
9.0 ×105PfSPZandGroup2b, 1.8× 106PfSPZ), older children
(6–10 years; Group 3a, 9.0 × 105 PfSPZ and Group 3b, 1.8 ×
106 PfSPZ), younger children (1–5 years; Group 4a, 4.5 × 105
PfSPZ and Group 4b, 9.0 × 105 PfSPZ), and infants (6–
11 months; Group 5a, 2.7 × 105 PfSPZ, Group 5b, 4.5 × 105
PfSPZ, andGroup 5c, 9.0 × 105PfSPZ). Only after the safety of
a given PfSPZ dose had been demonstrated in an older age
group was the same or a lower dose tested next in a younger
age group (age de-escalation). Likewise, within each age
group, safety was demonstrated with a lower PfSPZ dose
before immunizations began with a higher PfSPZ (dose es-
calation). At three time points during age de-escalation and
dose escalation, a three-member external Safety Monitoring
Committee reviewed safety reports and provided a recom-
mendation to proceed to the next study group.
Using this staggered approach, 10 subgroups of nine indi-
viduals received three doses of PfSPZ Vaccine at 56-day in-
tervals (days 1, 57, and 113), each comprising six vaccine and
three placebo volunteers randomized in a 2:1 ratio to PfSPZ
Vaccine or NS control. An exception was Group 5a (Table 1),
an 11th subgroup comprising three infants constituting the
ﬁrst ever recipients less than 1 year of age to receive injections
with PfSPZ Vaccine. This safety-only pilot group was admin-
istered a single reduced dose of PfSPZ Vaccine (2.7 × 105
PfSPZ); therewasno randomization andnoplacebo control. All
of the other 90 volunteers and the entire clinical teamexcluding
the pharmacy staff were blinded to treatment assignment, with
blinded status maintained throughout the study period.
Investigational product (IP). The IP used in this trial,
Sanaria PfSPZ Vaccine,12–19 consists of aseptic, puriﬁed,
vialed, metabolically active, nonreplicating (live, radiation at-
tenuated) cryopreserved PfSPZ stored in liquid nitrogen vapor
phase at −150 to −196C. Preparation of IP was done under
the supervision of the study pharmacist, who was not blinded
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to the study treatment for each volunteer. Vials of PfSPZ
Vaccine were thawed and diluted with phosphate-buffered
saline containing human serum albumin and the appropriate
numbers of PfSPZ in a ﬁnal volume of 0.5mL and drawn into
a 1-mL syringe. A volume of 0.5 mL of NS was similarly
drawn into a 1-mL syringe for placebo recipients. Dilution
and syringe preparation were performed under aseptic
conditions in a biological safety cabinet. The pharmacist
then handed the appropriate syringe for the speciﬁc study
subject to the blinded nurse through a window. Recon-
stituted PfSPZ is a clear, odorless, nonviscous liquid in-
distinguishable from NS. PfSPZ Vaccine or NS was
administered by direct venous inoculation (DVI) through a
25 G × 16-mm needle. In infants and young children, there
was an option to administer the vaccine through a 24-gauge
peripheral intravenous catheter.
Assessment of vaccine safety, tolerability of DVI, and
AEs. After vaccination, volunteers under the age of 18 years
were observed at the BCTU for approximately 24 hours during
which enquiry of AEs and focusedphysical examinationswere
performed at 1, 6, and 12 hours after vaccination and at the
time of discharge. Adult volunteers were observed at the
BCTU for approximately 2 hours during which enquiry of AEs
and focused physical examinations were carried out at 1 hour
after vaccination and at the time of discharge. Volunteerswere
given diaries and thermometers for recording of AEs and
temperatures thereafter. Volunteers were seen for safety
follow-up visits 2, 7, and 14 days after vaccination, with ad-
ditional follow-up visits by telephone on days 3–6 (and Day 1
for adults). Children and infants were also evaluated again 28
and 56 days after the ﬁnal immunization.
Local (site of injection) signsandsymptomswere solicited in
the 2 days following vaccination for adults, teenagers, and
older children (groups 1–3) or 7 days following vaccination for
younger children and infants (groups 4 and 5). Systemic signs
and symptoms were assessed for 7 days for all groups
(Supplemental Table 4). In addition, open-ended questioning
was used to identify unsolicited AEs through day 28
postimmunization.
During the period of follow-up, all solicited and unsolicited
events were recorded and graded by the attending physician
as follows: mild (no effect on activities), moderate (some in-
terference with normal activity), severe (prevented normal
activity and required medical intervention), life-threatening
(hospitalization, immediate medical intervention, or therapy
required to prevent death), or death. Axillary tempera-
ture was recorded as Grade 1 (> 37.9–38.4C), Grade 2
(> 38.4–38.9C), Grade 3 (> 38.9–40.0C), or Grade 4
(> 40.0C). Hematological and biochemical abnormalities
were also assessed at prespeciﬁed intervals as deﬁned in the
toxicity table of the study protocol, including prevaccination
and 7 days postvaccination.
Malaria parasite diagnosis.All participantswere screened
for malaria parasites at baseline and before vaccination by
TBS microscopy and retrospectively by quantitative poly-
merase chain reaction (qPCR). Slide preparation and reading
for TBS’s were performed according to standard proce-
dures.29 The theoretical limit of detection of TBS was 2 para-
sites/μL (0.5 μL blood examined) for standard reads and 0.5
parasites/μL (2.0 μL blood examined) for expanded reads
done when a volunteer was symptomatic. Quantitative poly-
merase chain reaction analyseswere basedonDNAextracted
from 180 μL whole blood and ampliﬁcation of the pan-Plas-
modium 18S gene30 and the Pf-speciﬁc telomere-associated
repetitive element 231 following essentially the published
procedures. The 18S gene DNA qPCR had a sensitivity of 50
parasites/mL. Plasmodium malariae (Pm) cases were identi-
ﬁed by a qPCR species identiﬁcation assay using Pm-speciﬁc
ampliﬁcation of plasmepsin 4 as described.32
Genotyping of parasites.DNA fromPf-positive samples was
used to genotype the parasites based on Pf Merozoite Surface
Protein-1 (PfMSP-1) and PfMSP-2 gene polymorphisms33 as
well as seven microsatellite markers.34 All Pf strains were
compared with the Pf vaccine strain (NF54).
TABLE 1
Vaccine and control groups by age, vaccine dose, dosing schedule, number of doses, and total number of Plasmodium falciparum sporozoites
(PfSPZ)
Groups Age (years) Subgroups details N PfSPZ/dose Dosing schedule (weeks) No. doses Total PfSPZ
Group 1 18–45 1a Vaccinees 6 9 × 105 0, 8, 16 3 2.7 × 106
NS controls 3 NS 0, 8, 16 3 0
1b Vaccinees 6 1.8 × 106 0, 8, 16 3 5.4 × 106
NS controls 3 NS 0, 8, 16 3 0
Group 2 11–17 2a Vaccinees 6 9 × 105 0, 8, 16 3 2.7 × 106
NS controls 3 NS 0, 8, 16 3 0
2b Vaccinees 6 1.8 × 106 0, 8, 16 3 5.4 × 106
NS controls 3 NS 0, 8, 16 3 0
Group 3 6–10 3a Vaccinees 6 9 × 105 0, 8, 16 3 2.7 × 106
NS controls 3 NS 0, 8, 16 3 0
3b Vaccinees 6 1.8 × 106 0, 8, 16 3 5.4 × 106
NS controls 3 NS 0, 8, 16 3 0
Group 4 1–5 4a Vaccinees 6 4.5 × 105 0, 8, 16 3 1.35 × 106
NS controls 3 NS 0, 8, 16 3 0
4b Vaccinees 6 9.0 × 105 0, 8, 16 3 2.7 × 106
NS controls 3 NS 0, 8, 16 3 0
Group 5 6–11 months 5a Vaccinees 3 2.7 × 105 0 1 2.7 × 105
5b Vaccinees 6 4.5 × 105 0, 8, 16 3 1.35 × 106
NS controls 3 NS 0, 8, 16 3 0
5c Vaccinees 6 9 × 105 0, 8, 16 3 2.7 × 106
NS controls 3 NS 0, 8, 16 3 0
Total 93
NS = normal saline.
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Antibody assays. Sera were assessed for antibodies by
enzyme-linked immunosorbent assay (ELISA) to the major
protein on the surface of sporozoites (Pf circumsporozoite
protein [PfCSP]), immunoﬂuorescence assay (aIFA) to air-
dried PfSPZ, and inhibition of sporozoite (PfSPZ) invasion
(aISI) of HC-04 cells (hepatocytes) as described.27
T-cell assays.T-cell responses in cryopreservedperipheral
blood mononuclear cells (PBMCs) were assessed by ﬂow
cytometry as described.15
Statistical analysis. The sample sizes of three to six vac-
cinees in each age group dosage group, 12–15 vaccinees in
each age category, and six controls in each age categorywere
selected to be appropriate for the initial assessment of safety,
tolerance, and immunogenicity of an investigational vaccine.
Categorical variableswere summarized using absolute (n) and
relative (%) frequencies. Continuous variables were summa-
rized usingmean and SD,median, and range. Comparisons of
categorical variables between groups were analyzed using
Barnard’s two-sided exact unconditional test, or a two-sided
Mantel–Haenszel test stratifying by age group. No corrections
were made for multiple comparisons because of the early
phase nature of this trial. Analyses of immunological data are
described with the data. A P value < 0.05 was considered
signiﬁcant. All data analyses and statistical computations
were conductedwith SAS software, version 9.3 or higher (SAS
Institute, Inc., Cary, NC) or GraphPad Prism, version 7.02
(GraphPad Software, LaJolla, CA).
RESULTS
Study population, experience with DVI, and tolerability.
A total of 105 Tanzanian volunteers (Figure 1) met the criteria
(Supplemental Tables 2 and 3) and were enrolled. Ninety-three
received either PfSPZ Vaccine (n = 63) or NS (n = 30) (Table 1).
The remaining 12 volunteers participated as infectivity controls
in the subsequent challenge portion (CHMI) of the protocol and
are not part of the analyses in this article. There were no sig-
niﬁcant differences between participants in any age group for
age, height, weight, or body mass index (BMI) (P > 0.05 for all
comparisons, one-sided analysis of variance (ANOVA)
(Table 2). All 93 volunteers received all scheduled immuniza-
tions. One volunteer in group 5b received only a partial vaccine
dose with the second immunization; all other volunteers re-
ceived the complete 0.5-mL injection at all time points.
Of 273 total injections, 234 were completed with a single
injection (85.7%); 225 of these (96.2%) were assessed as
simple to perform by the nurse performing the injection. In
volunteers aged £ 5 years old, DVI was successful on the ﬁrst
attempt in 25 of 39 for ﬁrst dose, 26 of 36 for second dose, and
31 of 36 for the third dose. The option to establish intravenous
access with an intravascular catheter was used for 12 ﬁrst
injections in volunteers £ 5 years old, and one ﬁrst injection in a
6–10-year old. An intravenous catheterwasusedonly once for
a second injection in an infant and was not used during the
third roundof injections, consistentwith evidenceof a learning
curve with the DVI technique in infants and young children.
Pain from DVI was assessed in volunteers aged 6–45 years
(groups 1a, 1b, 2a, 2b, 3a, and 3b); 157 of 161 injections
(97.5%) were associated with mild or no pain (Supplemental
Table 5).
Safety. A global summary of solicited AEs is provided in
Table 3. Among the 63 volunteers who received 183 doses of
PfSPZ Vaccine, one Group 1b adult volunteer who received
1.8 × 106 PfSPZ reported three solicited local AEs (tenderness
and pain after ﬁrst dose and tenderness after second dose); all
were Grade 1 in severity and resolved within 2 days. No soli-
cited local AEs were reported among the 30 volunteers after
receiving 90 doses of NS. Solicited systemic AEs were de-
tected after 3/183 injections of PfSPZ and 0/90 injections of
NS. All 16 AEs occurred in a single Group 2b volunteer (age 11
years) who received a dose of 1.8 × 106 PfSPZ. All AEs were
Grade 1 except elevated temperatures, which were Grade 2.
Symptoms included chills and feverishness after two of the
three injections with fatigue, headache, malaise, and elevated
temperature of 38.5C after all three injections. The AEs oc-
curred 12–24 hours after each immunization and resolved
within 24 hours. This individual had no change in total white
blood cell or absolute neutrophil counts or biochemistry val-
ues 2 days after each immunization but did have amild decline
in total lymphocyte counts that did not go below the lower limit
of normal on Day 2 after each immunization. No other vaccine
recipient experienced a systemic solicited AE. The local AEs in
the one adult and the systemic AEs in the one adolescent are
delineated in Figure 2. No signiﬁcant differences were found
between vaccinees and placebo recipients with respect to
systemic or local event rates whether assessed as overall
rates or speciﬁc rates for each type of AE (P = 0.60 for all by
Barnard’s test).
Twenty of 63 vaccinees (31.7%) experienced 30 unsolicited
AEs (0.48/individual) during the 28 days after each immuniza-
tion (Table 3). All unsolicited AEs were identiﬁed as unlikely
related to administration of IP. Three unsolicited AEs were
moderate (Grade 2) and one (the serious adverse event [SAE]
described subsequently) severe (Grade 3) in severity; all others
weremild (Grade 1). Ten of 30 controls (33.3%) experienced 13
unsolicited mild (Grade 1) AEs (0.43/individual) during this pe-
riod. Two episodes of fever in one volunteer (Group 4a, age 3
years receiving 4.5×105PfSPZ), occurring14and19days after
the ﬁrst dose of NS, were determined to be possibly related to
study product during the blinded safety assessment. Details of
the unsolicited AEs can be found in Supplemental Table 6.
One SAE was reported in a 2-year-old volunteer (Group 4a)
receiving 4.5 × 105 PfSPZ Vaccine who was hospitalized with
multiple injuries after she was struck by a motorcycle. She
subsequently recovered and completed participation in the
study.
Four volunteers developed parasitemia during the immu-
nization period. Three infections in adults were detected
retrospectively by qPCR (Supplemental Table 7); these indi-
vidualswere TBSnegative throughout this period of the study.
Two of the three cases were Pm infections and one case was
Pf, the latter conﬁrmed by genotyping to differ from the NF54
strain of Pf used in the vaccine (Supplemental Table 8). The
two individuals with Pm were determined retrospectively to be
positive byqPCRat the timeofﬁrst immunization and remained
positive during the entire 16-week immunization period until
treated after the third immunization. The individual with Pf in-
fection was negative at the time of the ﬁrst immunization, de-
veloped Pf infection before the second immunization, and
remained positive until treated after the third immunization. All
three volunteers were treated with artesunate–amodiaquine
once the polymerase chain reaction results were known. A
fourth volunteer, from Group 5 (ages 6–12 months), who re-
ceivedNS, was positive by qPCR for Pf genotypically distinct
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from the NF54 vaccine strain (Supplemental Tables 7 and
8) before the ﬁrst and second immunizations; parasitemia
in this infant was detected in real time by TBS before the
second immunization, leading to immediate treatment with
artemether–lumefantrine (Supplemental Table 7). No signs
of illness were reported by the mother for this infant, who
continued in the trial.
No clinically signiﬁcant laboratory abnormalities were at-
tributed to PfSPZ (Supplemental Table 9). The most com-
monly identiﬁed abnormalities listed in order of prevalence
included anemia, lymphopenia, and leukopenia, with no dif-
ference in frequency across age groups or between vaccine
recipients and NS controls in each age group. Two volunteers
experienced a Grade 3 laboratory abnormality: an isolated
FIGURE 1. Volunteer participation (CONSORT 2010 Diagram). Once allocated, no volunteers were removed, lost to follow-up, or excluded from
analysis. This ﬁgure appears in color at www.ajtmh.org.
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occurrence of lymphopenia in a Group 1b adult volunteer
28 days after the ﬁrst dose of 1.8 × 106 PfSPZ in association
with a concomitant viral infection, and neutropenia in a Group
5b volunteer receiving 4.5 × 105 PfSPZ determined to have
benign ethnic neutropenia. Both abnormalities resolved
without sequelae.
Antibody responses to Pf. Antibodies against PfCSP by
ELISA, PfSPZ by aIFA, and PfSPZ by aISI in sera taken before
immunization and2weeksafter last vaccinedoseare shown in
Supplemental Table 10, Figure 3, and Supplemental Figure 1
for vaccinees and Supplemental Table 11 for controls.
In the PfCSP ELISA, volunteers were considered to have
made a positive response if their net optical density (OD) 1.0
(Figure 3A–C) and OD 1.0 ratio (Supplemental Figure 1A–C),
calculated, respectively, by subtracting or dividing by the
prevaccination antibody OD 1.0, were ³ 50 and ³ 3.0, re-
spectively. By these criteria, 59/60 vaccinees developed an-
tibodies to PfCSP. The only volunteer who did not have a
positive response to immunization was a 20-year old who
received the 9.0 × 105 PfSPZ regimen (Supplemental
Table 10). The overall highest responses were in 6–10-year
olds who received 1.8 × 106 PfSPZ and had a median net OD
1.0 of 34,793 and median net OD 1.0 ratio of 15,515
(Supplemental Table 8). Only 2/30 of the NS controls, both
infants, developed antibodies to PfCSP (Supplemental
Table 11).
In the aIFA, volunteers with a net arbitrary ﬂuorescence unit
(AFU) 2 × 105 of ³ 150 (Figure 3D–F) and a ratio of post- to pre-
AFU 2 × 105 of ³ 3.0 (Supplemental Figure 1, panels D-F) were
considered to have made a positive response. By these cri-
teria, 57/60 volunteers made a positive response to immuni-
zation. The three volunteers who did not make a positive
response were 1 year, 7 months, and 9 months of age at the
time of ﬁrst injection and received the 9.0 × 105, 4.5 × 105, and
9.0 × 105 PfSPZ dosing regimens, respectively (Supplemental
Table 10). As with the PfCSP ELISA, the overall highest
TABLE 3
Global adverse event (AE) summary
Vaccine (N = 63) Placebo (N = 30)
All AEs
Possibly, probably, or
deﬁnitely related AEs All AEs
Possibly, probably, or
deﬁnitely related AEs
No. of volunteerswith at least one solicitedAEwithin
7 days of immunization (%)
2 (3.2%) 2 (3.2%) 0 (0.0%) 0 (0.0%)
Total no. of solicited AEs (maximum severity grade) 19 (Grade 2)* 18 (Grade 2)* 0 (NA) 0 (NA)
No. of volunteers with a solicited Grade 3 AE (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
No. of volunteers with at least one solicited local AE 1 (1.6%) 1 (1.6%) 0 (0.0%) 0 (0.0%)
Total no. of local AEs (maximum severity grade) 3 (Grade 1) 3 (Grade 1) 0 (NA) 0 (NA)
No. of volunteerswith at least one solicited systemic
AE (%)
1 (1.6%) 1 (1.6%) 0 (0.0%) 0 (0.0%)
Total no. of systemic AEs (maximum severity grade) 16† (Grade 2)* 15† (Grade 2)* 0 (NA) 0 (NA)
No. of volunteers with at least one unsolicited AE
within 28 days of immunization (%)
23 (36.5%) 0 (0.0%) 10 (33.3%) 1 (3.3%)
Total no. of unsolicited AEs within 28 days of
immunization (maximum severity grade)
34 (Grade 3) 0 (NA) 11 (Grade 1) 2 (Grade 1)
No. of volunteers with an unsolicited Grade 3 AE (%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
No. of volunteers experiencing an SAE (%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Total no. of SAEs (maximum severity grade) 1 (Grade 3) 0 (NA) 0 (NA) 0 (NA)
SAE = serious adverse event.
* The only Grade 2 AE was elevated temperature.
† All solicited systemic AEs occurred in a single individual.
FIGURE 2. Proportion of volunteers experiencing solicited adverse events (AEs) during the 7 days after each immunization. Ninety-one of 93
volunteers injected at least once experienced no solicited AEs during the 7 days after each immunization. One volunteer experienced threeGrade 1
local AEs (yellow bar) and one volunteer experiencedGrade 2 temperature elevation (38.5C) after each immunization accompanied bymild (Grade
1) chills, fatigue, headache, and malaise (blue bar). These AEs are further described in the text. This ﬁgure appears in color at www.ajtmh.org.
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responses were in 6–10-year olds who received the 1.8 × 106
PfSPZ regimenandhadamediannetAFU2×105of20,099and
mediannetAFU2×105 ratioof16,539 (SupplementalTable10).
Noneof theNScontrolsdevelopedantibodies toPfSPZbyaIFA
(Supplemental Table 11).
In the automated inhibition of sporozoite invasion assay
(ISI), volunteers with a net ISI activity of ³ 10% (Figure 3G–I)
and ratio of post to pre-ISI activity of ³ 3.0 (Supplemental
Figure 1, panels G-I) were considered positive. By these cri-
teria, 37/60 volunteers had a positive response to immuniza-
tion. The only group with a 100% response rate (6/6) was the
11–15-year olds who received the 1.8 × 106 PfSPZ regimen.
This group also had the highest median net 80% ISI activity
(41.3) andmedian net 80% ISI activity ratio (26.8). Only 2/30 of
the NS controls developed antibodies to PfSPZ by aISI, a
38 and a 13-year old (Supplemental Table 11).
Adults (18–35 years), teenagers (11–15 years), and older
children (6–10 years) received the 1.8 × 106 PfSPZ dosage
regimen, and these age groups and the younger children (1–5
years) and infants (7–11months) received the 9.0 × 105 PfSPZ
regimen; the younger children and infants also received the
4.5 × 105 the PfSPZ regimen. We, therefore, assessed the
effect of age on immunogenicity. This is shown graphically
using net values in Figure 3 and for ratios in Supplemental
Figure 1 and in Supplemental Tables 10 and 11. For the 1.8 ×
106 PfSPZ dosage regimen, the adults had the lowest anti-
body responses by all assays. The older children had the
highest responses in the PfCSP ELISA and aIFA and teenagers
FIGURE 3. Difference between postimmunization and preimmunization antibody results. Antibody assay results by dose in Plasmodium falci-
parum circumsporozoite protein enzyme-linked immunosorbent assay (A–C), immunoﬂuorescence assay (D–F), and inhibition of sporozoite
invasion (G–I) assays. Results were obtained by subtracting preimmune values from the values obtained from sera drawn 2 weeks after the third
dose. For the 9.0 ×105Plasmodium falciparum sporozoite dose (B,E, andH), previously assessed results fromclinical trial VRC314,17 conducted in
the United States with the same dosage regimen and in the same laboratory with the same assays as in the BSPZV2 trial assays, are shown as a
comparison. For theVRC314 trial17 the ﬁlled in circles indicateprotectedvolunteers and theemptycircles theunprotected volunteers.Medianswith
interquartile ranges are shown.
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for the aISI. For the 9.0 × 105 PfSPZdosage regimen, the adults
had the lowestmedian netOD1.0,median net AFU2×105, and
median net 80% ISI responses, and the lowest ratios for PfCSP
ELISA and aISI; infants had the highest responses for all of
these assays. For the median AFU 2 × 105 ratio, the teenagers
had the best response. For the 9.0 × 105 PfSPZ dosage regi-
men, themedianOD1.0 andmedianOD1.0 ratios in the PfSPZ
ELISA were 10.2 and 165.7 times higher in the infants as
compared with the adults. For the aIFA, they were 11.0 and 3.3
times higher and for aISI, they were 4.1 and 6.3 times higher,
respectively (Figure 3, Supplemental Figure 1, Supplemental
Table 10). Because of the small sample sizes (N = 6) and vari-
abilitywithin each group, the differences did not quite reach the
level of statistical signiﬁcance.
Adults, teenagers, and older children received the 1.8 × 106
or 9.0 × 105 regimens. For all three assays, the response to the
1.8 × 106 regimen was higher than the response to the 9.0 ×
105 regimen (Figure 3, Supplemental Figure 1, Supplemental
Table 10). Younger children and infants received the 9.0 × 105
and 4.5 × 105 regimens. For all three assays, the response to
the 9.0 × 105 PfSPZ regimen was higher than the response to
the 4.5 × 105 regimen in infants. However, for the younger
children, this was not the case (Figure 3, Supplemental
Figure 1, Supplemental Table 10).
In previous clinical trials with PfSPZ Vaccine in adults in
the United States with no previous exposure to malaria,
there has been a signiﬁcant correlation between the three
different antibody assays14–17 in sera taken 2 weeks after
the last dose of vaccine. In this clinical trial, we assessed the
correlation between the assays for sera taken 2 weeks after
the third (last) dose of vaccine from 60 volunteers. There
was a signiﬁcant correlation between the results of the
PfCSP ELISA and the aISI (R2 = 0.45, P < 0.0001). The
correlations between PfCSP ELISA and aIFA (R2 = 0.05,
P = 0.085) and aIFA versus aISI (R2 = 0.01, P = 0.40) were
not signiﬁcant.
Having demonstrated that median antibody responses in
Tanzanian infants were consistently higher than in Tanzanian
adults, we compared the Tanzanian responses to those in
adults in the United States who received three doses of
9.0×105PfSPZ (Figure3B,E,andH).Medianantibodyresponses
in U.S. adults and Tanzanian infants were, respectively:
1) 13,174 and 14,335 for PfCSP ELISA, 2) 8,176 and 6,131
for aIFA, and 3) 36.05 and 16.34 for aISI.
T-cell responses to PfSPZ. T-cell responses to PfSPZ
were assessed by polychromatic ﬂow cytometry on cry-
opreserved PBMCs acquired before immunization, 2 weeks
after theﬁrst doseofPfSPZVaccine and2weeksafter the third
dose of vaccine in subjects who received three doses of 9.0 ×
105 PfSPZ of PfSPZ Vaccine (Figure 4 and Supplemental
Table 12). Following the ﬁrst dose of PfSPZ Vaccine, 18–45-
year olds, 11–17-year olds, and 6–10-year olds all had sig-
niﬁcant increases in the frequency of cytokine-producing
memory CD4 T cells compared with the prevaccination time
point. However, only the 6–10-year-old group had a 100%
response rate to the vaccine. In addition, the responses in the
6–10-year-old group were signiﬁcantly higher than those in
the 1–5-year-old and 6–11-month-old groups, but not signif-
icantly different than the responses in the other groups (as
assessedby theKruskal–Wallis testwithDunn’s correction for
multiple comparisons). Following the third vaccination, only the
1–5-yearoldshadasigniﬁcant increaseover theprevaccination
time point. Infants did not have a signiﬁcant increase in
CD4 T-cell responses at any time point. At no time point were
PfSPZ speciﬁc memory CD8 T-cell responses detected over
background in any group.
DISCUSSION
Before this study, aseptic, puriﬁed, cryopreserved PfSPZ-
based products (Sanaria PfSPZ Vaccine, PfSPZ Chal-
lenge, and PfSPZ-CVac) had only been injected into
adults.13–19,27,29,35–41 This was the ﬁrst study to assess the
safety, tolerability, feasibility, and immunogenicity of any
PfSPZ-based product in adolescents, children, or infants.
Because no licensed vaccine against an infectious agent is
administered by DVI, there was initially a concern in the vac-
cinology community about the safety, tolerability, and feasi-
bility of administering PfSPZ-based products byDVI to adults.
Clinical trials in the United States, Germany, Spain, Mali,
Tanzania, and Gabon established that rapid administration by
DVI of PfSPZproducts in 0.5mLof diluent through a 25-gauge
needle was safe, extremely well tolerated, straightforward,
and protective.16,18,27,38,39,41 After establishing the safety,
tolerability, and feasibility of PfSPZ administration by DVI in
adults, therewasstill concern thatDVI administrationofPfSPZ
might be problematic in younger age groups as no pre-
ventative vaccine has ever been administered by intravenous
injection (IV)/DVI to these age groups. This concern was not
borne out by the ﬁndings of the present study.
There were no signiﬁcant differences in solicited AEs be-
tween vaccinees in any age group (N = 63) and corresponding
controls (N=30)who receivedNS (P=0.6). Furthermore, there
were no differences in AEs between different dosage regi-
mens, no differences between age groups, and no differences
between the ﬁrst, second, and third immunizations. PfSPZ
Vaccinewas extremelywell tolerated.Wehave no explanation
for the symptoms and elevated temperature experienced by
the 11-year-old girl after all three injections, which resolved
within 24 hours of each immunization. This has not occurred in
any subject in any other clinical trial of PfSPZ Vaccine; we will
monitor for this pattern in future trials.
Moreover, the administration process itself (DVI) was ex-
tremely well tolerated. Six- to 45-year olds were questioned
about pain after each injection. Direct venous inoculation was
associated with mild or no pain for 157 of 161 injections
(97.5%); 129 of 161 injections (80.1%) were associated with
no pain (Supplemental Table 5).
There was no signiﬁcant difference in the feasibility of ad-
ministration of PfSPZ (or NS placebo) to adults, adoles-
cents, 6–10-year olds, or 1–5-year olds. Administration was
achieved with the ﬁrst needle stick in 53/54 (98%) adminis-
trations in 18–45-year olds, 51/54 (94%) administrations in
11–17-year olds, 47/54 (87%) administrations in 6–10-year
olds, and 47/54 (87%) administrations in 1–5-year olds
(Supplemental Table 5). Administration success with one
needle stick decreased to 35/57 (61%) injections in infants
(Supplemental Table 5).However, in infants, the learning curve
of the nurses administering the vaccine was rapid. In infants,
DVI was successful on the ﬁrst attempt in nine of 21 (43%) for
ﬁrst dose, 11 of 18 (61%) for second dose, and 15 of 18 (83%)
for the third dose. The option to establish intravenous access
with an intravascular catheter was used for 12 ﬁrst injections
(nine infants), but only once for a second injection (one infant)
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and was not used during the third round of immunizations,
consistent with evidence of a learning curve with the tech-
nique when administering to infants.
The levels of antibodies to PfCSP by ELISA were 31 times
lower in adults in Mali than in U.S. adults and 4.3 times lower
in adults in Tanzania,20 who received the exact same im-
munization regimen.18 We hypothesized that this was due to
immunoregulation after long-term exposure to Pf infections
and that in malaria-endemic areas, antibody responses
would be higher in children and infants who had less expo-
sure to Pf than in adults with long-term exposure. Naturally
acquired immunity may also have affected the viability of the
sporozoites, and this also is most highly developed in adults
with long-term exposure. However, the levels of antibody
preimmunization and in the placebo controls were quite low,
arguing against this explanation for reduced immunogenicity
(Supplemental Tables 10 and 11). Results from this study are
consistent with the hypothesis that reduced immune re-
sponses in semi-immune African as compared with non-
immune American adults was due to immunoregulation after
long-term exposure to Pf infections, and that in malaria-
endemic areas antibody responses would be higher in chil-
dren and infants who had less exposure to Pf than in adults
with long-term exposure. Themedian antibody responses by
PfCSP ELISA, PSPZ aIFA, and PfSPZ aISI were highest in
infants and lowest in adults (Figure 3), and the antibody re-
sponses in infants were comparable with the antibody re-
sponses seen in adults in the United States who received the
identical immunization regimen (Figure 3). However, differ-
ences among age groups did not quite reach the level of
statistical signiﬁcance because of the small sample size and
the variance. Ongoing studies will establish whether this age
effect is consistent and signiﬁcant.
T-cell responses against PfSPZ have been demonstrated in
malaria-naı¨ve adults immunized with PfSPZ Vaccine in the
United States14,16 and in a previous study of PfSPZ Vaccine in
adults in Tanzania,20 but they were much lower in Tanzania
than in the United States after administration of the same
immunization regimen. In this trial, there were no CD8 T-cell
responses against PfSPZ detected. However, signiﬁcant in-
creases in peripheral CD4 T-cell responses were seen in all
age groups except infants after in vitro stimulation with PfSPZ
(Supplemental Table 12). The median adult responses were
about six times lower than they were after immunization with
the same regimen in the United States (Figure 4).17 Consistent
with all of our trials, the best responses in adults, 11–17-year
olds, and 6–10-year olds were seen after the ﬁrst dose of
PfSPZ Vaccine14–17 with the highest responses in 6–10-year
olds. We have previously hypothesized that the reason peak
T-cell responses are highest after the ﬁrst dose is that after the
ﬁrst dose the functionally important T cells are resident in the
liver and, thus, are not detected in the periphery.14 However,
after the third dose of PfSPZ Vaccine, the only signiﬁcant re-
sults were in 1–5-year olds; this was the best response
recorded for this age group. Perhaps, because of immuno-
logical immaturity, it took longer to prime 1–5-year olds, and if
they were administered more priming doses earlier, they
would have better responses. Infants did not have any evi-
dence of induction of T-cell responses. Such poor T-cell re-
sponsiveness in infants has also been observed following
hepatitis B and oral polio vaccinations.42,43 This is likely based
on the fact that T-cell repertoires in neonates and infants are
FIGURE 4. Plasmodium falciparum sporozoites (PfSPZ)-speciﬁc memory CD4 T-cell responses pre- and postvaccination. Percent of memory
CD4 T cells in the blood expressing interferon gamma (IFN-γ) interleukin 2 (IL-2) or tumor necrosis factor alpha (TNF-α) at preimmunization or 2
weeksafter the ﬁrst and third dosesof PfSPZVaccine (9.0×105). Results are thepercentageof cytokine-producingcells after incubationwithPfSPZ
minus the percentage of cytokine-producing cells after incubation with vaccine diluent (medium with 1% human serum albumin). Bars indicate
median valueswithin each group. Differenceswithin each age group between pre- and postvaccination groupswere assessedby two-wayANOVA
with Dunnett’s correction for multiple comparisons. *P < 0.05, **P < 0.01, ****P < 0.0001. Previously measured results from clinical trial VRC 31417
conducted in theUnitedStateswith the samedosage regimen and the sameassay conducted in the same laboratory as for theBSPZV2 trial assays
are shown as a comparison. This ﬁgure appears in color at www.ajtmh.org.
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skewed toward Th2-type responses.44–48 Since PfSPZ Vac-
cine is thought to rely primarily on T-cell responses tomediate
protection,14,15,17,49 the T-cell studies may indicate that chil-
dren, but not infants, will be protected by the immunization
regimen (three doses at 8-week intervals) used in this study.
We are now exploring priming regimens in which multiple
doses of PfSPZ are administered during the ﬁrst week,27 and
this may prove to be a more powerful method of priming and
could thereby overcome the poor T-cell responsiveness we
have identiﬁed in infants. However, we recognize that we will
be breaking new ground here, as to our knowledge, there are
no data in infants for any vaccine that this can be done. In
addition, we will explore the impact of booster doses during
the ﬁrst or second years of life, and we are developing an
adjuvant that may be useful.
By establishing the safety, tolerability, and feasibility of
administration of PfSPZ Vaccine to children and infants, this
trial was an important prelude to clinical trials in more than
300 infants being conducted in Kenya (ClinicalTrials.gov
NCT02687373) and Equatorial Guinea (ClinicalTrials.gov
NCT02859350). It also supported our long-term plans to use
PfSPZ Vaccine in mass vaccination programs (MVPs) to focally
eliminate malaria. Because high population coverage will be
needed to halt transmission, any vaccine intended for this pur-
pose must be extremely safe, easy to administer, and minimally
painful for the vaccinee, in all age groups. As there was no dif-
ference in the rate of AEs or laboratory abnormalities between
any vaccine group and placebo recipients and because 97.2%
of volunteersoldenough toevaluatepainexperiencednopainor
onlymild painduringadministration, PfSPZVaccine appeared in
the present study to be highly suitable for use in MVPs.
The results demonstrated that 6–10-year olds and 1–5-year
olds have the highest CD4 T-cell responses after the ﬁrst and
third doses of PfSPZ Vaccine, respectively. These ﬁndings
raise hope that the vaccine will be more protective in children
than it was in adults in Mali.18 This will soon be assessed in
1–12-year olds in Gabon. However, because no T-cell re-
sponses were identiﬁed in infants, we are concerned about
infants’ immunological capacity to mount protective T-cell
responses after this immunization regimen of PfSPZ Vaccine.
This is now being assessed in the Kenya study, and if it holds
up, wemay have to alter the immunization regimen (number of
PfSPZ per dose, number of doses, and interval between
doses). If this is not successful, we would likely initiate im-
munization only after the ﬁrst year of life. PfSPZ Vaccine is
intended to be used inMVPs to halt transmission of Pf and not
in a routine infant immunization program (Expanded Program
for Immunization). In such MVPs, we would cover the infants
with antimalarial drugs until they reached 1–2 years of age
when immunizations with PfSPZ Vaccine would begin.
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Abstract 
 
Controlled human malaria infections (CHMI) provide the opportunity to study immunologi-
cal responses to infection and parasite-host interaction in a controlled setting. We used the 
data from 159 individuals who participated in CHMI conducted in two different malaria en-
demic settings to characterise the impact of malaria pre-exposure on the parasites’ multiplica-
tion rate (PMR). Compared to malaria-naïve German volunteers, in Tanzanian and Equato-
Guinean volunteers, the parasite’s ability to replicate in the blood was significantly reduced. 
Among these volunteers, the PMR was especially low if they recently cleared parasitaemia 
from an ongoing P. falciparum single infection or P. falciparum and P. malariae co-
infection. We used CHMI data to investigate the impact of a repeated homologous CHMI on 
the PMR of P. falciparum parasites during a follow up second CHMI conducted in individual 
volunteers. A reduction in PMR was only observed if during the first CHMI blood-stage par-
asites were detected. Furthermore, the reduction in PMR resulted in an overall lower peak 
parasitaemia and subsequently less symptomatic volunteers. This data indicates the develop-
ment of stage-specific parasite growth reducing immune effector mechanisms. 
 
Keywords 
Controlled human malaria infection (CHMI), quantitative polymerase chain reaction (qPCR), 
thick blood smear (TBS) microscopy, Plasmodium falciparum, PfSPZ Challenge, diagnosis, 
immunity 
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Introduction 
 
Despite a significant global decline in malaria prevalence and reduction of mortality between 
2010 and 2017, malaria remains a global public health issue with an estimated 219 million 
cases which resulted in 435 000 deaths in 2017 (1). Control interventions such as the distribu-
tion of long-lasting insecticidal nets and indoor residual spraying programs as well as wide-
spread and rapid access to diagnostic testing and treatment have proven to be successful. But 
with the ultimate goal of malaria eradication new approaches, including safe and effective 
vaccines are needed (2). Controlled human malaria infection (CHMI), the deliberate inocula-
tion of volunteers with Plasmodium spp. sporozoites by mosquito bite or syringe and needle 
is increasingly being used to assess the efficacy of experimental malaria vaccines and con-
tributes to an acceleration in malaria vaccine development (3). 
During CHMI, the volunteers are closely monitored for signs and symptoms of malaria. Para-
sitaemia in whole blood is rigorously monitored and volunteers are treated before they devel-
op high parasitaemia levels and severe symptoms. Historically, the appearance of blood-stage 
parasitaemia was diagnosed using thick blood smear (TBS) microscopy while recently the 
more sensitive quantitative polymerase chain reaction (qPCR) is used as a primary diagnostic 
test in CHMI. Several CHMI conducting research sites have discussed the use and in particu-
lar the advantages of qPCR-based monitoring of parasitaemia in malaria-naïve (4–8) and pre-
exposed individuals (7, 9, 10). In summary, the implementation of qPCR in CHMI improves 
safety while reducing the clinical burden and costs without compromising the evaluation of 
protective efficacy for pre-erythrocytic vaccine candidates (4). 
CHMI studies are not only useful for the evaluation of vaccine candidates but also provide 
the opportunity to study parasite-host interactions in a highly controlled setting. Although, 
conducting CHMIs in malaria endemic regions would allow earlier assessment of vaccine 
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efficacy in target populations and provide insight into the immunological responses associat-
ed with naturally acquired immunity (NAI) (11), the vast majority of CHMI has been con-
ducted in malaria-naïve volunteers (12). In the past, the challenge to conduct CHMI in Africa 
was attributed to lack of high security facilities rearing P. falciparum-infected Anopheles 
mosquitoes (13). This obstacle had been overcome by Sanaria’s aseptic, purified, cryo-
preserved P. falciparum sporozoites (PfSPZ Challenge) that are highly infectious (14). In 
2012, a study in Tanzania showed for the first time that inoculation of malaria pre-exposed 
volunteers with PfSPZ Challenge is safe, well tolerated and highly infective (13). These find-
ings were later confirmed in studies conducted in Kenya (10) and Gabon (15, 16) and Mali 
(unpublished) where adult volunteers from malaria endemic regions were successfully infect-
ed with PfSPZ Challenge. 
Although the exact mechanisms of NAI are still poorly understood, it is thought that repeated 
infection with P. falciparum leads to the development of NAI mediated by a broad range of 
antibodies directed against blood-stage antigens which have the ability to limit parasite repli-
cation (17–19). The parasite multiplication rate (PMR), the fold change in number of para-
sites in the blood over one life cycle, has been used to characterize NAI in recent studies (10, 
15, 20, 21). PMR can be calculated based on the qPCR-derived parasite densities measured 
during the pre-patent periods of CHMI (22).  
In this study we describe parasitological data obtained from CHMI studies conducted in Tan-
zania and Equatorial Guinea to characterize the impact of malaria pre-exposure on the para-
sites’ multiplication rate and ability to diagnose P. falciparum.  
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Material and Methods 
 
Controlled Human Malaria Infection 
Parasitological and clinical data presented in this publication was obtained from CHMI used 
to assess PfSPZ Vaccine efficacy in five studies conducted in Tanzania and Equatorial Guin-
ea. Standardized CHMI protocols were used in all five studies with 3200 aseptic, purified, 
cryopreserved PfNF54 P. falciparum sporozoites (PfSPZ Challenge) administered by direct 
venous inoculation. The time point of sporozoite inoculation (herein referred to as CHMI) 
was defined as day 0. The period of active parasitemia monitoring, the days post CHMI when 
volunteers were admitted to the ward (herein referred to as ward period), varied between the 
different studies. For BSPZV1 (Clinical Trials.gov: NCT02132299), samples were collected 
twice daily from day 9 to 14 and once daily from day 15 to 21 after PfSPZ Challenge inocula-
tion. For BSPZV2 (Clinical Trials.gov: NCT02613520) and BSPZV3 (Clinical Trials.gov: 
NCT03420053), samples were collected twice daily from day 8 to 14 and once daily from 
day 15 to 20 after PfSPZ Challenge inoculation. For EGSPZV2 (Clinical Trials.gov: 
NCT02418962), samples were collected twice daily from day 8 to 14 and once daily from 
day 15 to 20 after PfSPZ Challenge inoculation followed by sample collection on alternate 
days until day 28. During the EGSPZV3 study (Clinical Trials.gov: NCT03590340) addition-
al samples were collected at day 6 and 7, before the sampling schedule of the EGSPZV2 
study was followed. At day 28 (BSPZV1, BSPZV2, BSPZV3 and EGSPZV3) or day 56 
(EGSPZV2) all TBS microscopy negative volunteers were treated with antimalarial drugs. 
Adverse events during the CHMI ward period were assessed for relationship to P. falciparum 
infection and considered related if the event was within 3 days before and 7 days after TBS 
microscopy was first positive. 
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Collection, processing and storage of blood samples for malaria diagnosis 
For all parasitological analysis, including TBS microscopy, qPCR and backup storage, 2 mL 
of EDTA-anticoagulated whole blood was collected and aliquoted. The aliquot for TBS mi-
croscopy was immediately processed and the aliquot for qPCR analysis was frozen at –80 °C 
until further processing. DNA was extracted manually from 180 μL whole blood and eluted 
with 50 μL Elution Buffer using Quick-DNA Miniprep Kit (Zymo Research, Irvine, CA). 
 
Thick blood smear microscopy 
In all five studies, TBS microscopy was performed following the same standard operating 
procedure as previously described (13). Briefly, 10 µL of blood was placed uniformly on a 1 
cm x 2 cm area of the slide, air dried, and stained with Giemsa, pH 7.2. Routine assessment 
of asymptomatic volunteers required the microscopist to read 6 passes (1 cm each) with the 
100x objective, which equals to approximately a blood volume of 0.5 µL. If the volunteer 
was symptomatic, a total of 24 passes of the slide was read corresponding to 2 µL of blood. A 
blood smear was declared positive when one reader saw two parasites in 0.5 µL of blood and 
the presence of parasites was independently confirmed by a second reader. This corresponds 
to a theoretical limit of detection (LOD) of 4 parasites/µL. Microscopists were trained and 
evaluated before each study and only highly qualified microscopists were allowed to read 
slides during CHMI studies. 
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Molecular diagnostic using qPCR 
Parallel to TBS microscopy, qPCR was used to determine and quantify parasitaemia. qPCR 
analysis was conducted on site and in real-time during the CHMI ward period. Since the trials 
were conducted in regions where non-falciparum Plasmodium species are endemic, our ap-
proach included both, a pan-species Plasmodium spp. and a P. falciparum-specific assay. For 
the first two trials (BSPZV1 and BSPZV2) we used two independent qPCR assays. A probe-
based duplex assay, amplifying the pan-species Plasmodium spp 18S rDNA (Pspp18S) (23) 
and as an internal control the human rnasep gene (HsRNaseP) was applied to the samples, 
followed by screening with an EvaGreen-based assay detecting the P. falciparum-specific 
telomere-associated repetitive element 2 (PfTARE2) (24). For the following studies 
(BSPZV3, EGSPZV2 and EGSPZV3) the diagnostic qPCR procedure was simplified and 
workload reduced by switching the P. falciparum-specific target to the acidic terminal se-
quence of the var genes (PfvarATS) (24). This allowed us to use a single qPCR assay for 
screening of Plasmodium spp. and P. falciparum parasites and therefore increased sample-to-
result turnaround by reducing the qPCR time significantly. All parasite densities are ex-
pressed as number of parasites per mL blood. P. ovale spp. and P. malariae parasites were 
identified as described elsewhere (25). Detailed information concerning molecular diagnostic 
assays used is provided in Table S1.  
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Data management and analysis 
The Cq values were obtained from the Bio-Rad CFX96 software and in case of the BSPZV1, 
BSPZV2 and EGSPZV2 studies, transferred to a Microsoft Access database designed for 
storage and analysis of qPCR data. For the BSPZV3 and EGSPZV3 studies, the Cq values 
were transferred and analysed to the ELIMU-MDx platform (manuscript in preparation). 
Parasite Multiplication Rate (PMR) was modelled using a linear model fitted to log10-
transformed qPCR data as previously published (22). PMR was calculated for all volunteers 
that developed blood-stage parasitaemia which lasted for at least two 48-hour cycles. Parasite 
densities based on the P. falciparum-specific qPCR assays, PfTARE2 or PfvarATS, were 
used to calculate PMRs. Data was analysed and plots created using R version 3.5.1 based on 
packages dplyr, ggpubr, gridextra and scales.  
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Results 
 
Data collection from malaria pre-exposed volunteers who developed blood-stage parasi-
taemia upon CHMI 
In two different malaria-exposed populations, one in East Africa (Bagamoyo, Tanzania) and 
one in Central-West Africa (Malabo, Equatorial Guinea), the efficacy of the PfSPZ Vaccine 
was assessed using CHMI. In this publication we combined the volunteers who developed 
blood-stage parasitaemia from both clinical trial sites to describe the CHMI associated blood-
stage growth dynamics of P. falciparum in malaria-exposed volunteers. In total, 90 Tanzani-
an volunteers participating in three clinical trials and 69 volunteers from Equatorial Guinea 
participating in two clinical trials were included in the analysis. 18 volunteers from Germany 
were used as a reference group for malaria-naïve volunteers (Table 1). Notably, all forty-six 
Tanzanian and five out of six Equato-Guinean volunteers who served as placebo controls in 
the PfSPZ Vaccine studies developed blood stage parasitaemia detectable by qPCR providing 
an overall infectivity rate of 98.0% (50/51). Sub-microscopic infections, parasitaemia not 
seen by thick blood smear microscopy, were observed in 9.4 % (15/159) of volunteers. Ma-
laria treatment was initiated 15.6 days (median and range: 15 [10-28 days]) after CHMI re-
sulting in a time period of 6.1 days (median and range: 5.5 [1.4-21.0 days]) of pre-patent pe-
riod which was used to study the parasite growth dynamics. 
 
 
 
  
 Chapter II – Malaria pre-exposure and P. falciparum multiplication rate  77 
Diagnosis of P. falciparum during CHMI using TBS microscopy and qPCR 
Primary study outcome was parasitaemia measured by TBS microscopy which was used to 
initiate treatment and therefore terminate the CHMI. The qPCR-derived parasitaemia at 
CHMI endpoint (TBS positivity) was compared between the German, Tanzanian and Equato-
Guinean volunteers (Fig 1A). Compared to Tanzania and Germany, significantly higher para-
sitaemia levels were detected in volunteers from Equatorial Guinea. The significantly higher 
parasitaemia levels at TBS positivity in Equatorial Guinea possibly reflects the lower level of 
experience of microscopists at this recently established CHMI site. Volunteers in Tanzania or 
Equatorial Guinea had median parasite densities of 46’893 parasite/mL (47 parasites/µL) at 
time of TBS positivity with more than 80% of volunteers having parasitaemia levels greater 
than 20’983 parasite/mL (21 parasites/µL) (Fig 1B). This lower limit of detection (LOD) of 
TBS microscopy is in the range of published LODs for experienced microscopists (26), but 
higher than the theoretical LOD of 2000-4000 parasite/mL (2-4 parasites/µL) reported for 
this TBS microscopy protocol (5, 27). A weak correlation between parasite densities deter-
mined by TBS microscopy and qPCR was observed (Fig 1C) which is most likely explained 
the low parasitaemia levels assessed. The Bland-Altman analysis revealed higher parasite 
quantities derived from qPCR compared to TBS microscopy (Fig 1D). Parasitaemia levels 
derived from the qPCR assay are as double as high compared to the parasitaemia levels ob-
tained from TBS microscopy (TBS/qPCR ratio: 0.52 with 95% CI: -1.19 - 2.22). Bejon et al 
demonstrated that large numbers of parasites are lost during preparation of the microscopy 
slides and concluded that this limits the sensitivity, and leads to underestimation parasite den-
sity by microscopy (28). On the contrary, qPCR–based measurement could overestimate par-
asite densities, for example if schizonts, containing multiple merozoites each carrying a com-
plete haplotype, are amplified. The contribution of schizont stages to the total estimates of 
parasite densities is described to be low for P. falciparum (29) as well as P. vivax (30). 
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The importance of molecular parasitaemia monitoring in pre-exposed volunteers partic-
ipating in CHMIs 
The benefits of using qPCR for monitoring parasitaemia levels over time becomes especially 
apparent if applied to populations with previous exposure to malaria. Given the high propor-
tion of sub-microscopic malaria infections, only highly sensitive qPCR assays have the po-
tential to ensure that volunteers are negative for malaria parasites before enrolled into CHMI. 
In our clinical trial sites, a considerable proportion of volunteers were found to be positive for 
malaria parasites prior to CHMI (Table 2). All of them were successfully treated and tested 
negative before they received the challenge strain. Proportions of volunteers positive for ma-
laria parasites in Equatorial Guinea and Tanzania where found at 13.2% (18/136) and 4.4% 
(5/113), respectively. P. falciparum was the most common malaria species, followed by P. 
malariae and P. ovale spp. Peak parasitaemia levels were low with a geometric mean of 618 
parasites/mL (0,618 parasites/µl), resulting in 73.9% (17/23) sub-microscopic infections (Ta-
ble 2). The same issue of detectability of low parasitaemia levels also applies to CHMI initi-
ated infections caused by the PfSPZ Challenge strain PfNF54. Unlike malaria-naïve volun-
teers, people with pre-existing NAI have the ability to control parasite multiplication, which 
can lead to sub-microscopic infections and therefore only will be identified by more sensitive 
qPCR assays. The ability to control the parasite replication over a long period of time is 
demonstrated with six volunteers from Equatorial Guinea (Figure 2). All six volunteers de-
veloped blood-stage parasitaemia early after CHMI, on average after 9.25 days (range: 8-15 
days), followed by a high variability in temporal blood stage parasitaemia. The volunteers 
were left untreated until day 56 post CHMI and never developed a positive TBS microscopy 
result and no clinical signs or symptoms indicative of an ongoing malaria infection. The para-
site densities remained low throughout the two months of follow-up, with a median peak par-
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asitaemia of 5005 parasites/mL (range: 129-37’169 parasites/mL). On average, only one third 
of the total 25 bleeding time points assessed were positive (range: 8-72%). 
 
Parasite multiplication rates in Tanzanian and Equato-Guinean volunteers 
The period between the appearance of blood-stage parasites, detected by qPCR, and treatment 
initiation, after detection by TBS microscopy, was used to calculate the PMRs. In the case of 
volunteers from Tanzania and Equatorial-Guinea, this period lasted on average 6 days which 
translates into three 48-hour blood stage cycles of P. falciparum and therefore allows to esti-
mate the PMR robustly.  
Since the PfSPZ Vaccine, acting as pre-erythrocytic stage vaccine, had no significant impact 
on the PMR compared to placebo controls (Wilcoxon test p=0.8), we decided to combine 
vaccinated volunteers and placebo controls. A significantly reduced PMR was observed 
among Tanzanian (median [range]: 5.5 [0.8-42.9]) and Equato-Guinean (median [range]: 5.5 
[0.6-21.2]) volunteers compared to malaria-naïve German volunteers (median [range]: 10.5 
[2.0-46.1]) (Fig 3A). Interestingly, no difference between the two populations from East and 
Central-West Africa was observed. A subset of Tanzanian volunteers were genotyped for red 
blood cell polymorphisms, including sickle cell trait, alpha thalassemia and Glucose-6-
phosphate dehydrogenase (G6PD) deficiency (31). Using this genotyping data, we compared 
Tanzanian volunteers which were wildtype for all three RBC polymorphism (wildtype con-
trols, n=33) with volunteers carrying heterozygous alpha thalassemia trait only (heterozygous 
alpha thalassemia, n=24). The volunteers with heterozygous alpha thalassemia trait were 
wildtype for sickle cell trait and G6PD deficiency. No significant difference in P. falciparum 
PMR in volunteers carrying heterozygous alpha thalassemia trait was observed (Fig 3B). Sta-
ble and controlled HIV infection under ART treatment did not impact PMR either (Fig 3C). 
Prior to CHMI, all subjects were screened by TBS microscopy and qPCR to identify all natu-
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rally acquired Plasmodium spp. infections. Six volunteers were found to be positive for P. 
falciparum, two carried an additional P. malariae co-infection. All six volunteers were suc-
cessfully treated and cleared parasitaemia before being enrolled into CHMI. Importantly, a 
highly reduced PMR was observed in these six volunteers who were cleared from a field P. 
falciparum single infection or P. falciparum and P. malariae co-infection upon PfSPZ Chal-
lenge (Fig 3D). 
 
The impact of two consecutive homologous CHMIs on the parasite multiplication rate 
In the BSPZV2 study, 16 Tanzanian volunteers were challenged twice with a time interval of 
seven to nine months between the two CHMIs. We grouped these participants according to 
the outcomes of the first CHMI. The first group consisted of seven subjects who did not de-
velop blood stage parasitaemia during the first CHMI (“CHMI-1 blood-stage negative”). The 
second group included nine subjects who developed blood stage parasitaemia during the first 
CHMI (“CHMI-1 blood-stage positive”). The third group consisted of eleven subjects who 
served as CHMI controls and were challenged only once (“controls”). The “controls” group 
had a median PMR of 4.3 (range: 1.0-13.3) and 10 out of 11 volunteers were detected by TBS 
microscopy (Fig 4A, “controls”). While being blood-stage negative during the first CHMI, all 
seven volunteers developed blood-stage parasitaemia after the second CHMI, which was de-
tectable in 6 out of 7 cases by TBS microscopy. The median PMR of 2.7 (range: 1.2-13.3) 
was not significantly different from the “controls” (p=0.79) (Fig 4A, “CHMI-1 blood-stage 
negative”). Among the “CHMI-1 blood-stage positive” volunteers, during the first CHMI all 
nine subjects did develop parasitaemia levels detectable by TBS microscopy, while during 
the second CHMI only four volunteers reached parasite densities high enough to be detected 
by TBS microscopy. The PMR was significantly lower in all nine subjects after the second 
CHMI compared to the first challenge (Fig 4A, “CHMI-1 blood-stage positive”). The reduced 
 Chapter II – Malaria pre-exposure and P. falciparum multiplication rate  81 
PMR during second CHMI resulted in significantly lower peak parasitaemia levels over the 
28-day follow-up as compared to the first CHMI (Fig 4B, “CHMI-1 blood-stage positive”). 
Although not statistically significant, during the second CHMI, only one “CHMI-1 blood-
stage positive” volunteer compared to four volunteers during the first CHMI, did show 
CHMI-related symptoms (Fig 4C, McNemar's test p=0.25). No difference in the proportion of 
volunteers with CHMI-related symptoms among the “controls” and “CHMI-1 blood-stage 
negative” volunteers was observed. No significant differences are observed for the liver-to-
blood inoculum (Fig 4D) and qPCR prepatent periods for “CHMI-1 blood-stage positive” 
volunteers between the first and second CHMI (Fig 4E). The parasite growth dynamics for 
each individual volunteer belonging to the “CHMI-1 blood-stage positive” group is shown in 
Supplementary Figure S1, separated by CHMI-1 and CHMI-2.  
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Discussion 
 
The use of PfSPZ Challenge for CHMI was the foundation for the establishment of CHMI 
platforms in malaria endemic regions. These platforms have the ability to contribute to an 
acceleration in malaria vaccine development in the target population. The standardized nature 
of CHMI, which includes exact time of infection, dose and strain of P. falciparum, also pro-
vides a unique opportunity to gain insight into the interaction of host genetics and/or NAI on 
the course and development of malaria infection.  
We publish here blood-stage parasitaemia data determined by TBS microscopy and qPCR 
from 159 individuals who participated in CHMI conducted in two different malaria endemic 
settings. We conducted all qPCR analysis before, during or shortly after the CHMI studies 
on-site in Bagamoyo and Malabo. This turned out to be the most efficient and cost-effective 
way for monitoring these parameters in experimental malaria vaccine studies. An additional 
benefit is that by using two independent diagnostic procedures, TBS microscopy and qPCR, 
false positive TBS microscopy results can be prevented which could affect clinical trial re-
sults (32). Furthermore, CHMI studies conducted in malaria endemic regions are an accelera-
tor for establishing laboratory infrastructure and provide an excellent training platform for 
human resource development for molecular diagnostics.  
We used this data set to describe the impact of malaria pre-exposure on diagnosis of P. falci-
parum parasites. A significant proportion of volunteers did not develop parasitaemia levels 
high enough to be detected by TBS microscopy during CHMI. We describe six cases where 
CHMI-induced parasitaemia was stable at sub-microscopic levels for two months. Notably, 
on average, qPCR detected parasites in only one third of the total 25 bleeding time points 
analysed in these volunteers. This temporal variation in blood parasitaemia demonstrates also 
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the limitation if malaria prevalence assessments are based on a single blood sample analyzed 
during cross-sectional studies (33). Another challenge is the occurrence of naturally acquired 
malaria infections in volunteers before enrolment into CHMI. Almost three quarter of these 
cases identified presented themselves as asymptomatic, sub-microscopic infections and re-
quired qPCR assays to be detected. 
We used the pre-patent period before malaria treatment commenced to calculate the PMR. 
Compared to malaria-naïve German volunteers, in both African populations, the parasite’s 
ability to replicate was significantly reduced. We showed that recently cleared parasitaemia 
from an ongoing P. falciparum single infection or P. falciparum and P. malariae co-infection 
leads to a significantly reduced PMR during the CHMI study conducted. 
We attempted to identify a genetic determinant of person-to-person variability in PMR by 
analysing the impact of the widely distributed heterozygous alpha thalassemia trait. While the 
exact mechanism remains unclear, a study conducted in two cohorts of children living at the 
costal area of Kenya concluded that alpha thalassaemia is strongly protective against severe 
and fatal malaria (34). Among volunteer with heterozygous alpha thalassemia only, no reduc-
tion of P. falciparum growth rates in vivo was observed contradicting several in vitro experi-
mental reports (35, 36). CHMI studies in combination with genotyping could provide a valu-
able platform to test old and new hypothesis on association between genetic traits and malaria 
as shown by our colleagues in Gabon (15) and as currently conducted in Kenya (37). The 
data on interaction between HIV and P. falciparum in the BSPZV3 study demonstrate the 
ability of CHMI also to provide the framework to study malaria in context of ongoing co-
infections.  
Molineux and colleagues used data collected between 1940 and 1963, when malaria therapy 
was used as a treatment for neurosyphilis, to study the impact of repeated malaria therapy 
(38). In addition to a reduction in parasite density, they also observed development of parasite 
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tolerance during a second malaria infection, suggesting the acquisition of anti-parasitic and 
antitoxic immunities. We used modern CHMI data to investigate the impact of a repeated 
homologous CHMI on the multiplication rate of P. falciparum parasites. A reduction in PMR 
can only be observed if during the first CHMI blood-stage parasites were detected. Repeated 
CHMI did not impact the liver-to-blood inoculum or qPCR prepatent period in those volun-
teers. This data is in agreement with the notion of stage-specific parasite growth reducing 
immune effector mechanisms in malaria. Furthermore, the reduction in PMR leads to an 
overall lower peak parasitaemia and subsequently less symptomatic volunteers confirming 
the link between parasitemia levels and clinical presentation. 
 
In summary we conclude that malaria pre-exposure has a significant impact on P. falciparum 
asexual blood-stage growth. We showed a reduced PMR in malaria-pre-exposed individuals 
compared to malaria-naïve volunteers, and after a cleared parasitaemia from an ongoing ma-
laria infection and finally after repeated homologous CHMI in volunteers who developed 
blood-stage parasitaemia during the first CHMI. Our data indicates the development of stage-
specific parasite growth reducing immune effector mechanisms.  
A consequence of this reduced asexual blood-stage growth due to malaria pre-exposure is 
that conventional diagnostic methods, such as microscopy and RDTs, fail to detect a substan-
tial number of infections during CHMI as well as naturally acquired malaria infections. 
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Table 1. Collection of volunteers who developed blood-stage parasitaemia during CHMI 
Country  Study  
Sampling for 
parasitological 
analysis (days) 
Number of volunteers 
with blood stage para-
sitaemia 
TBS 
microscopy 
positive 
Initiation of 
treatment (day)a 
Period of blood 
stage parasi-
taemia (days)a 
Tanzania BSPZV1 9.0-28.0 57 52/57 (91.2%) 
14 
(10-19) 
4.9 
(1.4-20.0) 
Tanzania BSPZV2 8.0-28.0 21 19/21 (90.5%) 
14 
(12-20) 
6.3 
(4.1-20.0) 
Tanzania BSPZV3 8.5-28.0 12 9/12 (75.0%) 
16 
(12-18) 
4.8 
(2.5-19.0) 
Equatorial 
Guinea EGSPZV2 8.0-28.0 21 
16/21 
(76.2%) 
16 
(13-28) 
6.5 
(4.0-20.0) 
Equatorial 
Guinea EGSPZV3 6.0-28.0 48 
39/48 
(81.3%) 
18 
(14-28) 
5.5 
(4.5-21.0) 
       
Total pre-
exposed - - 159 
144/159 
(90.6%) 
15 
(10-28) 
5.5 
(1.4-21.0) 
       
Germany TUECHMI2 6.0-28.0 18 18/18  (100.0%) 
11 
(11-18) 
5.0 
(4.0-11.0) 
 
aMedian values and ranges are indicated. 
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Table 2. Volunteers with naturally acquired malaria infections prior to CHMI 
 
Subject ID (Study) Country Species Peak parasitemia levels TBS microscopy 
001G1a (BSPZV2) Tanzania P. falciparum 35'290 parasites/mL no 
009G1a (BSPZV2) Tanzania P. malariae 200 parasites/mL no 
010G1a (BSPZV2) Tanzania P. malariae 4220 parasites/mL no 
032G2b (BSPZV3) Tanzania P. falciparum 140 parasites/mL no 
034G2b (BSPZV3) Tanzania P. falciparum 1'040'710 parasites/mL yes 
408G1a (EGSPZV2) Equatorial Guinea P. falciparum/P. malariae 3245 parasites/mL no 
416G1a (EGSPZV2) Equatorial Guinea P. falciparum/P. ovale 2407 parasites/mL no 
431G1a (EGSPZV2) Equatorial Guinea P. falciparum/P. malariae 1809 parasites/mL no 
519G1b (EGSPZV2) Equatorial Guinea P. falciparum 105 parasites/mL no 
525G1b (EGSPZV2) Equatorial Guinea P. falciparum 22'131 parasites/mL no 
530G1b (EGSPZV2) Equatorial Guinea P. falciparum 96 parasites/mL no 
031G1 (EGSPZV3) Equatorial Guinea P. falciparum* 16'310 parasites/mL no 
032G1 (EGSPZV3) Equatorial Guinea P. falciparum* 1310 parasites/mL no 
016G3 (EGSPZV3) Equatorial Guinea P. falciparum* 1840 parasites/mL yes 
134G3 (EGSPZV3) Equatorial Guinea P. falciparum* 227'420 parasites/mL yes 
148G4 (EGSPZV3) Equatorial Guinea P. falciparum* 27'100 parasites/mL no 
149G4 (EGSPZV3) Equatorial Guinea P. falciparum* 6'740'410 parasites/mL yes 
151G4 (EGSPZV3) Equatorial Guinea P. falciparum* 29'750 parasites/mL no 
154G4 (EGSPZV3) Equatorial Guinea P. falciparum* 14'440 parasites/mL no 
157G4 (EGSPZV3) Equatorial Guinea P. falciparum* 140 parasites/mL yes 
161G4 (EGSPZV3) Equatorial Guinea P. falciparum* 480 parasites/mL no 
162G4 (EGSPZV3) Equatorial Guinea P. falciparum* 536'560 parasites/mL yes 
173G4 (EGSPZV3) Equatorial Guinea P. falciparum* 700 parasites/mL no 
 
* Confirmed P. falciparum infection possible co-infections with non-P. falciparum species 
were not identified. 
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Figure 1. P. falciparum quantification using TBS microscopy and qPCR. (A) Parasitaemia levels at TBs positivity compared between volunteers from three different clinical trial sites. Groups were compared using 
Wilcoxon-Mann-Whitney test. (B) Density plot of qPCR-derived parasite quantities at time of TBS microscopy positivity (median parasite densities of 46’893 parasite/mL). The white vertical line represents the parasi-
taemia level of 20’983 parasite/mL at which more than 80% of the volunteers were detected by TBS microscopy. (C) Correlation plot of parasite densities quantified by TBS microscopy and qPCR assay. Spearman's 
rank correlation coefficient is indicated. (D) Bland-Altman measurement of agreement between P. falciparum quantification using TBS microscopy and qPCR assay. The average ratio (solid black line) and the 95% 
confidence interval indicated by the dashed lines are shown. 
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Figure 2. Long lasting asymptomatic, sub-microscopic infections induced by CHMI. Six Equato-Guinean volunteers developed asymptomatic, sub-microscopic infections after CHMI. Peak parasitaemia for each 
volunteer is indicated. The grey line represents the lower limit of qPCR positivity. Parasitaemia levels are plotted with an offset of 1 parasite/mL. A total of 25 individual blood samples were collected before malaria 
treatment was initiated at day 56 post CHMI. 
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Figure 3. Parasite multiplication rates in Tanzanian and Equato-Guinean volunteers participating in CHMIs. (A) PMRs compared 
between malaria-naïve volunteers (Germany) and volunteers from two malaria endemic regions (Tanzania and Equatorial Guinea). (B) 
Impact of heterozygous alpha thalassemia trait on PMR. (C) HIV status and PMR in Tanzanian volunteers. (D) Impact of naturally acquired 
malaria infection on PMR. All groups were compared using Wilcoxon-Mann-Whitney test. 
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Figure 4. Impact of repetitive CHMI on parasite growth dynamics. (A) PMR for all three groups calculated for first and second CHMI. 
(B) Peak parasitaemia levels for all three groups. (C) Proportion of symptomatic volunteers during first and second CHMI. (D) Liver to 
blood inoculum (LBI) between first and second CHMI. (E) qPCR pre-patent period (PPP) compared between first and second CHMI. Wil-
coxon matched-pairs signed rank test was used to compare PMR, peak parasitaemia, LBI and PPP between CHMI 1 and CHMI 2. 
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Supporting Information 
 
Table S1. qPCR assays used for molecular malaria diagnostics 
 PlasQ v 1.0 PlasQ v 2.0 
Studies assay was applied BSPZV1, BSPZV2 BSPZV3, EGSPZV2, EGSPZV3 
Sample analysed 2655 5048 
qPCR reagents 
5x HOT FIREPol® Probe Universal qPCR Mix 
and 5x HOT FIREPol® EvaGreen® qPCR Mix 
Plus (Solis Biodyne, Tartu, Estonia) 
Luna® Universal Probe qPCR 
Master Mix (New England Biolabs, 
Ipswich MA, USA) 
qPCR analysis duration Probe-based qPCR: 1h 51min EvaGreen-based qPCR: 2h 43min  Probe-based qPCR: 1h 29min 
P. falciparum target PfTARE2 PfvarATS 
LOD of P. falciparum target 50 parasites/mL 20-50 parasites/mL 
CV @ LOD for P. falciparum target 4.3% 3.2% 
Plasmodium spp. target 18S rDNA 18S rDNA 
LOD of Plasmodium spp. target 100-500 parasites/mL 100-200 parasites/mL 
CV @ LOD for Plasmodium spp. target 3.0% 3.0% 
Cq of internal control HsRNaseP (Mean/SD) 23.9 ± 1.4 25.7 ± 1.3 
CV of HsRNasePa 6.2% 5.0% 
 
LOD: Limit of detection, defined as the lowest parasitaemia level of the PfIS which was am-
plified in all replicates. 
CV: Coefficient of variance, calculated from the lowest detectable parasitaemia level of the 
PfIS standard across all individual standards for all five studies. 
SD: Standard deviation 
a Coefficient of variance was calculated based on Cq values of HsRNaseP for all samples. 
 
 Chapter II - Malaria pre-exposure and P. falciparum multiplication rate         94 
 
Figure S1. Parasiteamia growth dynamics of “blood stage positive” volunteers for first (black) and second (red) CHMI. Green dots indicate detection by TBS microscopy. 
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Chapter III 
Development of high-throughput, field deployable tools 
for malaria surveillance 
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Chapter 3 includes three manuscripts describing the development of novel techniques which 
could support molecular malaria surveillance efforts in endemic regions.  
First, in response to the emerging threat of P. falciparum strains lacking pfhrp2 and/or pfhrp3 
genes and therefore evading detection by PfHRP2-based RDTs, we developed qPCR-based 
assay which is well suited for high-throughput identification of pfhrp2 and pfhrp3 gene dele-
tions in P. falciparum isolates. The ability to detect “masked” pfhrp2/3 deletions is probably 
the most interesting feature of our approach, because it will allow to study the epidemiology 
of pfhrp2/3 deletions in malaria endemic regions with a high proportion of multiple strain co-
infections. 
The second manuscript describes our attempt to improve extraction of nucleic acids from 
used RDTs. We used an approach which enabled us to extract total nucleic acids, including 
DNA and RNA. This increased the overall sensitivity for the detection of Plasmodium spp. 
parasites in the small volume of blood which is available on an RDT stored at room tempera-
ture. Beside the detection and quantification of all malaria species, applying our protocol on 
thousands of RDTs, we can monitor pfhrp2 and pfhrp3 gene deletions in P. falciparum, anti-
malarial drug resistance markers or even other blood borne pathogens circulating in malaria 
endemic areas. 
The third manuscript describes our ELIMU-MDx platform. A web-based and open-source 
platform for storage, management and analysis of diagnostic qPCR data. In response to the 
vast amount of qPCR data generated during a series of CHMI studies with more than 250 
individuals enrolled and conducted in Tanzania and Equatorial Guinea, we decided to design 
and build this platform which facilities the rapid and automated analysis and interpretation of 
diagnostic qPCR data. 
 
Chapter III – Development of malaria surveillance tools  103 
This chapter contains the following manuscripts: 
 
Schindler et al. A multiplex qPCR approach for detection of pfhrp2 and pfhrp3 gene de-
letions in multiple strain infections of Plasmodium falciparum. currently under review by 
Scientific Reports 2019 
 
Guirou and Schindler et al. High Throughput Extraction and Analysis of Nucleic Acids 
from Rapid Diagnostic Tests for Molecular Surveillance of Malaria. manuscript to be 
submitted to Journal of Clinical Microbiology 2019  
 
Wehner and Schindler et al. ELIMU-MDx: A Web-Based, Open-Source Platform for 
Storage, Management and Analysis of Diagnostic qPCR Data. submitted to BioTech-
niques 2019 
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Abstract  
 
The rapid and accurate diagnosis of Plasmodium falciparum malaria infection is an essential factor 
in malaria control. Currently, malaria diagnosis in the field depends heavily on using rapid 
diagnostic tests (RDTs) detecting circulating parasite-derived histidine-rich protein 2 antigen 
(PfHRP2) in capillary blood. P. falciparum strains lacking PfHRP2, due to pfhrp2 gene deletions, 
are an emerging threat to malaria control programs. The novel assay described here, named 
qHRP2/3-del, is well suited for high-throughput screening of P. falciparum isolates to identify these 
gene deletions. The qHRP2/3-del assay can correctly identify pfhrp2 and pfhrp3 gene deletions in 
multiple strain co-infections, particularly prevalent in Sub-Saharan countries. Deployment of this 
qHRP2/3-del assay will provide cost efficient and rapid insight into the prevalence and potential 
spread of P. falciparum isolates that escape surveillance by RDTs.  
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Introduction 
 
Malaria is an infectious disease with an estimated 219 million cases globally and was responsible 
for 435’000 deaths in 2017. More than 90% of these malaria cases and deaths occurred in sub-
Saharan Africa with Plasmodium falciparum as the most pathogenic malaria parasite species, 
accounting for 99.7% of malaria cases 1.  
Advances have been made in malaria control which have contributed to the decline in malaria 
prevalence observed worldwide with improved diagnostic tests and better access to malaria 
treatment contributing significantly to this development 1. The rapid and accurate diagnosis and 
treatment of malaria cases is an essential factor in the control of malaria. Rapid diagnostic tests 
(RDTs) are becoming the most widely used method to diagnose malaria infections in the field with 
245 million RDTs distributed worldwide in 2017 1. In sub-Saharan Africa, RDTs have almost 
completely replaced light microscopy for malaria diagnosis, with an estimated 75% of malaria tests 
conducted using RDTs in 2017 1. Malaria RDTs are based on an immuno-chromatographic assay 
using a lateral-flow device which allows the detection of malaria antigens in usually 5 to 15 µL of 
capillary blood 2. RDTs provide results within 20 minutes and can be employed by inexperienced 
health workers operating in resource-limited settings 3. RDTs recognizing circulating histidine-rich 
protein 2 (PfHRP2) for sensitive and specific detection of P. falciparum make up more than 90% 
of RDTs currently in use 4. The relatively high abundance and stability of PfHRP2 in the blood of 
infected patients and expression by all P. falciparum erythrocytic stages make this antigen a 
valuable biomarker for malaria infection 5. PfHRP3, a protein also expressed by P. falciparum with 
high level of structural similarity to PfHRP2, might be also recognized by some of the monoclonal 
antibodies used in the RDTs 6.  
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RDTs are critical diagnostic tools for identifying symptomatic malaria infections; however, due to 
the reduced performance in infections with low parasite density, its use for the diagnosis of malaria 
infection in asymptomatic individuals is rather limited 7.  
 
Recent studies report on reduced diagnostic performance of PfHRP2-based RDTs which were 
attributed to genetic diversity of the pfhrp2/3 genes 6, differences in expression level of PfHRP2/3 
antigen in parasite field strains 8 or isolates lacking pfhrp2 and/or pfhrp3 genes 9. P. falciparum 
isolates lacking pfhrp2 and/or pfhrp3 genes are found around the world, with different proportions 
of the circulating P. falciparum population affected. The regions with the highest proportions of P. 
falciparum strains carrying pfhrp2 deletions are South America and sub-Saharan Africa 10. Since 
malaria control programmes depend on reliable diagnosis of malaria cases using RDTs, parasites 
lacking pfhrp2/3 genes pose a threat to malaria control and local elimination efforts 11. 
 
The presence or absence of pfhrp2/3 genes is usually determined by amplifying these genes by 
polymerase chain reaction (PCR). Several different (nested) PCR protocols have been published 
and a deletion is reported if there is no amplification of the pfhrp2/3 genes in the presence of an 
amplification signal of a P. falciparum single copy gene, which serves as a reference gene 12. There 
are methodological issues related to this approach which assumes identical PCR performance of 
the pfhrp2/3 and the reference genes. Particularly at lower parasitaemia levels with a small number 
of DNA target molecules present, unavoidable stochastic effects can play a major role and might 
lead to false reporting of pfhrp2/3 deletions. Additionally, conventional nested PCR methods are 
time consuming, requiring separate reactions for each target gene amplification as well as gel 
electrophoresis for visualization of the PCR products. Furthermore, none of the published methods 
detecting pfhrp2/3 deletions can identify “masked” deletions in multiple strain infections with only 
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one out of several P. falciparum strains carrying a pfhrp2 and/or pfhrp3 gene deletion 13. These 
limitations of recommended molecular monitoring methods could result in an underestimation of 
the prevalence of P. falciparum strains with pfhrp2/3 deletions, especially in regions with high 
proportions of multiple strain co-infections.  
 
This paper presents a novel, quantitative PCR-based method for detecting pfhrp2 and pfhrp3 gene 
deletions suitable for high throughput screening of P. falciparum isolates. The qHRP2/3-del 
(quantitative detection of pfhrp2 and pfhrp3 deletion) assay was developed as a multiplex assay, 
with the ability to amplify individually and specifically the pfhrp2 and pfhrp3 genes together with 
a single copy gene, the P. falciparum ribonucleotide reductase R2_e2 (pfrnr2e2) 14, as an internal 
reference. The quantitative nature of the qHRP2/3-del assay provides the basis for estimating the 
proportions of P. falciparum strains carrying pfhrp2 and pfhrp3 deletions in regions with multi-
clonal malaria infections. 
  
 Chapter III - qHRP2/3-del assay            109 
Results 
 
Design and evaluation of the novel qHRP2/3-del assay 
We aimed at improving the detection of pfhrp2 and pfhrp3 gene deletions by developing a quanti-
tative PCR-based assay able to detect and quantify pfhrp2 and pfhrp3 genes in a single reaction. 
Given the high nucleotide sequence similarity and the repetitive structure of the pfhrp2 and pfhrp3 
genes, nucleotide regions serving as targets for primers and probes were limited (Supplementary 
file 1). The primer and probe combinations selected for our assay (Table 1) bind to a region span-
ning exon 1 and exon 2 of both genes to detect entire and partial gene deletions described to occur 
on known chromosome breaking points 12. We designed a multiplex qPCR assay using three dif-
ferently labelled TaqMan assays detecting the pfhrp2 (PF3D7_0831800) and pfhrp3 
(PF3D7_1372200) genes with the single copy gene pfrnr2e2 (PF3D7_1015800) as the internal 
control. The sequence alignment of the pfhrp2 and pfhrp3 genes highlighting the oligo binding 
regions is shown in Supplementary file 1. 
The multiplexed assays correctly identify P. falciparum strains carrying known deletions of pfhrp2 
(PfDD2 strain) and pfhrp3 (PfHB3 strain) as well as a strain without deletion (PfNF54 strain) (Fig 
1A). The multiplexed assays show comparable characteristics in terms of sensitivity and qPCR 
performance. All three targets are detected in samples with parasitaemia as low as 1 parasite/µL 
and an inverse linear correlation between Cq values and parasite densities ranging from 1 to 10’000 
parasites/µL was observed. The qPCR efficiencies were calculated as 85.7%, 98.8% and 98.4% for 
the amplification of pfhrp2, pfhrp3 and pfrnr2e2, respectively (Fig 1B). The qHRP2/3-del assay 
was next tested using purified DNA from eight culture adapted P. falciparum strains from Africa 
(Pf3D7, PfNF54, PfNF166.C8), South and Central America (Pf7G8, PfDD2, PfHB3), South East 
Asia (PfNF135.C10) and Papua New Guinea (PfFC27) with known deletion status of the pfhrp2 
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and pfhrp3 genes (Fig 1C). The Cq values for amplification of pfrnr2e2 were comparable between 
the eight strains amplified demonstrating its robustness and accuracy as internal control. No sig-
nificant differences of Cq values for the pfhrp2 gene and pfhrp3 gene across the strains carrying 
the genes was observed. Sequence alignments of PfNF135.C10, Pf3D7, Pf7G8, PfNF54 and 
PfNF166.C8 did not reveal sequence variation in the oligo binding regions of pfhrp2 (Supplemen-
tary file 2) or pfhrp3 (Supplementary file 3) supporting these findings. DNA derived from five non-
falciparum Plasmodium species (P. ovale curtisi, P. ovale wallikeri, P. malariae, P. knowlesi, P. 
vivax) was tested with the qHRP2/3-del assay and did not result in amplification of any target 
demonstrating the specificity for P. falciparum (Fig 1D). In summary, we developed a P. falcipa-
rum-specific multiplex qPCR assay that allowed the simultaneous amplification of the pfhrp2, 
pfhrp3 and pfrnr2e2 genes in a single reaction with high efficiency and ability to correctly identify 
pfhrp2 and pfhrp3 gene deletions.  
 
Analysis of P. falciparum field strains with qHRP2/3-del assay 
The qHRP2/3-del assay was next tested using a collection of 254 P. falciparum isolates originating 
from East Africa, Central-West Africa and Latin America (Table 2). The infection status and par-
asitaemia levels were well established in these samples by using diagnostic qPCR assays deployed 
in the laboratories where the samples were obtained. The overall median parasitemia in these sam-
ples was 75.7 parasites/µL (IQR: 2.2-571.6), which is below the LOD of 100 parasites/µL for 
PfHRP2-based RDTs. First, the ability of the pfrnr2e2 singly copy gene to serve as internal assay 
control and to quantify parasitemia levels was assessed. Out of the 254 samples, 186 (73.2%) am-
plified the pfrnr2e2 singly copy gene. Failure in amplification of pfrnr2e2 was associated with low 
parasitemia levels (Fig 2A). In samples with parasitemia levels of 3 parasites/µL and above, more 
than 95% of all samples were amplified successfully. In samples with parasitemia > 100 
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parasites/µL, the lower limit of detection for PfHRP2-based RDTs, all qPCR reactions were posi-
tive for pfrnr2e2. Parasitemia levels determined by using the amplification of pfrnr2e2 correlated 
closely with parasite densities obtained from P. falciparum diagnostic qPCR assays (Fig 2B), this 
is supported by the findings of the Bland-Altman plot which demonstrates a high order of agree-
ment (Fig 2C). The average ratio of parasite quantification based on diagnostic qPCR assays and 
qHRP2/3-del assay is 0.8 (95% CI: -1.7-3.3). In summary, the qHRP2/3-del assay amplifies 95 % 
of samples with parasitemia levels of 3 parasites/µL and above and can be used to reliably quantify 
parasite levels in field samples. 
 
Identification of pfhrp2 and pfhrp3 gene deletions using qHRP2/3-del assay 
Next, we wanted to establish the performance of the qHRP2/3-del assay in comparison with the 
currently used gold standard. Samples with known pfhrp2/3 deletion status obtained from four 
different sources were included. Serial dilutions of DNA purified from PfDD2 (pfhrp2 deletion), 
PfHB3 (pfhrp3 deletion) and PfIS (no deletion) served as controls. Samples from CHMI using 
PfNF54 (no deletion) were added to test the specificity of the qHRP2/3-del assay. Two sample sets 
genotyped by nested PCR, one from Peru (PE), with a high proportion of pfhrp2/3 deletions and 
another one from Tanzania (TZ) dominated by P. falciparum strains without deletions were ana-
lysed. The qHRP2/3-del assay defines a deletion as failure of amplification of the pfhrp2/3 genes 
(Fig 3A, y axis, Cq set to 45) in samples which are positive for the internal control, pfrnr2e2 (Fig 
3A, x axis). Sensitivity is defined as the proportion of correctly identified pfhrp2/3 deletions, while 
specificity is the proportion of correctly identified strains without pfhrp2/3 deletions. All control 
samples with known deletion status were identified as expected (Fig 3A, first panel). Importantly, 
the qHRP2/3-del assay correctly identified samples with parasitemia levels ranging from 1-
10’0000 parasites/µL, demonstrating the dynamic range of at least 5 logs of this assay. In samples 
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collected from volunteers that have undergone CHMI with PfNF54 (CHMI, n=38), one sample 
with a double deletion of the pfhrp2/3 genes was detected wrongly, resulting in a reduced specific-
ity (Fig 3A, second panel). A high sensitivity was achieved with the Peruvian samples (PE, n=67), 
pfhrp2 and pfhrp3 deletions were detected with sensitivity of 94.4% and 94.9%, respectively (Fig 
3A, third panel). The low specificity of 76.9% and 87.5% for pfhrp2 and pfhrp3, respectively, is 
based on the incorrect detection of deletions in three samples. Among the samples from Tanzania 
(TZ, n=56), no pfhrp2/3 deletions were detected by the nested PCR. In contrast, the qHRP2/3-del 
assay identified three deletions, resulting in a specificity of 93.8% (Fig 3A, fourth panel).  
Grouping the samples with missed deletions (reducing the sensitivity) and the false deletions (re-
ducing the specificity) by parasitemia levels revealed a high proportion of false deletions among 
the samples with the lowest parasitemia levels (Fig 3B). Based on these findings, the inclusion 
criteria for samples to be analysed by qHRP2/3-del assay was changed. The threshold for the 
pfrnr2e2 gene amplification was reduced from Cq <40 to Cq <37.5, corresponding to parasitemia 
levels of 5 parasites/µL. Based on these new inclusion criteria, the qHRP2/3-del assay obtained 
results from 106 samples out of 127 samples (inclusion rate of 83.5%) (Fig 3C). 12 samples were 
not amplified by the qHRP2/3-del assay and an additional 9 samples excluded based on the new 
inclusion criteria. Samples which were not amplified by the qHRP2/3-del assay were mainly ultra-
low parasite density samples from Tanzania (11 out of 12). In 6 out of 11 samples (54.5%), the 
nested PCR had detected pfhrp2 and pfhrp3 deletions. In contrast, in the remaining 48 Tanzanian 
samples not a single deletion had been found. This significantly increased proportion (Fisher exact 
test, p < 0.0001) of deletions detected by nested PCR among samples with ultra-low parasitemia 
levels is a strong indicator that the gold standard is prone to report incorrect presence of deletions 
at low parasitemia levels.  
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In 99 out of 106 samples (93.4%), the pfhrp2/3 deletion status was identical when compared be-
tween qHRP2/3-del assay and nested PCR. This is reflected in the near perfect agreement between 
these two PCR based diagnostic methods for each of the amplified targets. Cohen’s kappa was 
calculated as 0.89 and 0.91 for pfhrp2 and pfhrp3, respectively. In summary, the qHRP2/3-del 
assay specificity (94.4% and 96.0% for pfhrp2 and pfhrp3, respectively) and sensitivity (94.2% 
and 94.6% for pfhrp2 and pfhrp3, respectively) were above 90%. The negative predictive value 
(NPV) was calculated as 94.5% and 94.1 % and the positive predictive value (PPV) as 94.2% and 
96.4%, for pfhrp2 and pfhrp3, respectively (Fig 3D). 
 
Multiple strain P. falciparum infections are masking pfhrp2 and pfhrp3 deletions 
In many malaria endemic regions, particularly in sub-Saharan Africa, infections with multiple 
strains of P. falciparum are common 15. A blood sample carrying multiple P. falciparum strains 
with and without pfhrp2/3 deletions will result in failure to detect the deletion by nested PCR if the 
parasitaemia level of the strain without deletion is sufficiently high for amplification. This limita-
tion leads most likely to an underestimation of the prevalence of pfhrp2/3 gene deletions in regions 
with high prevalence of multiple strain infections. We reasoned that the qHRP2/3-del assay could 
offer a solution by calculating the difference between the Cq values obtained for amplification of 
pfhrp2 or pfhrp3 and pfrnr2e2. To demonstrate the ability of the qHRP2/3-del assay to correctly 
identify and quantify “hidden” or “masked” pfhrp2/3 gene deletions in mixed infections, we first 
tested defined mixtures of DNA from PfNF54 (no pfhrp2/3 deletions) and PfDD2 (pfhrp2 deletion) 
or PfHB3 (pfhrp3 deletion) in a range of different ratios. For each combination of strain mixtures, 
PfDD2/PfNF54 or PfHB3/PfNF54, 10 mixtures were prepared containing varying ratios of strains 
with and without a pfhrp2/3 deletion (Fig 4A). The contribution from PfDD2 and PfHB3 strains to 
these mixtures ranged from 0.1% to 88% and 0.1% to 86%, respectively. In seven mixtures, the 
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strain with a deletion constituted the minority (with less than 50% abundance) and in three mixtures 
the majority (with more than 50% abundance). None of these mixtures failed to amplify the 
pfhrp2/3 genes, even if the strain carrying the deletion constituted the majority in the mixture. A 
positive correlation between abundance of isolate carrying a deletion and an increase of ∆Cq (Cq 
of pfhrp2 or pfhrp3 minus Cq of pfrnr2e2) is observed (Fig 4B). The qHRP2/3-del assay does not 
only successfully identify “masked” pfhrp2/3 deletions but can also discriminates between mix-
tures where the strain with the deletion constitutes the majority or minority (Fig 4C). A ∆Cq cut-
off value of 2.0 was chosen to identify “masked” pfhrp gene deletions. Applying this cut-off to our 
sample collections revealed that two isolates each from Tanzania and Peru have high ∆Cq values 
for both pfhrp genes indicative of the presence of “masked” pfhrp2/3 deletions (Fig 4D). Three 
additional samples from the Peruvian collection had a ∆Cq value > 2 for the pfhrp2 gene only. No 
∆Cq values above 2 were found in Equatorial Guinean isolates and among samples collected from 
volunteers undergoing CHMI (Fig 4D). These experiments demonstrate that by calculating the ∆Cq 
values between Cq for pfrnr2e2 and pfhrp2 or pfhrp3, “masked” deletions can be identified.  
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Discussion 
 
P. falciparum strains carrying pfhrp2/3 deletions are an emerging threat to malaria control and 
elimination programs around the world. Novel analysis tools enabling high-throughput screening 
of P. falciparum populations from the field are needed. The currently published methods, mostly 
based on nested PCR, have clear limitations in that these methods are extremely time consuming, 
prone to detection of incorrect deletions at low parasitemia levels and unable to identify “masked” 
deletions in multiple strain co-infections. 
The sensitivity and specificity of the PfHRP2/3-del assay is comparable to the nested PCR, 
currently the gold standard. However, the novel qHRP2/3-del assay is well suited for high 
throughput screening of P. falciparum isolates with approximately 30 samples analyzed in less than 
two hours - including DNA extraction and data analysis. Two additional major advantages of the 
qHRP2/3-del assay are obvious: firstly, the ability to quantify parasitemia levels and therefore 
include samples based on parasitemia and secondly, to identify “masked” deletions in multiple 
strain infections.   
The identification of pfhrp2/3 deletions in samples with low parasitemia levels is difficult since the 
absence of amplification could be due to lack of sufficient template leading to incorrect reports of 
deletions. The conventional method regards as valid for interpretation all biological samples for 
which a reference gene, usually msp2, is amplified demonstrating the presence of sufficient 
template in the PCR reaction. The qHRP2/3-del assay uses a better-defined inclusion criterion, 
based on the Cq value of its internal control. The pre-defined exclusion criteria of all samples that 
have parasitemia below 5 parasites/µL will improve the quality, reproducibility and comparability 
of malaria parasite survey data obtained with the qHRP2/3-del assay. 
The ability to detect “masked” pfhrp2/3 deletions is probably the most interesting feature of the 
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qHRP2/3-del assay, because it will allow studying the epidemiology of pfhrp2/3 deletions in 
malaria endemic regions with a high proportion of infections caused by multiplicity of infections, 
particular sub-Saharan Africa 15. The qHRP2/3-del assay correctly identified infections that contain 
two strains, one with a deletion and the other one without a deletion, based on a difference in the 
Cq values derived from the amplification of the pfhrp2/3 gene targets and the pfrnr2e2 control. 
However, currently we cannot exclude that nucleotide sequence variations located in the binding 
sites of the oligonucleotides used in the PfHRP2/3-del assay could potentially also lead to variation 
in ∆Cq values. 
For the first time we report the possible existence of pfhrp2 and pfhrp3 deletions in isolates 
collected in Tanzania. Two isolates had an increased ∆Cq value for both pfhrp genes. With Kenya 
[13], the Democratic Republic of Congo [14], Rwanda [15] and Mozambique [16] four out of six 
direct neighbouring countries have already reported the presence of pfhrp2/3 deletions, which 
makes the existence of such strains in Tanzania likely.  
The application of our novel PfHRP2/3-del assay in additional studies including a larger sample 
size will improve our understanding of the relevance of “masked” pfhrp2 and pfhrp3 gene deletions 
and their impact on reliability of malaria RDT test results. 
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Conclusion 
 
The qHRP2/3-del assay presented here is suitable for high-throughput screening of P. falciparum 
strains to identify pfhrp2/3 gene deletions in different malaria endemic settings, including areas 
with high a proportion of multiple strain co-infections. With growing availability of qPCR instru-
ments in reference laboratories in sub-Saharan countries, this assay could be used as surveillance 
method to monitor over time the potential expansion of P. falciparum strains carrying pfhrp2 and 
pfhrp3 deletions. 
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Methods 
 
P. falciparum Isolates from Tanzania, Equatorial Guinea and Peru 
In this study a total of 205 P. falciparum isolates collected from three different malaria endemic 
regions, East Africa, West-Central Africa and South America were included. The samples from East 
Africa (n=90) were collected in rural southern Tanzania (TZ) as part of a malaria baseline survey 
16. The West-Central African isolates (n=47) were identified among blood donors living in Malabo, 
Equatorial-Guinea (EG) 17. Both samples sets were analyzed locally, at the Bagamoyo branch of 
the Ifakara Health Institute and the laboratory of the Equatorial Guinea Malaria Vaccine Initiative 
using harmonized protocols. Briefly, genomic DNA was isolated either from 6 circles with 2mm 
diameter of dried blood spots (Tanzania) or 180 µL whole blood (Equatorial Guinea) using the 
Quick-DNA Miniprep kits (Zymo Research, Irvine, USA). P. falciparum was identified and 
quantified using published qPCR protocols based on varATS 18. Extracted DNA (n=68) from 
Peruvian isolates (PE), collected between 2008-2009 and 2015-2016 around Iquitos city, was 
shipped to the Swiss Tropical and Public Health Institute for pfhrp2/3 characterization by 
qHRP2/3-del assay.  
 
Additional Parasite Isolates and Laboratory Strains 
Forty-nine PfNF54 isolates from Controlled Human Malaria Infections (CHMI) conducted in 
Bagamoyo, Tanzania (ClinicalTrials.gov: NCT02613520 19) as well as genomic DNA isolated from 
8 laboratory strains with know pfhrp2/3 deletion status (Pf3D7, Pf7G8, PfDD2, PfHB3, 
PfNF135.C10, PfNF166.C8, PfNF54 and PfFC27) were used as controls. The 1st WHO 
International Standard for Plasmodium falciparum DNA Nucleic Acid Amplification Techniques 
(NIBSC code: 04/176, herein referred to as PfIS) was used to assess the performance of the 
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qHRP2/3-del assay. Non-falciparum Plasmodium species, including P. malariae (Pm), P. ovale 
curtisi (Poc), P. ovale wallikeri (Pow), P. vivax (Pv) and P. knowelsi (Pk) and an additional 28 
samples from malaria negative individuals living in Tanzania were used to assess specificity of the 
assay.  
 
Detection of the pfhrp2 and pfhrp3 genes by conventional nested PCR 
P. falciparum positive samples collected in Tanzania were selected for detection of pfhrp2 and 
pfhrp3 genes by nested PCR. As a reference gene, the msp2 gene was amplified using a previously 
described protocol 20. All isolates with successful msp2 amplification were analyzed for the 
presence of pfhrp2 and pfhrp3 genes using primers spanning exon 1, the intron, and exon 2 21. All 
PCR products were separated and visualized on a 2% agarose gel. Cultured parasite isolate PfDD2 
(pfhrp2 deletion) was used as a control for all nested PCR experiments on pfhrp2 while PfHB3 
(pfhrp3 deletion) was used as a control for all nested PCR experiments on pfhrp3. PfNF54 (no 
pfhrp2/3 deletion) was used as a positive control for both pfhrp genes. Pfhrp2/3 deletion status of 
the Peruvian P. falciparum isolates was analyzed previously following the procedures described in 
9 and the results were shared to be used for the evaluation of the qHRP2/3-del assay. 
 
Design of qHRP2/3-del assay 
Published pfhrp2/3 primer sequences for conventional PCR were adapted to the qPCR platform 
using EvaGreen® qPCR Mix (Solis BioDyne, Tartu, Estonia). The primers were tested with 
different DNA concentrations extracted from PfNF54, PfDD2 and PfHB3 strains. The best 
performing primer pairs, in terms of specificity and sensitivity, were then used in combination with 
newly designed TaqMan® hydrolysis probes. The pfhrp2/3 oligo sequences were systematically 
optimized using the trial-and-error approach. As the internal control of the qHRP2/3-del assay we 
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amplify a P. falciparum specific 107 bp long sequence of the ribonucleotide reductase R2_e2 
(pfrnr2e2), ), a distantly related paralog of the canonical eukaryotic  small subunit ribonucleotide 
reductase R2, that is unique to apicomplexan species 14. Genomic sequences for pfrnr2e2 
(PF3D7_1015800), pfhrp2 (PF3D7_0831800) and pfhrp3 (PF3D7_1372200) of Pf3D7 strain were 
obtained from PlasmoDB. A pfhrp2/3 sequence alignment including five reference strains from 
West-Africa (Pf3D7, PfNF54), Guinea (PfNF166.C8), Brazil (Pf7G8) and Cambodia 
(PfNF135.C10) revealed no SNPs in oligo binding regions suggesting a high degree of 
conversation within the target region of the pfhrp2/3 genes (Supplementary file 2 and 3). The 
Geneious version 8.1.9 software (Biomatters Ltd, Auckland, New Zealand) was used for sequence 
alignments and oligo designs. Relevant information concerning the oligos used in the qHRP2/3-
del assay is summarized in Table 1. 
 
Sample analysis with qHRP2/3-del assay 
Amplification and qPCR measurements were performed using the Bio-Rad CFX96 Real-Time 
PCR System (Bio-Rad Laboratories, California, USA). The thermal profile used for qHRP2/3-del 
assay is as follows: Taq polymerase activation for 5 min at 95 °C, followed by 45 cycles of 15 s at 
95 °C and 35 s at 57.5 °C. 2 µL DNA was added to 8 µL reaction master mix containing 1x Luna 
Universal Probe qPCR Master Mix (New England Biolabs, Ipswich, USA) and 1x qHRP2/3-del 
Primer Mix (Table 1). All qPCR assays were run in triplicates with appropriate controls including 
Non-Template Control and DNA from PfDD2, PfHB3 and PfNF54 as controls for the pfhrp2/3 
deletion status.  
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Data management and statistical analysis 
Preliminary analysis of qPCR data. Cq values were obtained from the Bio-Rad CFX96 Manager 
3.1 software (Bio-Rad Laboratories, California, USA) after setting the threshold manually. Cq 
values were transferred and linked to the samples’ metadata using a custom-designed database for 
storage and analysis of qPCR data. Only samples with a Cq ≤ 40.0 for the internal control, pfrnr2e2, 
were considered eligible for analysis of pfhrp2/3 deletion status. ∆Cq were calculated by 
subtraction of pfrnr2e2 Cq values from pfhrp2 or pfhrp3 Cq values. 
Analytical performance of qHRP2/3-del assay and quantification of parasitemia. Based on the PfIS 
a serial dilution ranging from 0.01-10’000 parasites/µL was prepared and used to assess the 
performance of the qHRP2/3-del assay. The slope, y-intercept, qPCR efficiency and R2 was 
established for each target. The Limit of Detection (LOD) was defined as the lowest PfIS 
parasitemia with a positive amplification in 4 out of 6 replicates. Parasitemia was estimated using 
linear regression derived from serial dilution of the PfIS and the pfrnr2e2 target which serves as 
the internal control of the qHRP2/3-del assay.  
Graphical representation and statistical analysis. We used R version 3.5.1 for creating ggplot2-
based graphs using the packages ggpubr, gridextra and scales. The Diagnostic test evaluation 
calculator (freely available at https://www.medcalc.org/calc/diagnostic_test.php) was used for 
analytical validation of qHRP2/3-del assay performance. Cohen's kappa including 95% confidence 
intervals, providing a measure of agreement, was calculated using STATA version 12.0 software 
(Stata Corp LP; College Station, Texas, USA). P values < 0.05 were considered as significant for 
all statistical analysis. 
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Table 1. Oligonucleotide sequences used for qHRP2/3-del assay 
Target gene Size Oligo name Oligo sequence [5’to 3’] Fluorophores Conc. in 5x 
PrimerMixa 
pfrnr2e2 
(PF3D7_1015800) 107 bp 
IC-PfRNR2E2 fwd AGTATCCAAAACACTATAATTCCAAGTAC - 1.5 µM 
IC- PfRNR2E2 rev ATTTTCTCCTTTCTTAACAGTTTCTTCC - 1.5 µM 
IC-PfRNR2E2 Cy5 CCTTTTAGTTGGCCCGAATTTACAA Cy5-BHQ2 1.125 µM 
pfhrp2 
(PF3D7_0831800) 286 bp 
PfHRP2 fwd GTATTATCCGCTGCCGTTTTTGCCb - 1.5 µM 
PfHRP2 rev TCTACATGTGCTTGAGTTTCGb - 1.5 µM 
PfHRP2 TxRd TTCCGCATTTAATAATAACTTGTGTAGC TexasRed-BHQ2 0.375 µM 
pfhrp3 
(PF3D7_1372200) 289 bp 
PfHRP3 fwd ATATTATCCGCTGCCGTTTTTGCT - 1.5 µM 
PfHRP3 rev CCTGCATGTGCTTGACTTTCGT - 1.5 µM 
PfHRP3 YY CTCCGAATTTAACAATAACTTGTTTAGC YakimaYellow-BHQ2 0.75 µM 
a All oligonucleotides are premixed as a 5x primer mix 
b oligonucleotide sequences obtained from Abdallah et al. 21 
 
Table 2. Field samples used for evaluation of qHRP2/3-del assay 
Sample set Description of sample set 
Number of P. falciparum 
positive samplesb 
Parasitemia in parasites/µL 
(Median/IQR) 
Amplification rate by 
qHRP2/3-del assay 
CHMIa 
CHMI in TZ with PfNF54 strain (no 
deletion) 
49 51.1 (1.5-152.5) 78% 
PE 
Peruvian samples around Iquitos city. 
High proportion of pfhrp2/3 deletions 
68 592.4 (186.7-1982.0) 99% 
EG 
Blood donors with asymptomatic 
malaria infection living on Bioko Island, 
Equatorial Guinea 
47 4.8 (1.0-45.3) 51% 
TZ 
Sampling of symptomatic volunteers at 
two health facilities in Southern 
Tanzania 
90 38.8 (0.7-808.6) 62% 
Combined  254 75.7 (2.2-571.6) 73% 
a Controlled Human Malaria Infection 
b all confirmed by diagnostic qPCR assays
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Figure 1. Multiplex detection of pfhrp2 and pfhrp3 genes using the qHRP2/3-del assay. (A) The qHRP2/3-del assay amplifies pfhrp2, pfhrp3 and pfrnr2e2 target sequences in a multiplex qPCR reaction 
and correctly identifies strains carrying either a pfhrp2 deletion (PfDD2), a pfhrp3 deletion (PfHB3) or no deletion (PfNF54). (B) Performance characteristic of each individual amplification assay, run within 
the multiplex qHRP2/3-del assay, is shown. Correlation with high linearity between serially diluted WHO international standard for P. falciparum NATs (PfIS) and Cq values was obtained and used to calculate 
the qPCR efficiency. Cq values above 40 (black line) are considered negative. (C) DNA extracted from cultured parasites diluted to 1000 parasites/µL was used to demonstrate performance of the qHRP2/3-
del assay in strains representing a global collection of P. falciparum parasites. (D) qHRP2/3-del assay specificity for P. falciparum was tested using DNA derived from non-falciparum Plasmodium species.
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Figure 2. Detection and quantification of field samples using qHRP2/3-del assay. (A) Amplification rate of pfrnr2e2 target, the internal control 
of qHRP2/3-del assay and association with parasitemia levels. Wilcoxon-Mann-Whitney test was used for comparison of parasitemia between 
groups. The dashed line at 3 parasites/µL represents the parasitemia at which more than 95% of the samples were amplified, while the dashed line 
at 100 parasites/µL represents the LOD of RDTs at which all samples are successfully amplified. (B) Correlation of parasitemia levels, obtained 
from diagnostic qPCR assays, and parasitemia, derived from the internal control of qHRP2/3-del assay, is shown. The color represents the different 
sample sets and R2 the Spearman's rank correlation coefficient. (C) Bland-Altman plot of average parasitemia (x-axis) and ratio of parasitemia levels 
calculated between internal control of qHRP2/3-del assay and diagnostic qPCR assays (y-axis). Average ratio (black line) and 95 % limits of 
agreement (dashed line) are depicted. 
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Figure 3. Diagnostic performance of qHRP2/3-del assay. (A) Samples with Cq values for pfhrp2 and pfhrp3 amplification > 40 (shown on y-axis, black line indicates cut-off) are considered to carry a 
pfhrp2/3 deletion. Reference deletion status, based on nested PCR, is color coded (red = deletion, grey = no deletion). (B) Proportion of correctly and incorrectly identified pfhrp2/3 deletion status grouped by 
parasitemia. (C) Number of samples included for analysis by qHRP2/3-del assay (n=106), excluded due to ultra-low parasitaemia (n=9) and not amplified (n=12). (D) Analytical validation of qHRP2/3-del 
assay performance was assessed by comparing it to nested PCR (gold standard). Standard parameters such as sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 
including their 95% confidence intervals are shown. 
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Figure 4. Identification of masked pfhrp2/3 deletions in multiple strain infections. (A) Mixtures containing two strains, one with a pfhrp deletion (PfDD2 or PfHB3) and no deletion (PfNF54), were 
generated. (B) Correlation between abundance of strain carrying deletion and ∆Cq is shown for both targets, pfhrp2 (red) and pfhrp3 (blue). (C) The ∆Cq approach distinguishes between strain mixtures not 
carrying deletions, mixtures with minority abundance as well as majority abundance of strains with deletions. Statistical comparison was performed using the Kruskal-Wallis test followed by Wilcoxon-Mann-
Whitney for pairwise comparisons. (D) The ∆Cq approach of the qHRP2/3-del assay was applied to four sample collections to identify “masked” pfhrp2/3 deletions. The control group, based on samples from 
CHMI, did not reveal isolates with increased ∆Cq values. The dashed lines represent the ∆Cq cut-off values for pfhrp2 (x-axis) and pfhrp3 (y-axis).
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Supplementary file 1. Sequence alignment (first 350 bp) of pfhrp2 and pfhrp3 genes including 
intron sequence (grey). qHRP2/3-del primer (black) and probe (green) binding regions are 
highlighted. Nucleotide sequence differences in oligo binding regions between pfhrp2 and 
pfhrp3 are indicated in red. 
 
 
pfhrp2             1 ATGGTTTCCTTCTCAAAAAATAAAGTATTATCCGCTGCCGTTTTTGCCTC     50 
                     ||||||||||||||||||||||||.||||||||||||||||||||||.|| 
pfhrp3             1 ATGGTTTCCTTCTCAAAAAATAAAATATTATCCGCTGCCGTTTTTGCTTC     50 
 
pfhrp2            51 CGTACTTTTGTTAGATAACGTAAGCATTTTAATTGCAAATAGAAATAAAT    100 
                     ||||||||||||||||||||||||.||||||||||||||||.|||||||| 
pfhrp3            51 CGTACTTTTGTTAGATAACGTAAGTATTTTAATTGCAAATATAAATAAAT    100 
 
pfhrp2           101 ATATCATTCAATTATAAAAATACATATAATAATAATATATATATATATAT    150 
                     |||.||.|.|.|||||||||||||||||||||||.||||||||||||||| 
pfhrp3           101 ATAACACTTACTTATAAAAATACATATAATAATATTATATATATATATAT    150 
 
pfhrp2           151 ATATATTTATATAT-----TGTATATATATAAATTTTTTCATTTTTAAAT    195 
                     ||||||.|||||||     |.|||||||.||.||||||.||||||||||| 
pfhrp3           151 ATATATATATATATATATATATATATATGTACATTTTTACATTTTTAAAT    200 
 
pfhrp2           196 GCTTTTTTATTTTTATATAGAATAATTCCGCATTTAATAATAACTTGTGT    245 
                     |.|||||.|||||  ||||||||||.||||.||||||.||||||||||.| 
pfhrp3           201 GATTTTTCATTTT--TATAGAATAACTCCGAATTTAACAATAACTTGTTT    248 
 
pfhrp2           246 AGCAAAAATGCAAAAGGACTTAATTTAAATAAGAGATTATTACACGAAAC    295 
                     |||||||||||||||||||||||||.|||||||||||||||||||||||. 
pfhrp3           249 AGCAAAAATGCAAAAGGACTTAATTCAAATAAGAGATTATTACACGAAAG    298 
 
pfhrp2           296 TCAAGCACATGTAGATGATGCCCATCATGCTCATCATGTAGCCGATGCCC    345 
                     |||||||||||.||.|||||||||||||||.|||||||||||.||||||| 
pfhrp3           299 TCAAGCACATGCAGGTGATGCCCATCATGCACATCATGTAGCTGATGCCC    348 
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Supplementary file 2. Sequence alignment (first 360 bp) of pfhrp2 for five reference strains 
from Africa (3D7, NF54, NF166.C8), Brazil (7G8) and Cambodia (NF135.C10). The oligo 
binding sites are highlighted in grey.  
 
NF135      ATGGTTTCCTTCTCAAAAAATAAAGTATTATCCGCTGCCGTTTTTGCCTCCGTACTTTTG 60 
3D7        ATGGTTTCCTTCTCAAAAAATAAAGTATTATCCGCTGCCGTTTTTGCCTCCGTACTTTTG 60 
7G8        ATGGTTTCCTTCTCAAAAAATAAAGTATTATCCGCTGCCGTTTTTGCCTCCGTACTTTTG 60 
NF54       ATGGTTTCCTTCTCAAAAAATAAAGTATTATCCGCTGCCGTTTTTGCCTCCGTACTTTTG 60 
NF166      ATGGTTTCCTTCTCAAAAAATAAAGTATTATCCGCTGCCGTTTTTGCCTCCGTACTTTTG 60 
           ************************************************************ 
 
NF135      TTAGATAACGTAAGCATTTTAATTGCAAATAGAAATAAATATATCATTCAATTATAAAAA 120 
3D7        TTAGATAACGTAAGCATTTTAATTGCAAATAGAAATAAATATATCATTCAATTATAAAAA 120 
7G8        TTAGATAACGTAAGCATTTTAATTGCAAATAGAAATAAATATATCATTCAATTATAAAAA 120 
NF54       TTAGATAACGTAAGCATTTTAATTGCAAATAGAAATAAATATATCATTCAATTATAAAAA 120 
NF166      TTAGATAACGTAAGCATTTTAATTGCAAATAGAAATAAATATATCATTCAATTATAAAAA 120 
           ************************************************************ 
 
NF135      TACATATAATAATAATATATATATATATATATATATTTATATATTGTATATATATAAATT 180 
3D7        TACATATAATAATAATATATATATATATATATATATTTATATATTGTATATATATAAATT 180 
7G8        TACATATAATAATAATATATATATATATATATATATTTATATATTGTATATATATAAATT 180 
NF54       TACATATAATAATAATATATATATATATATATATATTTATATATTGTATATATATAAATT 180 
NF166      TACATATAATAATAATATATATATATATATATATATTTATATATTGTATATATATAAATT 180 
           ************************************************************ 
 
NF135      TTTTCATTTTTAAATGCTTTTTTATTTTTATATAGAATAATTCCGCATTTAATAATAACT 240 
3D7        TTTTCATTTTTAAATGCTTTTTTATTTTTATATAGAATAATTCCGCATTTAATAATAACT 240 
7G8        TTTTCATTTTTAAATGCTTTTTTATTTTTATATAGAATAATTCCGCATTTAATAATAACT 240 
NF54       TTTTCATTTTTAAATGCTTTTTTATTTTTATATAGAATAATTCCGCATTTAATAATAACT 240 
NF166      TTTTCATTTTTAAATGCTTTTTTATTTTTATATAGAATAATTCCGCATTTAATAATAACT 240 
           ************************************************************ 
 
NF135      TGTGTAGCAAAAATGCAAAAGGACTTAATTTAAATAAGAGATTATTACACGAAACTCAAG 300 
3D7        TGTGTAGCAAAAATGCAAAAGGACTTAATTTAAATAAGAGATTATTACACGAAACTCAAG 300 
7G8        TGTGTAGCAAAAATGCAAAAGGACTTAATTTAAATAAGAGATTATTACACGAAACTCAAG 300 
NF54       TGTGTAGCAAAAATGCAAAAGGACTTAATTTAAATAAGAGATTATTACACGAAACTCAAG 300 
NF166      TGTGTAGCAAAAATGCAAAAGGACTTAATTTAAATAAGAGATTATTACACGAAACTCAAG 300 
           ************************************************************ 
 
NF135      CACATGTAGATGATGCCCATCATGCTCATCATGTAGCCGATGCCCATCATGCTCATCATG 360 
3D7        CACATGTAGATGATGCCCATCATGCTCATCATGTAGCCGATGCCCATCATGCTCATCATG 360 
7G8        CACATGTAGATGATGCCCATCATGCTCATCATGTAGCCGATGCCCATCATGCTCATCATG 360 
NF54       CACATGTAGATGATGCCCATCATGCTCATCATGTAGCCGATGCCCATCATGCTCATCATG 360 
NF166      CACATGTAGATGATGCCCATCATGCTCATCATGTAGCCGATGCCCATCATGCTCATCATG 360 
           ************************************************************ 
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Supplementary file 3. Sequence alignment (first 360 bp) of pfhrp3 for five reference strains 
from Africa (3D7, NF54, NF166.C8), Brazil (7G8) and Cambodia (NF135.C10). The oligo 
binding sites are highlighted in grey.  
 
NF166      ATGGTTTCCTTCTCAAAAAATAAAATATTATCCGCTGCCGTTTTTGCTTCCGTACTTTTG 60 
NF135      ATGGTTTCCTTCTCAAAAAATAAAATATTATCCGCTGCCGTTTTTGCTTCCGTACTTTTG 60 
3D7        ATGGTTTCCTTCTCAAAAAATAAAATATTATCCGCTGCCGTTTTTGCTTCCGTACTTTTG 60 
7G8        ATGGTTTCCTTCTCAAAAAATAAAATATTATCCGCTGCCGTTTTTGCTTCCGTACTTTTG 60 
NF54       ATGGTTTCCTTCTCAAAAAATAAAATATTATCCGCTGCCGTTTTTGCTTCCGTACTTTTG 60 
           ************************************************************ 
 
NF166      TTAGATAACGTAAGTATTTTAATTGCAAATATAAATAAATATAACACTTACTTATAAAAA 120 
NF135      TTAGATAACGTAAGTATTTTAATTGCAAATATAAATAAATATAACACTTACTTATAAAAA 120 
3D7        TTAGATAACGTAAGTATTTTAATTGCAAATATAAATAAATATAACACTTACTTATAAAAA 120 
7G8        TTAGATAACGTAAGTATTTTAATTGCAAATATAAATAAATATAACACTTACTTATAAAAA 120 
NF54       TTAGATAACGTAAGTATTTTAATTGCAAATATAAATAAATATAACACTTACTTATAAAAA 120 
           ************************************************************ 
 
NF166      TACATATAATAATATTATATATATATATATATATATATATATATATATATATATATATGT 180 
NF135      TACATATAATAATATTATATATATATATATATATATATATATATATATATATATATATGT 180 
3D7        TACATATAATAATATTATATATATATATATATATATATATATATATATATATATATATGT 180 
7G8        TACATATAATAATATTATATATATATATATATATATATATATATATATATATATATATGT 180 
NF54       TACATATAATAATATTATATATATATATATATATATATATATATATATATATATATATGT 180 
           ************************************************************ 
 
NF166      ACATTTTTACATTTTTAAATGATTTTTCATTTTTATAGAATAACTCCGAATTTAACAATA 240 
NF135      ACATTTTTACATTTTTAAATGATTTTTCATTTTTATAGAATAACTCCGAATTTAACAATA 240 
3D7        ACATTTTTACATTTTTAAATGATTTTTCATTTTTATAGAATAACTCCGAATTTAACAATA 240 
7G8        ACATTTTTACATTTTTAAATGATTTTTCATTTTTATAGAATAACTCCGAATTTAACAATA 240 
NF54       ACATTTTTACATTTTTAAATGATTTTTCATTTTTATAGAATAACTCCGAATTTAACAATA 240 
           ************************************************************ 
 
NF166      ACTTGTTTAGCAAAAATGCAAAAGGACTTAATTCAAATAAGAGATTATTACACGAAAGTC 300 
NF135      ACTTGTTTAGCAAAAATGCAAAAGGACTTAATTCAAATAAGAGATTATTACACGAAAGTC 300 
3D7        ACTTGTTTAGCAAAAATGCAAAAGGACTTAATTCAAATAAGAGATTATTACACGAAAGTC 300 
7G8        ACTTGTTTAGCAAAAATGCAAAAGGACTTAATTCAAATAAGAGATTATTACACGAAAGTC 300 
NF54       ACTTGTTTAGCAAAAATGCAAAAGGACTTAATTCAAATAAGAGATTATTACACGAAAGTC 300 
           ************************************************************ 
 
NF166      AAGCACATGCAGGTGATGCCCATCATGCACATCATGTAGCTGATGCCCATCATGCACATC 360 
NF135      AAGCACATGCAGGTGATGCCCATCATGCACATCATGTAGCTGATGCCCATCATGCACATC 360 
3D7        AAGCACATGCAGGTGATGCCCATCATGCACATCATGTAGCTGATGCCCATCATGCACATC 360 
7G8        AAGCACATGCAGGTGATGCCCATCATGCACATCATGTAGCTGATGCCCATCATGCACATC 360 
NF54       AAGCACATGCAGGTGATGCCCATCATGCACATCATGTAGCTGATGCCCATCATGCACATC 360 
           ************************************************************ 
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Abstract 
 
The use of malaria rapid diagnostic tests (RDTs) as a source for nucleic acids that can be de-
tected by nucleic acid amplification techniques (NATs) would have several advantages, in-
cluding the small amount of blood and cost-effectiveness regarding sample collection as well 
as simplified storage and shipping conditions under room temperature (RT). We developed 
systematically and evaluated extensively a procedure to extract total nucleic acids from used 
malaria RDTs. The ENAR (Extraction of Nucleic Acids from RDTs) protocol, co-extracts 
DNA and RNA from small volumes of dried blood and allows the detection and quantifica-
tion of P. falciparum parasites from asymptomatic patients with parasite densities as low as 1 
parasite/µL blood using reverse transcription quantitative PCR. The ENAR protocol was 
evaluated using controlled human malaria infections as a standardized platform which al-
lowed us to conclude that nucleic acids can be reliable recovered and amplified from RDTs, 
even after long-term storage at RT. Our approach is supported by custom-made software solu-
tions allowing to analyse thousands of RDTs in a standardized and high-throughput manner. 
 
Keywords: Nucleic Acid Extraction, Molecular Malaria Surveillance, Rapid Diagnostic Test 
(RDT), Quantitative Polymerase Chain Reaction (qPCR) 
 
Abbreviations: RDT (rapid diagnostic test), DBS (dried blood spot), ENAR (extraction of 
nucleic acids from RDT), CHMI (controlled human malaria infection), NA (nucleic acids), 
NAT (nucleic acid amplification technique), PfIS (WHO International standard for P. falcipa-
rum NAT), LOD (limit of detection), RT (room temperature)  
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Introduction 
 
Malaria is a vector-borne, global public health problem caused by apicomplexan parasites of 
the genus Plasmodium. WHO published that in 2017, 219 million cases in 87 countries oc-
curred with an estimated number of 435 000 malaria deaths (1). Currently used malaria con-
trol strategies include vector control measures like sleeping under insecticide-treated mosqui-
to nets and indoor residual spraying with insecticides as well as access to timely malaria diag-
nostic testing and prompt treatment (1). In Sub-Saharan Africa, the region which carries the 
highest burden of malaria, the majority of countries collect their malaria surveillance data 
through national health information systems (1). The parasite rate, the proportion of popula-
tion found to carry asexual blood-stage parasites in their peripheral blood, is the most com-
monly recorded measure of malaria prevalence, reflecting closely the malaria transmission 
intensity (2, 3).  
Malaria rapid diagnostic tests (RDTs) have become the most widely used method to measure 
parasite rates of asexual blood stage parasitaemia in endemic countries. In Sub-Saharan Afri-
ca, RDTs have almost completely replaced light microscopy for malaria diagnosis, with an 
estimated 75% of malaria tests conducted using RDTs in 2017 (1). This is the consequence of 
the relatively low costs, rapid generation of diagnostic results, wide availability and simplicity 
in use. In 2017 alone, 245 million RDTs were distributed worldwide (1). Technically, RDTs 
are based on a lateral flow device which detects circulating malaria antigens using antibodies 
in 5 to 20 μL of capillary blood (4). The vast majority of antibodies in use recognise the para-
site-derived histidine-rich protein 2 (PfHRP2) (5). It is well-established that the lower limit of 
detection (LOD) of currently used PfHRP2-based RDTs is around 100 parasites/µL (6, 7). 
This LOD prevents identification of a significant proportion of asymptomatic individuals car-
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rying lower parasitaemia levels, which can account for more than 50 % of the parasite rates 
observed in the population (8, 9).  
Increasingly, the presence of pfhrp2/pfhrp3 gene deletions in circulating P. falciparum popu-
lations that result in false negative PfHRP2-based RDTs is being reported, particularly in 
South America and Sub-Saharan Africa (10). On the contrary, there are also reports of false 
positive malaria RDTs. The high stability of the PfHRP2 antigen leads to persistence of this 
antigen circulating in blood up to several weeks post malaria treatment (11–13). An additional 
limit of RDTs is that based on the species restricted expression of PfHRP2 to P. falciparum, 
only presence of P. falciparum can be measured. Although there are RDTs available which 
use antibodies targeting Pan-Plasmodium antigens such as lactate dehydrogenase or aldolase, 
their sensitivity is lower than PfHRP2-based RDTs (5, 12). P. malariae and P. ovale infec-
tions which are often co-endemic with P. falciparum are usually characterized by very low 
parasitaemia (14) and will rarely be detected by RDTs.  
Nucleic Amplification Techniques (NATs) for P. falciparum diagnosis, such as polymerase 
chain reaction (PCR), are more sensitive and more specific than RDTs (15). These techniques 
were adapted to detect non-falciparum Plasmodium species. The use of NAT-based diagnos-
tic tests for detection and identification of malaria parasite species adds substantially more 
information to malaria control and surveillance programs (16). The commonly used procedure 
of blood sample collection for NAT based malaria diagnostic assays includes collection and 
storage of capillary blood on filter papers and is particularly suitable in resource-limited set-
tings (17). Recently, a protocol co-extracting RNA and DNA (herein referred to as nucleic 
acids, NA) from dried blood spots (DBS) was published which allows the ultrasensitive detec-
tion of malaria parasites based on reverse transcription quantitative PCR (RT-qPCR) (18).  
Over the past decade several reports have been published describing the use of DNA from 
RDTs for molecular characterization of malaria infections (studies reviewed in Table 1). 
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Apart from malaria parasites, it was also demonstrated that RDTs could serve as reliable 
source of NA for the detection of dengue virus (19) and antibiotic-resistant typhoid (20). The 
use of RDTs as a source for NA that can be used as an input for NATs would have several 
advantages, including the small amount of blood and cost-effectiveness regarding sample col-
lection as well as simplified storage and shipping conditions under room temperature (RT). 
However, most of the studies were small, between 40 and 855 RDTs included and focused 
rather on demonstrating the feasibility of extracting DNA than fitting this approach for mo-
lecular surveillance of malaria parasites at larger scale. 
Here, we developed systematically and evaluated extensively a procedure to extract NA from 
RDTs that have been used for malaria surveillance. We demonstrate that our ENAR (Extrac-
tion of Nucleic Acids from RDTs) protocol identifies and quantifies Plasmodium spp. infec-
tions by amplifying the extracted NA using RT-qPCR. Our approach is supported by custom-
made software solutions allowing to analyse thousands of RDTs in a standardized and high-
throughput manner.   
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Material and methods 
 
School-based survey in Mkuranga district 
CarestartTM HRP2/pLDH Combo RDTs (Access Bio, Inc., Somerset, NJ, USA) were used to 
determine the parasite rate in three primary schools in the Mkuranga district of Coastal Tan-
zania. Extraction protocol A, which is based on the Quick-DNA™ Miniprep Kit (Zymo Re-
search Corporation, Irvine CA, USA), was used to extract DNA for this school-based survey. 
Plasmodium spp. was detected by amplifying the pan-Plasmodium 18S rDNA (21, 22) fol-
lowed by the identification of P. falciparum using telomere-associated repetitive element 2 
(PfTARE2) (23) and the acidic terminal sequence of the var genes (PfvarATS) (23). P. ovale 
spp. was identified based on amplification of the reticulocyte binding protein 2 (PoRbp2) (24) 
and P. vivax based on the amplification of P. vivax-specific 18S rDNA (Pv18S) (25). Two 
independent assays were used to screen for the presence of P. malariae parasites, based on 
plasmepsin 4 (PmPlasp4) (26) and a novel P. malariae-specific multicopy target (PmRep3). 
For the PmRep3 assay, 2 µL extracted DNA was added to 8 µL of qPCR reaction mix. The 
qPCR reaction mix contained 1x HOT FIREPol® EvaGreen® qPCR Mix (Solis BioDyne, 
Tartus, Estonia), 0.2 µM each forward (5’-TTCATACTTAAACTGTAAGC-3’) and reverse 
(5’-GTTCAGAAMWTTTGAGGG-3’) primers. Amplification and qPCR measurements were 
performed using the Bio-Rad CFX96 Real-Time PCR System (Bio-Rad Laboratories, Cali-
fornia, USA). The thermal profile used for PmRep3 qPCR is as follows: 15 min at 95 °C; 45 
cycles of 15 s at 95 °C and 60 s at 55 °C. Specificity was assessed based on the melting tem-
perature of the amplicon, which was 71.7 °C for P. malariae. 
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Sample collection, analysis and storage during CHMI studies 
RDTs were collected during two CHMI studies conducted to evaluate Sanaria’s PfSPZ Vac-
cine in Bagamoyo, Tanzania. The first CHMI was conducted in 2016 (referred to CHMI-1, 
ClinicalTrials.gov Identifier: NCT02613520) the second CHMI was conducted in 2018 (re-
ferred to CHMI-2, ClinicalTrials.gov Identifier: NCT03420053). Fresh venous whole blood 
collected in EDTA tubes was pipetted onto the RDTs within 45 min after blood collection. 
During CHMI-1, 20 µL was applied to BinaxNOW® Malaria RDT (Alere, Cologne, Germa-
ny) and during CHMI-2, 5 µL was applied to CarestartTM HRP2/pLDH Combo RDT (Access 
Bio, Inc., Somerset, NJ, USA). The RDTs were read according to the manufacturers guide 
and then stored in a box at RT until extraction of nucleic acids.  
The same samples were used to monitor parasitemia during CHMI by thick blood smear mi-
croscopy and qPCR as described elsewhere (27, 28). All samples were processed and ana-
lysed at the laboratories of the Bagamoyo branch of the Ifakara Health Institute in Tanzania. 
 
Nucleic acid extraction methods from RDTs 
The cassettes of the RDTs were opened, the entire RDT strip removed, and cut into four small 
pieces in order to fit into a 1.5 mL microcentrifuge tube. A set of cleaned forceps and scissors 
were used with special attention given to the prevention of cross-contamination between sam-
ples. After processing sample, scissors and forceps were cleaned in 10% sodium hypochlorite 
and wiped with ethanol sprayed tissues and dried before processing the next sample. The four 
nucleic extraction protocols tested, named A-D, were all based on silica columns and are de-
scribed below.  
 
 
  
Chapter III - ENAR procedure  143 
Protocol A - Quick-DNA™ Miniprep Kit 
Protocol A is based on the Quick-DNA™ Miniprep Kit (Zymo Research Corporation, Irvine 
CA, USA). Briefly, 1 mL of Genomic Lysis Buffer was added to the pre-cut RDT strip in a 
1.5 mL microcentrifuge tube. Samples were incubated at 95°C for 20 minutes. The superna-
tant was transferred onto the extraction column and the manufacturers guide was followed for 
extraction. DNA was eluted in 50 µL of DNA Elution Buffer. In the modified version of pro-
tocol A the RDT strips were incubated at 60°C for 60 minutes. 
 
Protocol B – Quick-DNA™ Miniprep Plus Kit 
Protocol B is based on the Quick-DNA™ Miniprep Plus Kit (Zymo Research Corporation, 
Irvine CA, USA). Briefly, 600 μL of Solid Tissue Buffer (Blue) and 40 μL of Proteinase K 
was added to the pre-cut RDT strip in a 1.5 mL microcentrifuge tube and incubated at 55°C 
for 60 minutes. The supernatant was transferred to a clean 1.5 mL microcentrifuge tube and 
640 μL of Genomic Lysis Buffer was added and mixed thoroughly. The mixture was then 
transferred onto the extraction column and the manufacturers guide was followed for extrac-
tion. DNA was eluted in 50 µL of DNA Elution Buffer. The modified version of protocol B 
had an increased incubation duration of 180 minutes. 
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Protocol C – NukEx Pure RNA/DNA Kit 
Protocol C is based on NukEx Pure RNA/DNA Kit (Gerbion GmbH, Kornwestheim, Germa-
ny), which co-extracts DNA and RNA. Briefly, a working solution of 500 μL of Binding 
Buffer, 4 μL of Poly A and 50 μL of Proteinase K was added to the pre-cut RDT strip in a 1.5 
mL microcentrifuge tube and incubated at 60°C for 10 minutes. The supernatant was trans-
ferred onto the NukEx Spin Column and the manufacturers guide was followed for extraction. 
Total nucleic acids were eluted in 50 µL of Elution Buffer. The modified version of protocol 
C has an increased incubation duration of 180 minutes. 
 
Protocol D – Zainabadi et al. extraction method for DBS 
Protocol D is based on a recently published extraction protocol for total nucleic acids from 
dried blood spots (18). Identical buffer compositions were used and the protocol was adapted 
to extraction of NA from RDT strips. Briefly, the pre-cut RDT strip was incubated in 900 µL 
lysis buffer at 60°C for 120 minutes. The supernatant was transferred onto Omega HiBind 
RNA Mini Columns (Omega Bio-Tek, Norcross, USA) and nucleic acids extracted as de-
scribed. Total nucleic acids were eluted in 50 µL of Elution Buffer (Quick-DNA™ Miniprep 
Kit, Zymo Research Corporation, Irvine CA, USA).  
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High-throughput extraction protocol of nucleic acids from RDTs (ENAR protocol) 
We adapted protocol D to extract nucleic acids from used RDTs in a high-throughput manner. 
The main modification included a horizontal incubation of the entire uncut RDT strip by us-
ing sterile, RNase-/DNase-free 12-channel reservoirs (Axygen, Corning Inc, USA) and 
switching to a 96-well format for extraction. By removing the manual cutting of the RDT 
strip, the hands-on time during the extraction process is reduced, and the risk of cross-
contamination by carryover during the extraction process is minimized. Up to eight 12-
channel reservoirs, with a total of 96 samples, were processed in one batch. Lysis was con-
ducted by adding 900 µL lysis buffer to each RDT strip placed in the 12-channel reservoir 
followed by incubation at 60 °C for 2 hours with gentle shaking. All supernatants were then 
transferred to Omega E-Z 96 wells DNA plates (Omega Bio-Tek, Norcross, USA), washed 
with two wash buffers and finally eluted into a 96 well plate (DNA LoBind Plates, Eppen-
dorf) with 50 µL pre-warmed (60 °C) Elution Buffer (Zymo Research Corporation, Irvine 
CA, USA). With these adaptations to the protocol, nucleic acids from 96 RDTs are extracted 
in about three hours, with minimal hands-on time needed. One positive control (RDT spiked 
with 5 µL blood containing 200 parasites/µL) and one negative control (Lysis buffer only) 
were included with each extraction plate to control for plate-to-plate consistency and cross-
contamination. 
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Detection of nucleic acids by qPCR and RT-qPCR assays 
We used the PlasQ assay, a multiplex qPCR assay for Plasmodium spp. and P. falciparum 
screening and quantification (28), to analyse the NA extracted from RDTs. This assay consists 
of two independent Plasmodium targets. The Pan-Plasmodium 18S DNA and RNA (Pspp18S) 
is targeted (21, 29), as well as the P. falciparum-specific acidic terminal sequence of the var 
genes (PfvarATS) (23). The human RNaseP gene (HsRNaseP) (21) served as an internal con-
trol to assess the quality of nucleic acid extraction and qPCR amplification. The PlasQ assay 
was run as a qPCR assay, targeting DNA only, with the same concentrations and conditions as 
previously described (28). In order to run the PlasQ as a RT-qPCR assay, targeting DNA and 
RNA templates, we added 1x Luna WarmStart RT Enzyme Mix (New England Biolabs, Ips-
wich, USA) and did start the qPCR program with a reverse transcription step at 55 °C for 15 
min. All qPCR and RT-qPCR assays were run on a Bio-Rad CFX96 Real-Time PCR System 
(Bio-Rad Laboratories, California, USA). Samples were analysed in duplicates with positive 
(P. falciparum NF54 DNA), negative (malaria negative individual) and non-template (molec-
ular biology grade H2O) controls. The mean Cq of the two replicates was calculated and in 
case of one replicate interpreted as positive and the other replicate negative, then the assay 
had to be repeated and the result was considered positive if two positive replicates were ob-
tained out of the total four replicates.  
A RT-qPCR assay for P. falciparum female gametocytes was used targeting the 
PF3D7_0630000 gametocyte- transcript (30). Briefly, 2 µL of extracted nucleic acids were 
added to 8 µL reaction mix consisting of 0.6 µM of primers, 0.3 µM probe and Luna® Uni-
versal Probe One-Step RT-qPCR Kit (New England Biolabs, Ipswich, USA). The qPCR pro-
gram included reverse transcription for 15 min at 53 °C, followed by polymerase activation 
for 1 min at 95 °C and 45 cycles with 15 s at 95 °C and 45 s at 53 °C. 
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P. falciparum reference samples 
Different reference samples were used to test performance of the ENAR procedure. Experi-
ments with reference were conducted using CarestartTM HRP2/pLDH Combo RDTs were 
used. 
The WHO International Standard for P. falciparum DNA Nucleic Acid Amplification Tech-
niques (NIBSC code: 04/176, herein referred to as PfIS) (31) was used for quantification of P. 
falciparum parasitaemia. Whole blood was spiked with different parasite densities, ranging 
from 10’000 to 0.1 parasites/µL and 5 µL applied onto RDT. Cultured P. falciparum strains 
PfNF54, PfDD2 and PfHB3 were diluted with whole blood to parasite densities correspond-
ing to 1000 parasites/µL. Using these concentrations, serial dilutions were prepared and 5 µL 
were applied onto RDTs. Stage V gametocytes were obtained from culture as described pre-
viously (32). 5 µL gametocyte culture were applied onto RDTs and extracted using the ENAR 
protocol after a three-week storage at RT.  
 
Data analysis and statistics 
All qPCR and RT-qPCR data generated with the ENAR protocol was uploaded to a custom-
designed laboratory management and information system named ELIMU-MDx (manuscript in 
preparation). The ELIMU-MDx platform supports automated quality control, management 
and analysis of qPCR data. Data was analysed and plots created using R version 3.5.1 based 
on packages dplyr, ggpubr, gridextra and scales.  
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Results 
 
Blood stored on RDTs is a source of Plasmodium spp. DNA 
First, we conducted a literature search in Google Scholar of reports describing the use of 
DNA and RNA extracted from RDTs as input templates for NAT based molecular detection 
of malaria (Table 1). A total of 8 studies were published between 2006 and 2019. DNA stored 
on these RDTs were extracted with a variety of different extraction methods. The majority of 
studies used the Chelex method (33) for DNA extraction and two described automated extrac-
tion systems. One study extracted DNA from the entire RDT strip, all other studies used only 
predefined fragments of the RDT strip. In summary, these studies demonstrated that P. falci-
parum DNA can be recovered from RDTs and amplified then by nested PCR or qPCR. In 
these studies, most RDTs had been probed with blood from RDT or microscopy positive pa-
tients or even febrile clinical malaria cases, indicating high parasitaemia levels. Beside the 
identification of P. falciparum parasites, the DNA isolated from RDTs was used for drug re-
sistance screening and assessing the multiplicity of infection (Table 1).  
First, we employed RDTs collected in a school-based malaria survey conducted in three pri-
mary schools in the Mkuranga district of Coastal Tanzania, as study to test feasibility of using 
DNA on RDTs for molecular malaria surveillance. RDTs collected from 190 children from 
two primary schools, in Bupu and Mkerezange, with high (56.7% and 44.3%, respectively) 
and one primary school in Ngunguti (8.3%) with low parasite prevalence as assessed by RDT 
were used. DNA from RDTs was extracted following protocol A and human DNA was suc-
cessfully amplified from all 190 RDTs. P. falciparum DNA was recovered in 91.4% (64/70) 
of PfHRP2-positive RDTs as detected by the PfvarATS assay. Two additional children were 
positive by the PfTARE2 assay. Two out of the four remaining children with PfHRP2-
positive RDTs but negative for P. falciparum DNA self-reported to have received antimalarial 
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treatment during the past two weeks. Additionally, the PfvarATS assay detected P. falciparum 
DNA in 11.7% (14/120) of negative RDTs. P. falciparum was the most prevalent Plasmodium 
species, followed by P. malariae. These two species were found in children from all three 
primary schools, while P. ovale spp. was found in only two RDTs, both collected in Bupu 
(Figure 1A). 
Based on the P. falciparum-specific PfvarATS qPCR assay, the parasite densities were esti-
mated in the blood collected on RDTs (Figure 1B). RDTs which were negative did have the 
lowest P. falciparum parasitaemia levels, followed by RDTs positive for PfHRP2. RDTs posi-
tive for both antigens, PfHRP2 and pLDH, had the highest parasitaemia levels. These results 
reflect the well known LODs for PfHRP2 (100 Pf/µL) and pLDH (1000 Pf/µL). Notably, the 
lowest parasite density found was 7.6 Pf/µL, indicating that detection based on DNA extract-
ed from RDTs has a reduced sensitivity among infections with ultra-low (< 1 parasite/µL) 
parasite densities. 
 
Comparison of protocols for nucleic acid extraction from RDTs 
Encouraged by the outcome of the school-based survey, we aimed to improve the extraction 
method of NA from RDTs further. The Cq value of the human rnasep gene (HsRNaseP tar-
get), which is the internal control of the previously published PlasQ assay (28), was used to 
assess the overall performance of the NA extraction procedure. Four different extraction pro-
tocols were compared. Protocol A and B are limited to isolation of DNA (Fig 2A), while pro-
tocols C and D extract both RNA and DNA (Fig 2B). For the DNA only extraction proce-
dures, the performance of protocol B, which uses an extraction buffer for solid tissues, was 
significantly better than protocol A (more than 4 Cq difference), which is our standard proto-
col for extracting DNA from whole blood. Protocol modification, including increased incuba-
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tion times did not improve the performance of either of the protocols (not shown). Among the 
methods capable of co-extracting DNA and RNA, protocol D did yield more NA than proto-
col C. Lower Cq values were observed when RNA is also targeted for amplification using 
RT-qPCR in samples extracted with protocol D, although the difference was not statistically 
significant (p=0.14, paired Wilcoxon test). 
Side by side comparison of DNA extracted by using protocol A from the Tanzanian school-
based survey with a selection of 71 RDTs collected in Bagamoyo and extracted with protocol 
D confirmed the superior performance of protocol D based on the detection of DNA only 
(p<0.0001, Wilcoxon-Mann-Whitney test) (Fig 2C). In summary, side by side comparison of 
four protocols for extracting NA from malaria RDTs showed that protocol D performed best 
and was therefore renamed as ENAR (Extraction of Nucleic Acids from RDTs) and used for 
all following experiments.  
 
Detection and quantification of P. falciparum parasites based on ENAR protocol 
Three RDT strips from RDTs probed with 5 µL fresh whole blood and six RDTs probed with 
5 µL frozen whole blood samples were cut into three pieces, containing the sample pad (prox-
imal part), the detection area (middle part) or the absorption pad (distal part). Each of these 
three parts was used to extract nucleic acids separately, followed by analysis with PlasQ RT-
qPCR assay (Fig 3A). In RDTs probed with fresh blood, P. falciparum NA are found in all 
three parts, with more than 87% of total DNA enriched in the middle part. RDTs probed with 
frozen blood that is associated with red blood cell lysis resulted in a more equal distribution of 
NA along the RDT strip.  
The ability of the ENAR protocol to extract RNA is demonstrated with the following experi-
ment. 5 µL of an in vitro generated gametocyte culture was applied to RDTs and stored at RT 
for three weeks before NA were extracted. The gametocyte-specific transcript 
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PF3D7_0630000 was reverse transcribed and amplified using a published assay which does 
not require DNase treatment for specific detection of gametocytes (30). Extracted NA from 5 
µL undiluted and 1:100 diluted culture amplified specifically the gametocyte marker, while 
the control without reverse transcription step did not result in amplification (Fig. 3B).  
One of the advantages of qPCR assays are the possibility to quantify parasitaemias. Therefore, 
the 1st WHO International Standard for P. falciparum DNA Nucleic Acid Amplification 
Techniques (PfIS) was used to explore the feasibility of quantifying P. falciparum parasites. 
Different parasite densities, ranging from 0.1 to 10’000 parasites/µL of the PfIS, were spiked 
into whole blood and 5 µL of this mixture was pipetted onto RDTs. A total of 56 individual 
RDTs, with different parasitaemia levels were extracted and analysed with the RT-qPCR 
PlasQ assay (Fig 3C). A reversed correlation between parasitaemia levels and Cq values were 
observed for both targets, the P. falciparum specific PfvarATS and the pan-Plasmodium tar-
get Pspp18S. 18S ribosomal RNA, detected by the Pspp18S assay, is highly and constant ex-
pressed during the lifecycle of Plasmodium spp. (34, 35), while the acidic terminal sequence 
of the var genes (PfEMP1), detected by the PfvarATS assay, has lower expression levels (36). 
The Pspp18S based assay detects total NA while the PfvarATS assay is limited to amplifica-
tion of DNA only. Based on the slope, RT-qPCR efficiencies of 75.4% and 124.3% were cal-
culated for PfvarATS and Pspp18S, respectively. RDTs negative for PlasQ assay amplifica-
tion (Cq > 45, colored in red) carried mostly dilutions representing parasitaemia levels ≤ 1 
parasite/µL. Two exceptions were observed where the Pspp18S assay failed to amplify two 
RDTs probed with higher parasitaemia levels (5 and 10 parasites/µL, respectively). RDTs 
probed with 1 parasite/µL were detected in 4 (PfvarATS) and 7 (Pspp18S) out of 10 RDTs. 
The higher detection rate at low parasitaemia levels for Pspp18S compared to PfvarATS is an 
indicator for the co-amplification of DNA and RNA in these samples. 
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We also evaluated the ENAR protocol with cultured P. falciparum strains including 
PfNFDD2, PfHB3 and PfNF54 by preparing serial dilutions in whole blood with parasite den-
sities corresponding to 0.1 – 1000 Pf/µL (Fig 3D). RDTs were then probed with 5 µL of this 
mixtures and NA extracted. In all three cultures and using RT-qPCR, the PfvarATS assay did 
not amplify the NA from RDTs containing 0.1 parasites/µL, while the Pspp18S assay was 
able to amplify 0.1 Pf/ µL in two out of three P. falciparum strains. If analysed by qPCR, par-
asite densities of 0.1 parasites/µL were not detected. 
In summary, NA from P. falciparum are highly concentrated in the middle part of the RDT 
when fresh whole blood is applied. RNA can be preserved and extracted from RDTs as shown 
with the detection of the gametocyte-specific transcript PF3D7_0630000 and increased sensi-
tivity of the Pspp18S RT-qPCR assay, which amplifies the highly abundant 18S rRNA. Quan-
tification of parasitaemia can be performed, based on a correlation between parasitaemia lev-
els and Cq values obtained from the RT-qPCR assays. The lower limit of detection (LOD) for 
RT-qPCR-based amplification of NA from RDTs is around 1 parasite/µL, although 10x lower 
parasitaemia levels can be detected as demonstrated with the freshly cultured PfNFDD2, 
PfHB3 and PfNF54 strains. 
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Evaluation of ENAR protocol using Controlled Human Malaria Infection studies as a 
platform 
Controlled Human Malaria Infection (CHMI) has been shown to be safe, well tolerated and is 
now regarded as a reliable tool to test protective efficacy of vaccine candidates in clinical tri-
als (37, 38). qPCR is increasingly used in CHMI studies, also in malaria endemic countries, to 
closely monitor asexual blood stage parasitemia levels for safety of study participants and as 
study endpoint (39). Blood collected from volunteers undergoing CHMI studies represent 
well-characterized samples with a defined parasite strain, time and dose of infection and can 
therefore be used to evaluate novel malaria diagnostic approaches. 
The ENAR protocol was evaluated with samples collected during CHMIs assessing the effi-
cacy of Sanaria’s PfSPZ Vaccine in clinical trials in Bagamoyo, Tanzania. RDTs were used 
and stored as part of two CHMIs, the first CHMI was conducted in 2016 and the second 
CHMI in 2018 (Table 2). As part of the standard diagnostic procedures, whole blood was col-
lected in EDTA tubes and DNA was extracted from a total of 180 µL whole blood. DNA-
based qPCR assay was run and parasitaemia quantified (defined as WB-qPCR). Parasitaemia 
densities as low as 0.05 parasites/µL are detected with the WB-qPCR protocol. All RDTs 
were conducted during the CHMIs with fresh whole blood from asymptomatic subjects col-
lected 9 to 18 days post experimental malaria infection. CHMI-1 and CHMI-2 used two dif-
ferent types of RDTs which required 20 µL and 5 µL of whole blood, respectively. RDTs 
collected during CHMI-1 were stored 605 days on average, while RDTs collected during 
CHMI-2 were stored 18 days on average before processing following the ENAR protocol. 
During the entire storage period, RDTs were kept at RT in a closed box and protected from 
light and dust. During CHMI-1, RDTs were collected later (around day 14), resulting in high-
er parasitemia than during CHMI-2 (around day 12.7). 
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NA were extracted from the RDTs using the ENAR protocol and parasites were detected and 
quantified by qPCR and RT-qPCR using the PlasQ assay (Table 3). First, we analysed the 
impact of RDT storage time on the parasite detection rates. No statistically significant differ-
ences between CHMI-1 and CHMI-2 were observed for qPCR (0.56 vs 0.40, Fisher’s exact 
test p = 0.29) or RT-qPCR (0.67 vs 0.42, Fisher’s exact test p = 0.07). The same trends are 
observed, for qPCR (0.72 vs 1.0, Fisher’s exact test p = 0.14) and RT-qPCR (0.94 vs 1.0, 
Fisher’s exact test p = 0.54) if only blood samples with parasitemia levels ≥1 parasite/µL were 
considered. We cannot exclude the possibility that the higher blood volume, 20 µL instead of 
5 µL, used during CHMI-1 has compensated for degradation of NA over time.  
If the data of both CHMIs is combined, the overall sensitivity was 47% for qPCR and 54% for 
RT-qPCR when compared to WB-qPCR (Table 3). RT-qPCR is significantly more sensitive 
than qPCR for the Pspp18S assay (0.27 vs 0.47, McNemar test p =0.0026), but not for the 
PfvarATS assay (0.47 vs 0.47, McNemar test p =1.0). Interestingly, among the long-term 
stored RDTs collected in 2016, the detection rate of the Pspp18S assay was also significantly 
higher for RT-qPCR compared to qPCR (0.52 vs 0.22, McNemar test p =0.01). This is a 
strong indicator that RNA is preserved even during long term storage. False positive detec-
tions were also observed, the specificity of RT-qPCR (3 false positive) was lower than qPCR 
(1 false positive).  
Parasitaemia levels determined by WB-qPCR versus the parasite densities obtained with the 
ENAR-based RT-qPCR method showed significant positive correlation (Fig 4A). The correla-
tion was stronger with the PfvarATS assay (r2 = 0.72) than with the Pspp18S assay (r2 = 0.39). 
Probably because the reference parasite density assessed by WB-qPCR was based on DNA 
only. Interestingly, the parasite quantities estimated from RDTs with shorter storage time 
(CHMI-2) are closer to the reference parasitaemia levels assessed by WB-qPCR than the es-
timates from RDTs collected in 2016 (CHMI-1) (Fig 4B). Detection of NA from RDTs is 
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highly associated with parasite density in whole blood and failure in detection is associated 
with ultra-low parasitemia levels (Fig 4C). Interestingly, a highly similar in vivo parasite 
growth dynamics between parasitemia determined in whole blood and extracted from RDTs is 
observed (Fig 3D). Once parasitemia reaches a density of 1 Pf/µL (dashed line) the detection 
probability of the ENAR approach is close to 100% (Fig 4D). 
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Development of a high-throughput version of the ENAR protocol 
Around the ENAR protocol we wanted to develop an analysis pipeline that allows to analyse 
the molecular malaria epidemiology based on RDTs collected during a malaria indicator sur-
veys (Fig 5A). First, instead of disposing the RDTs after probing and reading, they are la-
belled with a barcode with the intention to connect each RDT with other survey data like 
questionnaires or geo-referenced data (Fig 5B). As an example, we started our project with 
13’505 of unsorted, barcoded RDTs collected during the 2018 malaria indicator survey on 
Bioko Island. For each of these barcode-labelled RDTs additional informed consent for anon-
ymized molecular analysis was obtained from the participants. For the sorting and selection of 
distinct RDTs that we wanted to analyse, we developed the RDTselect app (40), a browser-
based application which identifies barcode-labelled RDTs based on an input list containing all 
barcodes of a certain selection. To enable tracking of an individual RDT throughout the 
ENAR extraction process the RDTallocator app was built (41). The barcodes are scanned 
with a mobile phone camera and the RDTallocator app allocates the associated RDT strip to 
the next available position in a 12-channel reservoir and subsequently 96-well plate (Fig 5C). 
Next, without cutting the RDTs, NA are extracted using the ENAR protocol (Fig 5D). After 
opening the RDT shell, the entire RDT strips are incubated in a 12-well long-format plate 
followed by extraction in 96-well format following the ENAR protocol. All extracted samples 
undergo initial screening for Plasmodium spp. parasites and quality control using the PlasQ 
RT-qPCR assay (Fig 5E). 
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Discussion and conclusion 
 
The idea of using the blood stored on RDTs for molecular analysis of malaria parasites is not 
novel, during the past decade several protocols and approaches have been published (re-
viewed in Table 1). RDTs collected during epidemiological surveys provide a convenient way 
to get access to blood samples for molecular analysis. The small blood volume, usually 5 to 
10 µL, applied onto RDTs is a great advantage regarding blood collection in the field because 
it is more acceptable by participants (42) and also more secure during collection and shipping 
of samples (43). The small amount of blood is at the same time also a limitation. In malaria 
endemic populations, a high proportion of P. falciparum infections identified are character-
ized by low parasite densities undetectable by conventional diagnostic tools. Therefore, we 
aimed to maximize the amount of NA recovered from RDTs. First, we used the entire RDT 
strip to recover as much NA as possible, contrary to previous studies that used only parts of 
the strip thought to contain most of the NA (43–47). Second, we expanded the pool of possi-
ble target molecules for amplification to DNA and RNA by adapting a previously described 
extraction method of total NA (18). We found a significantly higher detection rate of malaria 
parasites based on amplification of the 18S ribosomal RNA using RT-qPCR compared to 
qPCR, most likely based on its high abundance as RNA with an estimated 10’000 copies ex-
pressed per ring form (34). Additionally, the preservation and extraction of RNA was con-
firmed by the detection of the gametocyte-specific transcript PF3D7_0630000 (30) in NA 
extracted from 5 µL of in vitro stage V gametocyte culture applied onto RDTs and stored at 
RT for three weeks. 
We extensively evaluated the performance of the ENAR approach for detection of malaria 
parasites. Lower LODs, ranging from 0.02 – 50 Pf/µL for malaria detection based on extract-
ed DNA from RDTs have been reported (summarized in Table 1). Using external reference 
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samples, such as parasites from P. falciparum culture or diluted blood from infected patients, 
to determine lower LOD, might lead to overestimated sensitivities and is reported to be diffi-
cult to reproduce (48). LODs derived from serial dilution experiments, based on external 
standards, might often represent the best-case scenario and not the performance under real-life 
conditions. We demonstrated that the LOD of the ENAR-based protocol is 10x lower if cul-
tured P. falciparum parasites are used as an external reference compared to the PfIS (31), 
based on lyophilized blood. The availability of RDTs collected during two CHMI studies en-
ables us to evaluate the ENAR approach under highly controlled but real-life, ex vivo condi-
tions. Compared to parasitaemia data obtained from fresh whole blood using qPCR, the detec-
tion rate of ENAR-based RT-qPCR was found to be overall 54%. Especially in regards to the 
low-density P. falciparum infections observed during CHMI studies, this level of sensitivity is 
remarkable high. Side by side comparison using identical blood sample, the overall detection 
rate was significantly higher than detection by microscopy (9%) or PfHRP2 antigen capture 
by RDT (12%) or LAMP (26%). Furthermore, parasites are detected early on during blood 
stage infection since we found detection rate of 30% during the first week of blood stage par-
asitaemia using our ENAR approach. Given all the information provided, we concluded that 
the lower LOD should be set at 1 Pf/µL. This lower LOD also applies to the sensitivity of 
ENAR from RDTs which had been stored for longer time periods with no special preserva-
tion. 
We did not find conclusive evidence that long-term storage has a negative impact on the de-
tection rate of P. falciparum NA, which is similar to what previous studies have concluded 
(42, 43, 45, 46, 49). Contradictory, we did observe an impact of storage on parasite quantities, 
longer storage periods had significantly lower parasitaemia levels than RDTs which were 
stored for shorter periods.  
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Robinson et al., concluded that the skew towards higher parasitaemia values derived from 
DBS when compared to DNA extracted from RDTs may be indicative of lower DNA quality 
found on RDTs (42). However, the preservation of NA from human and parasite origin on 
RDTs gives enough time for shipping RDTs from the field to a central laboratory at RT in a 
malaria endemic country. At central reference laboratories, ENAR-based extraction could be 
performed followed by (RT)-qPCR analyses. Blood stored on well-documented RDTs could 
provide for a unique and cheap biobank that will enable retrospective molecular studies over 
several years following distinct malaria genotypes or trends in malaria species co-infections. 
We aimed to increase significantly the RDT sample extraction and analysis throughput to 
transform it into an amendable tool for larger scale surveillance studies. By using the entire 
RDT strip without cutting into pieces by scissors followed by NA extraction in the 96-well 
format, the processing time was reduced significantly. With the ENAR procedure, 96 RDTs 
can be processed in about 3 hours including the incubation time of 2 hours. Importantly, the 
risk of cross-contamination by carryover of DNA or RNA between samples was reduced.  
In summary, our study demonstrates the feasibility of extracting and analyzing thousands of 
RDTs probed with blood samples in a high-throughput manner backed by smartphone apps 
that allow easy tracking of each RDT sample throughout the ENAR process. The costs per 
sample processed by the ENAR protocol are comparable to the $1.77 per sample which was 
estimated for the extraction of total NA from DBS as published by Zainabadi et al (18). This 
high-throughput analysis of extracted NA will enable us to identify and quantify P. falcipa-
rum in various, highly diverse endemic settings. Our ENAR method could be used for the 
detection of pfhrp2 and pfhrp3 gene deletion in P. falciparum, the discrimination of the dif-
ferent Plasmodium species, the detection of mutations associated to antimalarial drug re-
sistance and even other blood-borne pathogens. 
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Table 1. Review of published protocols for the extraction of nucleic acids to detect malaria parasites.  
Publication/ 
Year 
Veron et al. 
2006 (49) 
Ishengoma et al. 
2011 (45) 
Cnops et al. 
2011 (46) 
Morris et al. 
2013 (47) 
Mze et al. 
2015 (44) 
Nabet et al. 
2016 (43) 
Boyce et al. 
2018 (50) 
Robinson et al. 
2019 (42) 
Origin of RDTs French Guiana Tanzania Belgium Tanzania Senegal, Comoros Islands Mali Uganda Kenya 
Storage time and 
temperature 6-36 months at RT 28-65 days at RT 
1 week – 16 month at 
RT 1-9 months at RT not specified 14 months at RT 2 years at RT 14 months at −20 °C 
Number of samples for 
clinical evaluation 40 165 121 855 204 134 299 141 
Brand of RDT used for 
clinical evaluation 
Optimal®,  
ICT Now® 
ParaHIT®f,  
Paracheck Pf® 
12 different RDT 
brands were as-
sessed, OptiMAL 
and SDFK60 were 
used to determine 
sensitivity 
Paracheck-Pf, SD-
Bioline Malaria 
Ag P.f/Pan 
SD Bioline 05FK50, 
Malaria pLDH/HRP2 
Combo 
SD BIOLINE Malar-
ia Ag P.f® and 
P.f/Pan® 
Standard Diagnostics 
05FK60 Malaria Ag 
P.f/Pan 
SD BIOLINE 
05FK60 
Part of RDT used for 
clinical evaluation proximal part proximal part proximal part Distal part proximal part entire strip distal part central part 
Extraction method 
Phenol/chloroform 
extraction performed 
better than Chelex 
method or QIAamp 
DNA mini blood kit 
Chelex method 
Simple boil and spin 
method outperformed 
QIAamp DNA mini 
kit 
Chelex method 
outperformed simple 
boil and spin method 
and ABI-based 
extraction 
QIAamp DNA Mini 
kit 
Automated extraction 
using NucliSENS 
EasyMAG instru-
ment 
Chelex method  
Chelex method and 
robotic extractions 
using QIAsymphony 
gave comparable 
results 
Parasite detection 18S rDNA nested PCR 18S rDNA nested PCR 18S rDNA qPCR 
18S rDNA nested 
PCR, cytochrome b 
nested PCR, 
and 18S rDNA qPCR 
Nested PCR and 
HRM-qPCR for 
genotyping 
18S rDNA qPCR pfldh qPCR pgmet-tRNA qPCR 
Quantification of 
parasites no no no no no yes no yes 
Analytical sensitivity 
50 Pf/µL with 15 µL 
diluted blood from 
malaria patient 
1 Pf/µL with 10 
µL diluted blood 
from malaria 
patient 
0.02 Pf/µL with 
diluted blood from 
malaria patient 
2 Pf/µL with 5 µL 
diluted P. falciparum 
culture 
not specified not specified not specified 
0.05 Pf/μL based on 
detection on a single 
RDT 
Clinical evaluation  
(detection rates) 
94.3% detection rate 
for samples with 
parasite densities ≥ 
400 parasites/µL   
91.0% detection 
rate for samples 
positive by 
microscopy   
100% detection rate 
of clinical samples 
with parasite densi-
ties ≥ 1 parasites/µL   
No difference in 
detection rates com-
pared to DBS sam-
ples from febrile 
patients  
98.5% amplification 
rate for genotyping 
among positive 
RDTs  
79.8% detection rate 
among positive 
RDTs collected from 
symptomatic febrile 
patients 
96.0% amplification 
rate among RDTs 
from patients with 
severe malaria 
81.25% agreement 
with DBS from 
children with positive 
RDT s 
Non-P. falciparum 
species detected by 
NAT 
P. vivax no P. vivax, P. ovale, P. malariae no no no no no 
Other application of 
extracted DNA no 
Antimalarial 
drug resistance 
screening 
(pfdhfr) 
no 
Antimalarial drug 
resistance screening 
(pfmdr1, pfcrt) 
Antimalarial drug 
resistance screening 
(pfdhfr, pfdhps) 
multiplicity of infec-
tion (msp1, msp2) 
Multiplicity of 
infection (8 microsa-
tellite markers) 
NGS-based amplicon 
sequencing of 
pfama1 for multiplic-
ity of infection 
analysis  
no 
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Table 2. Overview of blood samples collected during two CHMIs and stored on RDTs. 
 
Table 3. P. falciparum detection from RDTs collected during CHMIs using the ENAR extrac-
tion protocol. 
 CHMI-1 (2016) CHMI-2 (2018) combined 
 qPCR  RT-qPCR  qPCR  RT-qPCR  qPCR  RT-qPCR  
PfvarATS detection ratea 0.56 (0.35, 0.75) 
0.67 
(0.46, 0.83) 
0.39 
(0.22, 0.59) 
0.29 
(0.13, 0.49) 
0.47 
(0.34, 0.61) 
0.47 
(0.34, 0.61) 
Pspp18S detection rate 0.22 (0.09, 0.42) 
0.52 
(0.32, 0.71) 
0.31 
(0.15, 0.51) 
0.42 
(0.25, 0.61) 
0.27 
(0.16, 0.40) 
0.47 
(0.34, 0.61) 
PlasQ detection rate combined 0.56 (0.35, 0.75) 
0.67 
(0.46, 0.83) 
0.40 
(0.23, 0.59) 
0.42 
(0.25, 0.61) 
0.47 
(0.34, 0.61) 
0.54 
(0.40,0.67) 
       
PfvarATS detection rate  
(> 1 Pf/µL in WB-qPCRb) 
0.72 
(0.47, 0.90) 
0.89 
(0.65, 0.99) 
1.00 
(0.63, 1.00) 
1.00 
(0.59, 1.00) 
0.81 
(0.61, 0.93) 
0.92 
(0.74, 0.99) 
Pspp18S detection rate  
(> 1 Pf/µL in in WB-qPCR) 
0.33 
(0.13, 0.59) 
0.78 
(0.52, 0.94) 
0.89 
(0.52, 1.00) 
1.00 
(0.66, 1.00) 
0.52 
(0.32, 0.71) 
0.85 
(0.66, 0.96) 
PlasQ detection rate combined 
(> 1 parasite/µL in in WB-qPCR) 
0.72 
(0.47, 0.90) 
0.89 
(0.65, 0.99) 
1.00 
(0.63, 1.00) 
1.00 
(0.66, 1.00) 
0.81 
(0.61, 0.93) 
0.93 
(0.76, 0.99)        
 
a Detection rate: proportion of detected positive samples (value between 0 and 1) 
b WB-qPCR: reference parasitaemia based on qPCR detection of parasites in 180 µL of whole 
blood.  
Study (Year) CHMI-1 (2016) CHMI-2 (2018) 
RDT brand 
BinaxNOW® 
Malaria RDT 
CareStart™ 
Malaria (Pf/PAN) Combo 
Sampling days post CHMI  
(mean and range) 14.0 (10.5-18.0) 12.7 (9.0-18.0) 
blood volume on RDT 20 µL 5 µL 
storage time in days  
(mean and range) 605 (596-616) 18 (10-48) 
storage conditions RT RT 
number of RDTs collected 71 50 
% positive by WB-qPCR 38.0% (27/71) 62.0% (31/50) 
WB-qPCR parasite density 
(parasites/µL, geom. mean and range) 4.7 (0.05-840.0) 0.3 (0.01-1041.0) 
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Figure 1. Pilot study to test feasibility of extraction and detection of Plasmodium spp. from RDTs. (A) Detection rates of P. falciparum 
by RDT compared to NAT-based detection of P. falciparum, P. malariae and P. ovale spp. from extracted RDTs collected in three primary 
schools in Tanzania. (B) Quantification of P. falciparum based on PfvarATS qPCR grouped by RDT outcome. Parasitaemia levels between 
groups were compared using Wilcoxon-Mann-Whitney test. 
  
Chapter III - ENAR procedure  163 
 
Figure 2. Evaluation of nucleic acid extraction protocols. (A) Comparison of protocol A and B, both extracting DNA, using the Cq value 
of the human rnasep gene as a proxy for the amount of nucleic acids extracted. Wilcoxon-Mann-Whitney test was used. (B) Comparison 
protocol C and D, extracting total NA, using qPCR and RT-qPCR. Wilcoxon matched-pairs signed rank test was used. (C) Side by side 
comparison of extraction protocols A and D in field samples collected in Mkuranga (n=190) and Bagamoyo (n=71). Wilcoxon-Mann-
Whitney test was used to compare Cq values between protocol A and D. 
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Figure 3. ENAR-based extraction and quantification of nucleic acids from RDTs. (A) Identification of location of P. falciparum NA 
captured on RDTs. (B) Detection of the gametocyte-specific transcript PF3D7_0630000 in blood on RDTs after three weeks of storage at 
RT. (C) RDTs containing 5 µL whole blood spiked with various PfIS densities, ranging from 0.1 to 10,000 parasites/µL, were extracted with 
ENAR and amplified by RT-qPCR PlasQ assay. Samples which did not result in amplification are indicated in red. Assay performance 
characteristics are given in the box. (D) Serial dilution of cultures of laboratory-adapted P. falciparum strains PfDD2, PfHB3 and PfNF54 
were used to determine the lower LOD for RT-qPCR detection NA extracted with ENAR. 
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Figure 4. Evaluating the performance ENAR approach using CHMI as a platform. (A) Parasitaemia derived from ENAR protocol 
correlated to P. falciparum quantities determined in 180 µl of whole blood. Spearman's rank correlation coefficient is indicated. (B) Bland-
Altman ratios (ENAR/WB-qPCR) compared between the two different CHMIs (and storage periods). (C) Parasitaemia in whole blood 
grouped by qPCR/RT-qPCR outcomes. Groups were compared using Wilcoxon-Mann-Whitney test. (D) P. falciparum growth kinetic during 
CHMI observed in whole blood and on parasitaemia derived by ENAR approach. 
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Figure 5. Adaptation of ENAR protocol for analyzing large numbers of barcoded RDTs. (A) Malaria indicator survey is conducted 
which includes a detailed questionnaire. (B) Malaria prevalence is determined by RDT followed by storage of barcode labelled RDTs. (C) 
Sorting and tracking of RDTs using smartphone apps. (D) High throughput protocol for extraction of NA from RDTs using the ENAR 
approach. (E) Detection, quantification and genotyping of P. falciparum and non-falciparum malaria parasite.  
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Abstract 
 
The Electronic Laboratory Information and Management Utensil for Molecular Diagnostics 
(ELIMU-MDx) is a user-friendly platform designed and built to accelerate turnaround time of 
diagnostic qPCR assays. ELIMU-MDx is compliant with the MIQE guidelines and has exten-
sive data import capabilities for all major qPCR instruments by using the RDML data standard. 
Designed as a web-based software tool and can run natively all major operating systems. 
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Background 
 
The global market of in vitro diagnostics (IVD), comprising of tools to detect, diagnose, or 
monitor diseases, is estimated to be worth US$ 40–45 billion (1). One of the fastest growing 
areas is the identification of infectious diseases using molecular diagnostics which is becoming 
an integral part of medical practice and public health worldwide (2). Molecular diagnostic 
tools, especially nucleic acid amplification techniques (NATs), provide faster, more sensitive, 
and often more cost-effective diagnosis than traditional culture methods for microbiological 
analysis (3). Quantitative polymerase chain reaction (qPCR) is a well-established method for 
the detection, quantification, and typing of bacteria, viruses and protozoa in the areas of clinical 
and veterinary diagnostics as well as food safety (4). Among the biggest advantages of qPCR-
based diagnosis are the universality in designing and developing new assays as well as the 
widespread availability of the technology. Moreover, qPCR also allows to quantify and geno-
type pathogens. With the rapid spread of qPCR into routine diagnostics, standardization and 
validation processes of qPCR assays and data had to be addressed (4). A first step was the 
publication of the MIQE (minimum information for publication of quantitative real-time PCR 
experiments) guidelines (5), which has led to a certain degree of standardization in the valida-
tion process of qPCR assays across different laboratories. In order to standardize the qPCR 
data format the Real-time PCR Data Markup Language (RDML, www.rdml.org) was designed 
(6). RDML stores the raw data acquired by the qPCR instrument as well as the information 
required for its interpretation, such as sample annotation and cycling protocol. A comprehen-
sive review of 27 open-access software packages and tools for qPCR data analysis reported 
that most tools use their own file format and only a fraction of the currently existing tools 
support the standardized data exchange format RDML (7). The lack of a common standard for 
qPCR data makes it difficult to share and analyse data across different qPCR platforms. 
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The high-throughput character of qPCR analysis in infectious disease diagnosis easily leads to 
a rapid accumulation of raw data which needs to be quality controlled and interpreted in order 
to correctly identify and quantify parasites. Therefore, access to well-designed, user-friendly 
and semi-automated software facilitating the storage, quality controlling and analysis of diag-
nostic qPCR data is needed.  
Controlled Human Malaria Infection (CHMI), the deliberate exposure of human volunteers to 
infectious malaria parasites, has proven to be safe and well tolerated and accelerates the eval-
uation of malaria vaccines candidates in clinical trials (8, 9). Volunteers participating in CHMIs 
are closely monitored. Blood is drawn daily for up to two weeks and screened for P. falciparum 
parasites by thick blood smear microscopy and after the first appearance of blood-stage para-
sites antimalarial treatment is initiated. Nowadays, more sensitive qPCR is increasingly used 
in CHMI to closely monitor parasitaemia levels which improves the safety of participants (10). 
In order to manage the vast amount of qPCR data generated during a series of CHMI studies 
with more than 250 individuals, conducted in Tanzania and Equatorial Guinea, we decided to 
design and build a platform which facilities the analysis and interpretation of diagnostic qPCR 
data. We identified several key features which in our opinion would be required for such soft-
ware. I) Highly adaptable and integrative: a solution which can be easily adapted to a variety 
of qPCR assays, supports semi-automated data analysis and integrates into existing sample 
workflow. II) Data traceability throughout analysis process: the use of an audit trail and com-
munity data standards to ensure high data integrity. III) Accessibility and reliability of soft-
ware: Platform-independent, open-source, and low maintenance software which could be de-
ployed rapidly to new laboratories and other projects using qPCR analysis as monitoring tool. 
To address these needs, we developed the web-based, open-source platform ELIMU-MDx 
(Electronic Laboratory Information and Management Utensil for Molecular Diagnostics).  
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Material and Methods 
 
ELIMU-MDx development 
ELIMU-MDx combines a relational SQL database with a user-friendly web interface pro-
grammed in PHP 7.2 using the framework Laravel 5.8 and the tool Laravel Nova 2.0. The 
platform is accessed through the web-browser (Google Chrome, Firefox and Safari were suc-
cessfully tested). It validates user provided data and stores it in a MySQL 5.7 database where 
appropriate constraints ensure consistency. 
 
Analysis of qPCR data by ELIMU-MDx 
qPCR data generated for diagnostic purposes has different requirements to software than data 
generated for other qPCR applications. Most important, the consistency and reliability of the 
data needs to be ensured. Each qPCR run needs to have controls in place to test for contamina-
tion (preventing false positive results) and to test the performance of extraction and qPCR re-
action (preventing false negative results). All data uploaded to ELIMU-MDx is quality con-
trolled based on several controls and predefined criteria. Only samples which pass all QC 
thresholds are considered for further analysis. Additionally, a sample measured multiple times 
with the same assay is automatically considered as technical replicates, even if the data is de-
rived from different experiments. This allows to repeat samples if needed. 
ELIMU-MDx processes qPCR data derived from both major qPCR detection technologies. 
Assays using dye–based (e.g. SYBR- or Eva-Green dyes) or TaqMan-based detection can be 
analysed. The Cq values, the number of cycles needed to reach a fluorescence threshold, is 
extracted from the RDML file and used for qualitative and quantitative interpretation of the 
qPCR assay. In case of a dye-based detection, only Cq values from samples whose amplicon 
has a melting temperature within a pre-defined range are considered for further analysis. Since 
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the melting temperatures are not included in the RDML version 1.1 from Bio-Rad CFX Maes-
tro (Version 4.1.2433.1219) and RDML version 1.2 from MyGo Pro PCR Software (Version 
3.4), they need to be uploaded separately in addition to the RDML file. 
The current version of ELIMU-MDx supports absolute quantification of the qPCR target mol-
ecules using the slope and intercept derived from the linear relationship between Cq values and 
a calibration curve generated by using serially diluted standards of know concentrations.  
The Assay Definition File (ADF) includes all assay-specific parameters which together define 
the assay. The advantage of defining all assay parameters in one single file is its universality 
and easy adaption to new qPCR assays. An example for an ADF is provided as excel file (sup-
plementary file 1).  
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Results 
 
ELIMU-MDx overview 
The structure of ELIMU-MDx is shown in Figure 1. Basically, ELIMU-MDx consists of three 
modules, the sample module, the assay module and the data module which are connected by 
an experiment. Each of the modules is supplied with data and parameters from specific com-
ponents. These components contain sample, assay or data specific information which are nec-
essary to interpret and document the experiments. The ADF, which contains all parameters 
necessary to analyse samples measured with the appropriate qPCR assay, is linked through the 
assay to the experiment. The experiment is considered the central node of ELIMU-MDx and 
combines the sample and assay metadata with data. Upload of standardized data is followed by 
initial quality control and automated analysis and eventually results in a downloadable result 
file which can be used for generating reports or statistical computing and data visualization by 
any statistical software. 
Examples of the ELIMU-MDx user interface are illustrated in Figure 2. All features are acces-
sible through a sidebar (Fig 2A). The oligo details are shown as an example for the level of 
detail which is provided by ELIMU-MDx virtual freezer (Fig 2B). As part of the built-in sam-
ple inventory, the storage position of each sample can be displayed (Fig 2C). Results are auto-
matically displayed after uploading the qPCR RDML files and samples with inconclusive re-
sults can be easily identified using the custom-build filters (Fig 2D). The integrated audit trail 
records all major events and therefore ensure high data integrity (Fig 2E). 
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ELIMU-MDx is built as an open-source web-app  
ELIMU-MDx is a user-friendly platform designed and built to accelerate turnaround time of 
diagnostic qPCR assays. The advantages of web applications include rapid deployment, cross-
platform compatibility and easy application development (11). A detailed guide to setup the 
platform, with step-by-step instructions, is provided at https://sparclex.github.io/elimu. The 
low-maintenance structure is an additional advantage, particularly in resource-limited settings. 
The source code is open source and distributed under a MIT license and is publicly available 
for download. It is unlike most commercially available qPCR software not a black box. All 
features of ELIMU-MDx are completely disclosed and can be improved or changed by other 
member of the scientific community or even used separately in other software. 
The ELIMU-MDx can be accessed through https://elimu.ch where we have created a specific 
user account for demonstration purposes (login: demo.user@elimu.ch, password: elimu2019). 
 
ELIMU-MDx uses the RDML data standard making it qPCR instrument independent  
ELIMU-MDx supports RDML, a structured and universal data standard for exchanging qPCR 
data. RDML files contain all information to understand the experimental setup, re-analyse the 
data and interpret the results. The use of the RDML data standard allows to use data from 
different qPCR instruments. The platform was successfully tested with RDML files version 1.1 
and 1.2 from the Bio-Rad CFX96 Real-Time System and the MyGo Pro qPCR instrument. 
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The semi-automated data quality control and analysis improves sample-to-result turna-
round times 
The use of the standardized data format of RDML files allowed us to automate quality control, 
analysis and validation of qPCR data. Initial quality control includes the automated analysis of 
the Positive Control (PC), Negative Control (NC) and Non-template Control (NTC) of each 
qPCR run uploaded based on provided cut-off values. The internal control (IC) of each sample 
is used to validate the extraction and amplification performance. Based on the Cq values pro-
vided by the RDML file and a set of assay specific parameters, as defined by the ADF, quality 
control as well as qualitative and/or quantitative analysis is performed. 
The ELIMU-MDx platform was extensively tested with diagnostic qPCR data generated during 
CHMI studies in Tanzania (total of 478 samples) and Equatorial Guinea (total of 2907 sam-
ples). We observed a significant reduction in time spent on the quality control review process 
of the qPCR data when compared to our previously used custom-built Microsoft Access data-
base. 
 
ELIMU-MDX simplifies documentation, statistical analysis and visualization of qPCR 
experiments  
A qPCR experiment, as defined by the ELIMU-MDx, contains all information required by the 
MIQE guidelines. The electronic laboratory notebook-like feature of ELIMU-MDx documents 
and links information from the sample module, the assay module and the data module for each 
experiment and sample. Additionally, assay-specific information is provided by the ADF (Ta-
ble 1).  
 Chapter III - ELIMU-MDx   186 
The ELIMU-MDx platform also serves as a laboratory information and management system 
(LIMS). We added general features of a LIMS to the ELIMU-MDx platform. A unique storage 
position can be assigned to each sample in order to keep track of sample storage. If samples 
are shipped, all details of the shipment will be logged. Apart from qPCR data, all other types 
of results can be uploaded and attached to the samples and therefore linked with the qPCR 
result. Importantly, the structured data generated by ELIMU-MDx allows to use the R language 
and environment for statistical computing and visualization of qPCR data without extensive 
data manipulation and cleaning. 
 
Integrity and traceability of qPCR data in ELIMU-MDx 
All qPCR data uploaded to ELIMU-MDx is protected from accidental or intentional modifica-
tions. The qPCR raw data, as a RDML file, is attached to the results. The Cq values cannot be 
changed or deleted, the only option is to exclude replicates. Exclusion of Cq values is visually 
indicated and can be reversed. Each modification of the data is attributed to a user. The use of 
personal accounts which are password protected and the automatic creation of an audit trail 
which records and logs all major changes are in line with the FDA regulations on electronic 
records and electronic signatures (FDA regulation 21 CFR Part 11).  
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Discussion 
 
The qPCR represents a powerful tool which has spread in different areas of infectious disease 
diagnostics. The technology has become indispensable for the detection of viruses, bacteria or 
protozoa and increasingly replaces traditional diagnostic techniques (4). For laboratories, es-
pecially if they generate diagnostic data for clinical trials the adequate storage, curation and 
analysis of qPCR data can be a challenge. Currently available software solutions, commercial 
or open-source, are not well suited for the management and analysis of diagnostic qPCR data. 
Often a combination of several tools is used with an inadequate documentation of this essential 
step of the qPCR workflow.  
We have built the ELIMU-MDx platform as a response to the large amount of qPCR data 
generated during clinical trials including CHMI studies. Due to its integration into the sample 
workflow and automation of the qPCR QC and preliminary analysis the use of ELIMU-MDx 
accelerates the sample-to-result turnaround time significantly. The use of the RDML standard 
allows to analyse the qPCR data in a streamlined and transparent way without losing the asso-
ciation between the final result (interpretation of the qPCR data) and the actual raw data (fluo-
rescent data of the qPCR run). We also placed importance on the documentation of the qPCR 
experiments by attaching metadata from the samples and assays to the qPCR data. 
ELIMU-MDx is open source licensed under the permissive MIT license. Disclosing the soft-
ware code used for data analysis should be the standard and will definitely help to increase the 
reproducibility of data analysis (12). Because ELIMU-MDx is an open-source project, contri-
butions and feedback from the community is highly encouraged and will be an important factor 
in improving ELIMU-MDx. 
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Conclusion 
 
ELIMU-MDx has the potential to connect all qPCR-data associated processes in a laboratory 
environment. Starting from documenting the qPCR experiment using its electronic laboratory 
notebook-like feature, to large-scale qPCR data management and collection. Finally, research-
ers can analyse the pre-processed and cleaned qPCR data using the third-party software solu-
tions of their choice and perform final statistical analysis. All these steps are combined in a 
user-friendly and open-source web-application which is compliant with the MIQE guidelines.  
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Table 1. Information documented for each experiment and sample. 
 
Modules Component Description 
Sample module 
 
Sample metadata 
Required is a unique identifier, collection date and 
biological type of sample. Optional information 
such as demographics can be added. 
Sample inventory Contains information related to storage and ship-ment of samples. 
Assay module 
 
Lab journal  
 
Contains detailed information for the associated 
protocols and standard operating procedures 
(SOPs). 
 
Instruments 
 
A detailed repository for qPCR instruments, which 
also includes maintenance logs. 
 
Virtual freezer 
 
Contains information for: 
 
- Oligonucleotides: sequences, link to original     
   publication. 
- Reagents: qPCR reagents with lot number and  
  expiry date and extraction kits for nucleic acids. 
- Controls: name and concentration of positive  
  Controls. 
- qPCR programs: Cycling conditions and detection  
  channels used. qPCR instrument software name  
  and version. 
 
Data module 
qPCR raw data Cq values and melting temperatures provided by RDML file.  
qPCR metadata Metadata for each run are saved within the RDML file. 
Assay  
Definition  
File 
Analysis parame-
ters 
Assay-specific parameters which are used to ana-
lyse and interpret the qPCR data. For details refer 
to the ELIMU-MDx user guide. 
Documentation 
parameters 
Additional assay-specific parameters, e.g. qPCR ef-
ficiencies, which are used for documentation pur-
poses only. 
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Figure 1. Structure of ELIMU-MDx. The sample, assay and data modules are connected to create an experiment, which is the central node of the platform. Assay-specific parameters are provided through the Assay 
Definition File (ADF). 
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Figure 2. User interface of ELIMU-MDx. (A) Side bar for navigation within ELIMU-MDx. (B) Oligo details as an example for an ELIMU-
MDx component. (C) Automatically assigned storage position for samples. (D) Samples which need special attention can be filtered in the 
results section. (E) ELIMU-MDx audit trail. 
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Availability and Requirements 
Software name: ELIMU-MDx 
Software home page: https://www.elimu.ch 
Software source: https://github.com/Sparclex/elimu 
Open-source license: MIT license 
Operating systems(s): OS independent, designed as a web-app Supported browsers: Firefox, 
Google Chrome and Safari. 
Programming languages: PHP 
Other requirements: https://sparclex.github.io/elimu/dev-docs/requirements.html 
Any restrictions to use by non-academics: no limitations 
 
Supporting Information 
S1. Example of assay definition file (xlsx file)  
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Chapter 4 includes data on active surveillance of asymptomatic P. malariae and P. ovale spp. 
infections in Tanzania and Equatorial Guinea. In collaboration with the central blood bank in 
Malabo, Equatorial Guinea we analysed 200 blood donations for the presence of Plasmodium 
spp. parasites by qPCR. In order to identify the Plasmodium species infecting the blood do-
nors, we developed a novel multiplex qPCR assay for parallel malaria parasite identification. 
Using this assay, the main five human infectious malaria species can be detected qualitatively 
in a single tube rendering it highly cost efficient. We found that more than one quarter of the 
blood donations contained malaria parasites and that 75% of P. falciparum and 100% of P. 
malariae and P. ovale spp. infections were missed by RDT and microscopy.  
We also published a report, describing two cases of P. malariae infections that were identi-
fied during a study evaluating the safety, tolerability and efficacy of the PfSPZ Vaccine in 
Bagamoyo, Tanzania. Since these two participants were enrolled into a clinical trial, we were 
provided with a unique opportunity to study clinical manifestations of P. malariae over four 
months of follow up period.  
 
This chapter contains the following publications: 
 
Schindler et al. Molecular monitoring of the diversity of human pathogenic malaria spe-
cies in blood donations on Bioko Island, Equatorial Guinea. Malaria Journal 2019 
 
Schindler et al. Two cases of long‑lasting, sub‑microscopic Plasmodium malariae infec-
tions in adults from coastal Tanzania. Malaria Journal 2019 
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Abstract 
Background: Malaria can be transmitted by blood transfusion from human to human and it is responsible for the 
majority of transfusion-transmitted infectious diseases worldwide. In sub-Saharan Africa, it had been estimated that 
almost a quarter of blood donations contain malaria parasites. Since rapid diagnostic tests and thick blood smear 
microscopy lack sensitivity for low density parasitaemia, particularly in asymptomatic adults, the most reliable method 
to assess the problem of transfusion-transmitted malaria are nucleic acid-based molecular approaches such as quanti-
tative polymerase chain reaction. The study was undertaken to determine the prevalence of sub-microscopic malaria 
parasite infection among blood donors in Malabo, Equatorial Guinea.
Methods: Between July and August 2017, a total of 200 individual blood samples from blood donors at the Malabo 
Blood Bank were collected and screened by rapid diagnostic tests and thick blood smear microscopy. Retrospectively, 
the same samples were analysed for the presence of undetected, low-density malaria parasites using quantitative 
polymerase chain reaction.
Results: In comparison to 6.5% (13/200) by rapid diagnostic test and 2.0% (4/200) by microscopy, the proportion of 
Plasmodium falciparum positive blood donations analysed by quantitative polymerase chain reaction was significantly 
higher (26%, 52/200). Densities of P. falciparum positive blood donations were ranging from 0.06 to 3707.0 parasites/
µL with 79.6% below 100 parasites/µL and therefore not detectable by non-molecular malaria diagnostic tests. qPCR 
based species identification revealed that P. falciparum was the dominating species responsible for 88.1% (52/59) of 
positive blood donations, followed by Plasmodium malariae (15.3%, 9/59) and Plasmodium ovale (3.4%, 2/59).
Conclusions: This study confirms that in malaria endemic settings, sub-patent malaria infections among blood 
donors are prevalent. In blood collected from healthy donors living in Malabo, P. falciparum, P. malariae and P. ovale 
parasites were identified. Currently widely used malaria diagnostic tools have missed more than 75% of P. falciparum 
containing blood donations, demonstrating the value of quantitative polymerase chain reaction to reliably detect 
low density P. falciparum infections. Since the availability of molecular diagnostic methods in malaria endemic 
countries is still limited, the blood recipients living in malaria endemic countries should be treated following WHO 
recommendations.
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Background
Malaria is a vector-borne parasitic tropical disease found 
in 55 countries globally [1]. Six Plasmodium species are 
known to infect humans including Plasmodium falcipa-
rum, Plasmodium vivax, Plasmodium malariae, Plas-
modium ovale curtisi, Plasmodium ovale wallikeri and 
Plasmodium knowlesi [2]. Malaria is transmitted to the 
human host through the bite of a female Anopheles mos-
quito when the sporozoite stage is inoculated during the 
feeding. The parasite undergoes a pre-erythrocytic liver 
stage reproduction that is clinically silent and lasts 1 to 
2 weeks before the release of merozoites into the blood-
stream. These merozoites rapidly infect red blood cells, 
starting the asexual blood stage whereby the parasite 
undergoes cycles of asexual replication that include the 
ring, trophozoite, and schizont stages leading to regular 
fever episodes [2]. In adult human populations living in 
malaria endemic countries, the prevalence of sub-patent 
malaria infections is up to 80% [3] with certain parasite 
clones surviving in the human host more than 300 days 
[4].
Diagnosis of malaria is performed in blood samples 
collected from potentially infected humans. The gold 
standard for malaria diagnosis remains light microscopy 
of stained blood smears. Thick blood smears provide 
sensitivity and thin smears allow the identification of dif-
ferent malaria species and the quantitation of infection 
[5]. Rapid diagnostic tests (RDTs) are widely used since 
they offer less dependence on the availability of labora-
tory infrastructure, and can also be employed by inex-
perienced health workers [6]. RDTs are often based on 
parasite-derived histidine-rich protein 2 (PfHRP2) for 
sensitive and specific detection of P. falciparum, and lac-
tate dehydrogenase enzyme (LDH) or aldolase for a Pan-
Plasmodium detection of all human infective malaria 
species [7]. The lower limit of detection (LOD) for 
microscopy is between 50 and 500 parasites/µL depend-
ing on the expertise of the microscopist [5] and 100 para-
site/µL for the PfHRP2 based P. falciparum RDTs [8]. 
Differential diagnosis of P. ovale, P. malariae, P. vivax and 
P. knowlesi is hampered by the low density blood stage 
infections and the difficulty in distinguishing these spe-
cies based on morphology of trophozoites using micros-
copy [9].
Nucleic acid amplification technologies (NATs) are 
more expensive and require advanced laboratory infra-
structure but provide much better sensitivity. The 
parasites’ multi-copy 18S small subunit ribosomal deox-
yribonucleic acid (rDNA) and/or its highly expressed 
ribonucleic acid (rRNA) is the most frequently used bio-
marker for NATs [10]. Different methods for 18S rDNA/
rRNA detection are currently in use with a great varia-
tion in sensitivity. Qualitative methods targeting 18S 
rDNA, such as nested polymerase chain reaction (PCR) 
[11] and LAMP [12], reach LODs of 0.1–10 parasites/µL. 
The use of quantitative PCR (qPCR) [13], does not only 
allow absolute quantification of infections but also lowers 
the LOD to less than 1  parasite/µL. The use of Reverse 
Transcription quantitative PCR (RT-qPCR), amplifying 
total nucleic acids (RNA and DNA) of the 18S genes [14–
16], and qPCR assays targeting alternative multi-copy 
genomic sequences [17] further increase sensitivities of 
NATs. Apart from increased sensitivity of NATs, molecu-
lar detection using PCR has improved species discrimi-
nation compared to either microscopy or RDTs [18].
Screening for transfusion transmitted infections should 
follow the World Health Organization (WHO) recom-
mendations which include searching for chronic infec-
tious diseases including HIV-1, HIV-2, Hepatitis B, 
Hepatitis C and Treponema pallidum (syphillis) [19]. 
Based on the local epidemiological infectious disease 
situation, the WHO recommends that blood donations 
should also be screened for malaria [19, 20]. Malaria 
can be efficiently transmitted by blood transfusion from 
human to human and is undoubtedly responsible for the 
majority of transfusion transmitted diseases in the world 
[21]. The rate of transfusion-transmitted malaria (TTM) 
in malaria endemic sub-Saharan regions is estimated 
between 14 and 28% [22]. Several reports describe that P. 
falciparum [22], P. vivax [23], P. malariae [24], P. knowlesi 
[25] and P. ovale [26] can be transmitted either through 
blood donations or solid organ transplantations.
Malaria species circulating in Equatorial Guinea 
include P. falciparum, P. malariae, P. ovale and P. vivax 
[27–29]. The Bioko Island Malaria Control Project 
(BIMCP) started in 2004 with the aim to reduce malaria 
transmission and to control the burden of disease and 
has received substantial funding from the Government 
of Equatorial Guinea and private donors including Mara-
thon EG Production Limited, Noble Energy, and Atlan-
tic Methanol Production Company. The malaria control 
strategy of the BIMCP rests on vigorous vector control 
measures, effective case management, prevention of 
malaria during pregnancy, behavioural change commu-
nications and regular monitoring and evaluation [30]. 
The BIMCP has had significant success in reducing P. fal-
ciparum parasite prevalence in the 2–14  years old chil-
dren and adolescent from 45% (95% CI 40–50%) in 2004 
(baseline) to 12.1% (95% CI 11.2–13.3%) in 2016 based on 
annual Malaria Indicator Survey (MIS) data [30].
Since RDTs and microscopy lack sensitivity for low-
level parasitaemia, particularly in asymptomatic adults, 
the most reliable method to assess the problem of TTM 
are NATs such as qPCR. This study has set out to analyse 
a selection of 200 blood samples from the blood bank in 
Malabo using qPCR to identify sub-patent P. falciparum 
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infections that cannot be detected by commonly used 
RDTs and microscopy. In addition, the presence of other 
TTM causing Plasmodium species was analysed using a 
newly developed single tube multiplex qPCR assay.
Methods
Study site and participant recruitment
The study was conducted at the Central Blood Bank in 
Malabo on Bioko Island. Bioko Island, located in West-
central Africa and home of Equatorial Guinea’s capi-
tal city Malabo, is 32  km from the coast of Cameroon. 
The approximately 250,000 people, who mainly reside 
in Malabo are at risk of malaria year-round [30]. Adults 
willing to donate blood and who are Hepatitis B, Hepa-
titis C, and HIV negative were eligible for blood dona-
tion. Microscopy and RDT (CareStart™ Malaria HRP2/
pLDH Pf/PAN Combo) were used for malaria screen-
ing at the blood bank and the results were kept at the 
blood bank until the end of qPCR analysis. The Malabo 
Central Blood Bank processes around 100 donors per 
month; the majority being donors assisting friends and 
families during emergency situations, and the remain-
der are donors that voluntarily donate blood on a regular 
basis. The blood bank is run by a public–private coopera-
tion between the Ministry of Health and Social Welfare, 
the University of Valencia Hospital, and funded by the 
AGEM-GUINEA company.
Sample collection for molecular diagnostics
Between July and August 2017, a total of 200 individual 
blood donations from routine visitors were selected to 
conduct this study. 1  mL of whole blood was collected 
in EDTA tubes as part of the usual blood donation pro-
cedures in the blood bank. The blood was immediately 
used for microscopy and RDT, with the remaining blood 
immediately stored at − 20  °C. The samples were trans-
ported in a cooling box to the laboratory of the Equa-
torial Guinea Malaria Vaccine Initiative (EGMVI) in 
Malabo. The laboratory infrastructure of the EGMVI, 
located on the premises of the La Paz Hospital in Malabo, 
which conducted the first clinical trial in the history of 
the country [31], was used for qPCR analysis of the blood 
donations.
The 200 blood samples, from healthy, Hepatitis B, 
Hepatitis C, and HIV-1 and HIV-2 negative blood donors 
were analysed for the presence of possibly undetected, 
low-level malaria parasites using high-sensitive qPCR 
assays. DNA extraction was done manually from 180 µL 
whole blood using Quick-DNA Miniprep kits (Zymo 
Research, Irvine, USA) following manufactures’ guide-
lines and DNA was eluted with 50  µL Elution Buffer. 
DNA samples were kept at − 20  °C prior to qPCR 
analysis.
qPCR for Plasmodium screening and quantification (PlasQ 
assay)
Plasmodium spp. and P. falciparum parasites were quan-
tified using the PlasQ assay. This assay consists of two 
independent Plasmodium targets combined in a multi-
plex assay. The Pan-Plasmodium 18S rDNA sequence 
(Pspp18S) [13, 32], and the P. falciparum-specific acidic 
terminal sequence of the var genes (PfvarATS) [17] were 
used for detection and quantification of parasites. The 
human RNaseP (HsRNaseP) gene served as an internal 
control to assess the quality of DNA extraction and qPCR 
amplification.
Amplification and qPCR measurements were per-
formed using the Bio-Rad CFX96 Real-Time PCR System 
(Bio-Rad Laboratories, California, USA). The thermal 
profile used for PlasQ qPCR is as follows: 60 s at 95  °C; 
45 cycles of 15  s at 95  °C and 45  s at 57  °C. Each reac-
tion contained 2 µL DNA and 8 µL reaction master mix 
containing 1× Luna Universal Probe qPCR Master Mix 
(New England Biolabs, Ipswich, USA) and 1× PlasQ 
Primer Mix (Additional file 1). All qPCR assays were run 
in duplicates with appropriate controls including Non-
Template Control [NTC] and P. falciparum 3D7 DNA 
as positive control [PC]. The mean Cq of the two repli-
cates was reported and in case of one qPCR replicate 
interpreted as malaria positive and the other replicate 
negative, then the assay had to be repeated to arrive at an 
unequivocal result.
Using the first WHO International Standard for P. fal-
ciparum DNA Nucleic Acid Amplification Techniques 
(NIBSC code: 04/176), a serial dilution ranging from 0.05 
to 10,000 parasites/µL was prepared and used for quan-
tification of P. falciparum. The WHO standards were 
run as duplicates in two out of the total 13 qPCR runs 
conducted.
qPCR for Plasmodium species identification (PlasID assay)
Several published [17, 33–37] and unpublished qPCR 
assays, detecting P. falciparum, P. malariae, P. ovale, P. 
vivax and P. knowlesi were evaluated and the best per-
forming primer and probes for each Plasmodium spe-
cies were combined into a new multiplex assay (PlasID). 
The primers and probe combinations used for this novel 
pentaplex malaria qPCR assay is provided in Additional 
file 1.
Amplification and qPCR measurements were per-
formed using the Bio-Rad CFX96 Real-Time PCR System 
(Bio-Rad Laboratories, California, USA). The thermal 
profile used for the PlasID qPCR is as follows: 15 min at 
95 °C; 45 cycles of 15 s at 95 °C and 60 s at 55 °C. Each 
reaction contained 2 µL DNA and 8 µL reaction master 
mix containing 1× HOT  FIREPol® Probe qPCR Mix Plus 
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(Solis Bio Dyne, Tartu, Estonia) and 1× PlasID Primer 
Mix (Additional file  1). All qPCR assays were run in 
duplicates with appropriate controls including Non-Tem-
plate Control [NTC] and DNA of six Plasmodium species 
as positive controls [PC]. DNA controls for P. falciparum, 
P. knowlesi, P. malariae, P. vivax, P. ovale curtisi and P. 
ovale wallikeri were used to evaluate species specificity of 
the PlasID assay. The positive controls were reconfirmed 
by two commercial qPCR assay (GeneFinder™ Malaria 
RealAmp Pf/Pv/Pk and Pf/Pm/Po). Samples with a Cq 
value less than 45 for any of the five Plasmodium targets 
were considered positive for the corresponding Plasmo-
dium species.
Data management and analysis
Geneious version 8.1.9 (Biomatters Ltd, Auckland, New 
Zealand) was used for sequence alignments and oligo-
nucleotide designs. Cq values were obtained from the 
Bio-Rad CFX96 Manager 3.1 software (Bio-Rad Labora-
tories, California, USA) and transferred to a Microsoft 
Access based in-house database designed for storage 
and analysis of qPCR data. Cq values were transformed 
to parasite densities and linked to patient’s metadata col-
lected at the blood bank. Categorical variables were com-
pared by Fisher’s exact test and continuous variables by 
Mann–Whitney using GraphPad Prism version 7.00 for 
Windows (GraphPad Software, La Jolla, USA). P val-
ues < 0.05 were considered to be significant.
Results
Development and implementation of multiplex qPCR 
assays for malaria screening
Two independent qPCR assays were systematically used 
for the screening and identification of malaria parasites. 
The use of two consecutive qPCR assays maximizes the 
amount of information generated by the analysis. The 
first assay (PlasQ), applied to all samples, was designed 
to identify and quantify P. falciparum and/or non-falci-
parum species. Additionally, the internal control serves 
as a general control for quality and performance of the 
DNA extraction and qPCR reaction. The performance 
of the PlasQ assay is shown in Fig. 1a. For both targets, 
PfvarATS and Pspp18S, the Cq values for different par-
asite densities, ranging from 0.05 to 10,000 parasites/
µL were obtained (Pearson r − 0.9969 and − 0.9968, 
respectively). Similar qPCR efficiencies for both targets 
were observed (87.6% and 89.7%). The PfvarATS target 
did detect two additional samples carrying low parasite 
densities (0.1 and 0.05 parasites/µL) resulting in 10 times 
lower LOD compared to the Pspp18S target. The second 
assay (PlasID), which is applied to all Plasmodium spp. 
positive samples, was designed for rapid identification 
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Fig. 1 Analytical performance of PlasQ (a) and PlasID (b) assay. a Correlation of P. falciparum standards and the Cq values for both targets, Pspp18S 
(black circles) and PfvarATS (white circles) of the PlasQ assay. Based on these quadruple replicates of the WHO standards, LODs and qPCR efficiencies 
were calculated. b The ability of the PlasID assay identifying five different malaria species is shown by a representative, composite amplification plot. 
DNA from the six Plasmodium species were analysed in separate tubes during the same qPCR experiment
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of five different malaria causing Plasmodium species. 
Performance of the PlasID assay was assessed using 
well-defined clinical samples as references and this novel 
assay’s ability of identifying P. falciparum, P. malariae, P. 
ovale curtisi, P. ovale wallikeri, P. vivax and P. knowlesi is 
demonstrated in Fig. 1b.
Baseline characteristics of blood donors attended Malabo 
Central Blood Bank
Blood donor characteristics are given in Table  1. All 
donors were Equato-Guineans living in Malabo on Bioko 
Island except two persons, one originating from neigh-
bouring Douala, Cameroon and the other from the 
United States. The majority were male (88.5%) with a 
median age of 32 years, ranging from 18 to 57 years. Sev-
enty-seven donations were from voluntary blood donors 
and 123 donations were from replacement donors, who 
donate blood when required by a member of the patient’s 
family or community (Table 1). Except for the blood pres-
sure, no significant difference in relation to gender, age, 
weight, pulse and anaemia status between these two 
donor groups were observed.
Prevalence of malaria positive blood donations
The flow diagram depicting the sequential malaria diag-
nostic tools applied to the blood donations is summa-
rized in Fig.  2. In the Malabo blood bank, all samples 
were screened using thick blood smear microscopy and 
RDT. Microscopy identified four P. falciparum posi-
tive donations, while RDTs detected 13 malaria positive 
donations. Three donations were positive for both anti-
gens, the P. falciparum specific HRP2 and the Plasmo-
dium spp. LDH antigens. The remaining ten donations 
were positive for HRP2 only. Microscopy and RDT posi-
tive blood donations were not considered for donation 
and were included blinded into this study sample col-
lection on purpose to test the performance of the PlasQ 
assay.
Upon arrival at the EGMVI laboratory all samples were 
screened with the first multiplex qPCR assay (PlasQ), 
targeting P. falciparum (PfvarATS), Plasmodium spp. 
(Pspp18S) and the human RNAseP gene (as an internal 
control). All 200 samples amplified the internal control 
with Cq < 28 and were therefore eligible for further analy-
sis. Over 70% (n = 141) of blood donations were negative 
for any malaria species. Forty-six donations were positive 
for both Plasmodium targets, while six and seven dona-
tions were positive only for P. falciparum or Plasmodium 
spp., respectively. All samples (n = 53) with a positive 
amplification of the Pspp18S target were analysed with 
the species identification assay (PlasID). Apart from con-
firming P. falciparum (n = 33) cases, we also found cases 
of P. malariae (n = 9) and P. ovale (n = 2). Amongst the 
200 blood samples analysed, no P. vivax or P. knowlesi 
was detected.
The assay identified P. malariae or P. ovale in all seven 
samples which were positive for Plasmodium spp. and 
negative for P. falciparum, highlighting the assays abil-
ity to identify non-falciparum species. Compared to the 
PlasQ assay, a reduced sensitivity (71.7%, 33/46) for P. fal-
ciparum detection using the PlasID assay was observed. 
The 13 P. falciparum positive samples missed by the 
PlasID assay had moderate parasitaemia (median of 36.9 
with IQR of 1.3–380.0  parasites/µL) and the five sam-
ples with the highest parasitaemia were positive by RDT. 
None of these samples were positive for any other non-P. 
falciparum species.
An additional 29 malaria negative blood samples were 
also run with the PlasID assay to test specificity of the 
assay. No false positive Plasmodium spp. cases were 
detected, resulting in 100% specificity.
Notably, none of the non-falciparum species had been 
identified by microscopy or RDT. Pan-positive RDTs, 
which detected the Plasmodium spp. LDH, were rather 
associated with higher P. falciparum density than with 
the detection of non-falciparum malaria parasite species. 
The three HRP2 and LDH positive RDTs had a geometric 
mean of 916.3  parasites/µL (range 244.1–3707.0) while 
the nine HRP2 only positive RDTs had a geometric mean 
of 106.0 parasites/µL (range 11.2–543.3) (Table 2).
In summary, 59 blood donations were positive for at 
least one malaria species (29.5%). Plasmodium falcipa-
rum was the dominating species responsible for 88.1% 
of positive blood donations, followed by P. malariae 
(15.3%) and P. ovale (3.4%). Mixed species infections 
were found in 6.8% (4/59) of the malaria positive blood 
donations. One blood donation carried a P. malariae 
and P. ovale co-infection and three donations contained 
Table 1 Comparison of  health characteristics between   
voluntary and replacement donors
a Variables were compared by Fisher’s exact test for categorical variables or 
Mann–Whitney test for continuous variables
b Values expressed as medians with ranges
Voluntary 
donors
Replacement 
donors
P  valuesa
Number of donors 77 123 –
% male 84.4% (65/77) 91.1% (112/123) 0.175
Age in  yearsb 32 [19–55] 32 [18–57] 0.888
Weight in  kgb 73.9 [51–116] 72.0 [52–116.6] 0.593
Blood pressure in 
 mmHgb
126.7 [97.7–169.0] 130.8 [103.6–198.9] 0.035
Pulse in  bpmb 74 [48–101] 73 [51–102] 0.788
Haemoglobin in 
g/dLb
14.6 [12.2–19.6] 14.7 [6.4–18.0] 0.808
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a combination of P. falciparum and P. malariae. The 
observed co-infection proportion between P. falcipa-
rum and P. malariae was slightly higher than expected 
(1.5% versus 1.2%, P = 0.037).
Plasmodium falciparum densities in malaria positive blood 
donations
Data obtained from the PlasQ assay was used to quan-
tify P. falciparum positive blood donations. Para-
site densities calculated based on both targets show a 
high correlation (Spearman r 0.894, Fig.  3). Identified 
non-falciparum species are indicated with green dots. 
Quantification based on the Pspp18S assay revealed, 
that the parasitaemia of these non-falciparum species 
is around or below 10  parasites/µL which was sup-
ported by the high Cq values obtained from the PlasID 
assay. The geometric mean Cq value of the nine P. 
malariae positive samples was 36.9 (range 35.3–39.0) 
and the two positive P. ovale samples had Cq values of 
37.9 and 39.8.
A strong association between the diagnostic tests 
and the parasitaemia in P. falciparum positive blood 
Samples positive for
Pf (n=33), Pm (n=9), Po (n=2), 
Pv (n=0), Pk (n=0)
Samples collected at Blood bank in 
Malabo
n=200
Samples positive 
for Pf only
n=6
Samples positive 
for Pf and Pspp
n=46
Samples positive 
for Pspp only
n=7
Samples negative 
for Pf and Pspp
n=141
Screening and quantification 
of Pf and Pspp by PlasQ assay
(n=200)
Microscopy and RDT screening 
at Blood Bank
Identification of Plasmodium
species by PlasID assay 
(n=53)
Microscopy 
positive
Pf=4
RDT positive
Pf=10
Pan/Pf=3
Fig. 2 Overview of blood sample analysis. Blood donations were systematically screened for the presence of malaria parasites by microscopy, RDT 
and qPCR assays
Table 2 Parasitaemia of blood donations detected with different diagnostic methods
a Quartiles (Median, 25th and 75th percentile)
b Geometric mean and 95% confidence interval
c Pf- and Pf/Pan-RDT results combined
d Pf-RDT results only
e Pf/Pan-RDT results only
Diagnostic tool Median/IQR (parasites/µL)a Geometric mean (parasites/µL)b Range (parasites/µL)
qPCR-PfvarATS 4.6 [0.8–49.0] 5.6 [2.6–12.1] 0.06–3707.0
qPCR-Pspp18S 7.8 [1.3–65.1] 9.5 [4.5–19.8] 0.07–3707.0
RDT  combinedc 134.6 [65.1–536.5] 181.7 [68.98–478.7] 11.16–3707.0
HRP2-RDTd 112.5 [52.2–331.2] 106.0 [42.4–265.1] 11.16–3707.0
HRP2/LDH-RDTe 850.4 [244.1–3707.0] 916.3 [31.11–26990.0] 244.1–3707.0
Microscopy 380.1 [145.4–2909.0] 478.7 [44.03–5205.0] 112.5–3707.0
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donations was observed. Non-cumulative parasite den-
sity data grouped by diagnostic test is shown in Fig.  4 
(scatter plot, left y-axis).
In Table 2, the parasite densities grouped by diagnostic 
tool are summarized. Densities of P. falciparum positive 
blood donations ranged from 0.06 to 3707.0 parasites/µL 
with a median of 4.6 parasites/µL (IQR 0.8–49.0), which 
is lower than the LOD for conventional diagnostic tests. 
Only samples with the highest parasitaemia were detect-
able by microscopy (381.1 [145.4–2909.0] parasites/
µL) and RDTs (134.6 [65.1–536.5] parasites/µL), while 
the two qPCR assays detected additional infections with 
lower parasite densities. The median parasitaemia was 
7.8  parasites/µL (IQR 1.3–65.1) for the Pspp18S target 
and 4.6 parasites/µL (IQR 0.8–49.0) for the PfvarATS tar-
get (Table 2).
Performance of diagnostic methods for P. falciparum 
detection in blood donations
In total, 48 previously undetected P. falciparum infec-
tions were identified by conducting the varATS based 
qPCR analysis compared to microscopy, increasing 
the proportion of infected blood donations from 2.0 to 
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Fig. 3 Parasite densities of positive blood donations obtained from 
qPCR assays. Strong correlation between the two targets is observed 
(Spearman r 0.894). The green dots highlight samples containing 
non-falciparum malaria species. An offset of 0.05 parasites/µL was 
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Fig. 4 Association between parasitaemia and sensitivity of diagnostic methods applied in this study. Median and interquartile ranges of 
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26.0%. The detection rate for RDTs and 18S based qPCR 
were 6.5% and 23.0%, respectively (Fig. 4, bar plot, right 
y-axis). This increased detection rate of the qPCR assays 
is also reflected in analytical sensitivities of the diagnostic 
tests. Using the PfvarATS qPCR results as the gold stand-
ard for P. falciparum detection, Pspp18S qPCR (88.5%), 
RDT (23.1%) and microscopy (7.7%) have all reduced sen-
sitivities. Specificities were for all tests above 95%. One 
RDT positive sample could not be confirmed by qPCR, 
while the specificity for Pspp18S was reduced because of 
non-falciparum malaria parasite species, which are also 
detected (Table 3).
Identification of risk factors for malaria positivity
Malaria positive and negative donors were stratified 
according to the differences in the questionnaire that all 
blood donors must fill before proceeding to blood dona-
tion (Additional file  2). The major risk factor for being 
a malaria positive blood donor was reporting fever or 
malaria during the past 3 weeks (Additional file 2). When 
comparing the anthropometric measurements between 
malaria positive and negative donors, marginal differ-
ences in age and weight become apparent (Table 4). An 
increased rate of positive blood donations in replace-
ment donors (29.3%) compared to voluntary donors 
(20.8%) was observed, as well as an increased parasitae-
mia among replacement donors (8.9 versus 2.1 parasites/
µL). However, these differences were not statistically 
significant.
Discussion
This study, conducted in Equatorial Guinea, extends pre-
vious observations of presence of TTM in sub-Saharan 
Africa, and demonstrates the value of NAT approaches to 
reliably detect sub-patent P. falciparum and non-falcipa-
rum malaria parasites including P. malariae and P. ovale. 
Apart from P. falciparum, other malaria causing spe-
cies such as P. vivax, P. malariae, and P. ovale have been 
described to circulate on Bioko Island—similar to neigh-
bouring West African countries [27, 28]. Transfusion of 
any of these malaria species during blood donations have 
the potential to cause severe disease in recipients. In sub-
Saharan Africa, those most at risk are anaemic infants 
and children, pregnant women, or women who suffer 
from high blood losses while giving birth [25, 38, 39]. 
Although, there is a high frequency of TTM in malaria 
endemic regions, the semi-immunity of recipients may 
largely control parasite replication and therefore clinical 
outcome [40].
In malaria non-endemic countries, TTM needs also be 
taken into account to ensure safe blood donations [41]. 
Here, blood the recipients are mainly malaria naïve and 
the immunological control of potentially transfused para-
sites is non-existent resulting in in-creased risk of severe 
malaria disease. P. falciparum parasites have been found 
to survive in blood donations for up to 14 days limiting 
the potential to neutralize malaria during blood donation 
processing and storage [42].
This study demonstrates the challenges blood banks in 
malaria endemic countries encounter. The blood donors 
at the Malabo blood bank were mainly male adults within 
an age range of 18–57 years. Because of their pre-exist-
ing immunity, blood donors of that age tend to have low 
levels of parasites without exhibiting clinical symptoms. 
Ninety-seven percent (97.0%) reported to be in good 
health at the time of blood donations. Apart from self-
reported malaria and/or fever episodes within the last 
3 weeks, no other risk factor had been identified based on 
the provided questionnaire. Since only about 3% (6/198) 
had reported to have malaria and/or fever episodes, the 
use of this risk factor to pre-select blood donors would 
not be very efficient. Deferral of about a quarter of blood 
Table 3 Analytical comparison of methods deployed for P. 
falciparum detection
a Sensitivity and 95% confidence interval
b Specificity and 95% confidence interval
c Positive predictive value and 95% confidence interval
d Negative predictive value and 95% confidence interval
e Specificity and PPV of Pspp18S qPCR assay is reduced because non-falciparum 
Plasmodium species are also detected
Diagnostic tool Sensa Specb PPVc NPVd
qPCR-PfvarATS Gold standard
qPCR-Pspp18S 88.5%
[76.6–95.7]
95.3%
[90.5–98.1]e
86.8%
[76.0–93.2]e
95.9%
[91.7–98.0]
RDT 23.1%
[12.5–36.8]
99.3%
[96.3–99.9]
92.3%
[61.5–100.0]
79.0%
[76.0–81.0]
Microscopy 7.7%
[2.1–18.5]
100.0%
[97.54–100]
100%
–
75.5%
[74.0–76.9]
Table 4 Anthropometric differences in  P. falciparum 
positive versus P. falciparum negative blood donors
a Fisher’s exact test for categorical variables or Mann–Whitney test for 
continuous variables was applied
b Values expressed as medians with ranges
Negative donors Positive donors P  valuesa
Number of donors 148 52 –
% male 86.5% (128/148) 94.2% (49/52) 0.205
Age in  yearsb 33 [18–57] 29 [20–55] 0.013
Weight in  kgb 74.6 [51–116.6] 69.2 [53–110] 0.025
Blood pressure in 
 mmHgb
128.7 [97.7–198.9] 128.3 [100.6–156.9] 0.326
Pulse in  bpmb 74 [48–102] 72 [51–96] 0.519
Haemoglobin in 
g/dLb
14.6 [6.4–19.6] 14.7 [11.6–16.5] 0.319
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donors that are sub-patent malaria carriers in a region 
where blood supply shortage is eminent could be even 
more damaging to public health.
Conventional diagnostic tests are important tools, 
since they are affordable and can be applied immedi-
ately at blood banks, but lack in sensitivity limits their 
usefulness. Microscopy is still an important tool for 
malaria detection since it allows for species identifica-
tion and quantification. The detection limit of an expert 
microscopy is close to 20–50 parasites/µL, but for non-
experienced microscopists, it is up to tenfold higher 
(i.e. 500  parasites/µL) [5]. Currently available RDTs 
are based on detection of circulating, parasite derived 
HRP2, aldolase or lactate dehydrogenase in serum or 
whole blood samples. These RDTs have the ability to 
detect Plasmodium spp. infections with a LOD between 
100 and 1000  parasites/µL which is significantly higher 
when compared to NATs [43]. In addition, there is cur-
rently no single RDT available that could distinguish all 
five malaria species infections posing a clear limitation to 
comprehensive malaria infection status monitoring [44, 
45]. Infections with P. malariae [46], P. ovale [47] and P. 
vivax [48] are usually characterized by low parasitaemia 
levels, rendering these infections largely undetectable by 
using currently available RDT technologies [49].
In this study, more than three-quarter of P. falcipa-
rum and all non-falciparum infections were missed by 
the conventional diagnostic tools. A suitable screening 
method for malaria detection in blood units must have 
high sensitivity, high negative predictive value, must 
include all Plasmodium species, and should be cost effi-
cient. Such a test must enable a reduction of TTM risk, 
as well as that of falsely deferred blood donors found to 
have false positive results.
The PlasQ malaria screening assay applied in this 
study meets some of these requirements. With a LOD of 
0.05 parasites/µL, PlasQ has high sensitivity for P. falci-
parum and includes all other relevant Plasmodium spe-
cies. This assay was extensively used during controlled 
human malaria infections in Tanzanian and Equatorial 
Guinean volunteers and no issues with specificity were 
observed (unpublished). As a limitation, qPCR analysis 
requires an advanced laboratory infrastructure, trained 
personnel and the costs for reagents and consumables for 
this assay is about USD 5, which is higher than the costs 
for RDT or microscopy-based malaria diagnosis.
This study was used to obtain more information about 
non-falciparum malaria species circulating in Malabo. 
Therefore a novel multiplex qPCR assay for parallel 
malaria parasite identification was developed. Using the 
PlasID assay, the main five human infectious malaria spe-
cies can be detected qualitatively in a multiplex assay 
rendering it highly cost efficient since only one DNA 
extraction and qPCR reaction needs to be run. This novel 
malaria species identification assay should be used in 
combination with the PlasQ assay, based on the finding 
that in the PlasID assay, a reduced sensitivity for P. fal-
ciparum is observed. Further development of diagnostic 
assays for the detection of P. malariae and P. ovale, should 
include the ability of species-specific quantification. Esti-
mations based on Pspp18S target of the PlasQ assay, indi-
cate that P. malariae and P. ovale single infections had a 
geometric mean density of about 0.6 parasites/µL, which 
is more than 14 times lower than P. falciparum single 
infections (8.8 parasites/µL).
Educating the general public in malaria endemic 
regions via TV, radio, and pamphlet about the existence 
of TTM and its potential health impact might help to 
raise the awareness of this malaria transmission route, 
both in potential blood donors and medical and nursing 
staff involved in blood transfusions [50]. This study con-
firms prior reports that replacement blood donors are 
particularly prone to harbour sub-patent malaria para-
sites [51]; hence this sub-population of donors are opti-
mal for such awareness campaigns regarding potential 
TTM when donating blood for a family or friend. In addi-
tion to becoming aware of the potential TTM, medical 
and nursing staff should also use anti-malarial interven-
tions when the potential for TTM is high and the malaria 
diagnostic infrastructure is limited. Ultimately, if the goal 
of malaria elimination is pursued vigorously, tackling 
TTM in sub-Saharan Africa needs to be included into the 
malaria elimination agenda.
Conclusions
More than one quarter of blood donations from healthy 
donors living in Malabo were infected with malaria para-
sites. Three species, including P. falciparum, P. malariae 
and P. ovale were detected using two different qPCR 
assays. The majority of these infections were not identi-
fied by the currently widely used malaria diagnostic tools 
such as RDTs and microscopy. Since the availability of 
molecular diagnostic methods in malaria endemic coun-
tries is still limited, the blood recipients living in malaria 
endemic countries should be treated following WHO 
recommendations.
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CASE REPORT
Two cases of long-lasting, sub-microscopic 
Plasmodium malariae infections in adults 
from coastal Tanzania
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Abstract 
Background: Malaria is endemic in Tanzania with majority of clinical cases caused by Plasmodium falciparum. 
Additionally, Plasmodium malariae and Plasmodium ovale spp. are also present and clinical manifestations caused by 
these infections are not well described. Clinical episodes caused by P. malariae infections are often characterized by 
a relatively mild illness with a low number of parasites, which can persist for long periods. In this report, two cases of 
P. malariae infections that were identified during a clinical trial evaluating the P. falciparum malaria vaccine candidate, 
PfSPZ Vaccine are described. The two participants were followed up and monitored for clinical and laboratory param-
eters to assess vaccine safety providing the opportunity to study clinical manifestations of P. malariae over 4 months.
Case presentation: Two young, healthy Tanzanian men infected with low density asexual blood stage P. malariae 
diagnosed by quantitative polymerase chain reaction (qPCR) are described. Retrospective analysis of collected and 
stored blood samples revealed that the two volunteers had constant asexual blood stage parasitaemia for more than 
4 months. During the 132 days of infection, the volunteers’ vital signs, body temperature and serum biochemistry all 
remained within normal ranges. Haematological abnormalities, which were transiently outside normal ranges, were 
regarded as not clinically significant. During this time period, four consecutive evaluations of blood samples by thick 
blood smear microscopy conducted by an experienced microscopist were all negative, indicating the presence of 
low-density sub-microscopic infections.
Conclusions: The two cases of P. malariae infections presented here confirm the ability of this Plasmodium species to 
persist at low density in the human host for extended time periods without causing clinical symptoms. The presented 
data also demonstrate that clinical study sites in malaria endemic regions need to have a strong malaria diagnostic 
infrastructure, including the ability of capturing sub-microscopic parasitaemia and differentiation of Plasmodium 
species.
Trial registration ClinicalTrials.gov: NCT02613520, https ://clini caltr ials.gov/ct2/show/NCT02 61352 0, Registered: Novem-
ber 24th 2015, Enrolment of the first participant to the trial: December 15th 2015, Trial was registered before the first 
participant was enrolled
Keywords: Plasmodium malariae, Asymptomatic malaria, Quantitative polymerase chain reaction (qPCR)
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Background
Malaria is endemic in Tanzania with more than 90% of 
the population at risk and 5.6 million cases reported by 
the public health sector in 2017 [1]. While Plasmodium 
falciparum is the dominant malaria species responsible 
for majority of infections and deaths, other Plasmodium 
species are also endemic in Tanzania. David Clyde, who 
served as the director of the Malaria Service of the East 
African Malaria Institute at Amani, described the occur-
rence of four human malaria  species, including P. falci-
parum, Plasmodium vivax, Plasmodium ovale spp. and 
Plasmodium malariae in his 1967 book “Malaria in Tan-
zania” [2]. Plasmodium vivax was attributed to importa-
tion by Indian immigrants during the first world war and 
since 1917 this influx has virtually ceased. Plasmodium 
malariae was observed in 10–20% of malaria infections, 
mainly as co-infections with  P. falciparum and during 
childhood [2]. More recently, a microscopy-based cross-
sectional survey conducted in the Tanga region of coastal 
Tanzania found very few infections with P. malariae 
(0.3%) or P. ovale spp. (0.1%) [3]. Data collected in coastal 
Tanzania, confirm these low numbers of non-P. falcipa-
rum Plasmodium infections. Diagnosis by qPCR revealed 
low prevalence for P. malariae (0.7–5.8%) and P. ovale 
spp. (0.9–1.1%) among asymptomatic school children 
(Schindler et  al., unpublished data). Since microscopic 
diagnosis of P. malariae asexual blood stage parasites is 
hampered by the low parasitaemia and morphological 
similarities to P. falciparum, molecular based, highly sen-
sitive diagnostic methods are needed to establish the true 
prevalence of this parasite in the population [4]. Lack of 
sensitive P. malariae diagnosis methods applicable in the 
field and the research focus on P. falciparum has resulted 
in significant knowledge gaps regarding spectrum of 
potential clinical manifestations and burden of P. malar-
iae infections [5].
It is well established that P. malariae is widespread 
throughout sub-Saharan Africa, South East Asia and 
Latin America and the biology of P. malariae was 
reviewed by Collins et  al. [6]. Treatment of syphilis by 
controlled infections with P. malariae provided valu-
able insight into human-parasite interactions. The red 
blood cell cycle lasts 72 h with an average of 8 merozoites 
released per schizont and the parasite prefers to infect 
and develop in older erythrocytes. So far, no evidence for 
a dormant liver stage as described in P. vivax and P. ovale 
spp. has been observed. Faster acquisition of immu-
nity against P. malariae compared to immune responses 
against P. falciparum has been described [6].
Clinical episodes of P. malariae infections are charac-
terized by a mild illness caused by low numbers of para-
sites which can persist for extremely long periods, often 
for years or even decades [6]. There are reports of cases 
of P. malariae caused illness from Greece [7] and Trini-
dad and Tobago [8] decades after eradication of malaria 
from these regions. Chronic P. malariae  infections have 
been considered a major cause of the nephrotic syn-
drome in the past, although the incidence of P. malaria-
associated nephrotic syndrome has been dramatically 
reduced in recent decades [7–9]. Recently, it was dem-
onstrated that the controlled infection of two volunteers 
with cryopreserved P. malariae-infected erythrocytes 
was well tolerated and no severe or serious adverse effect, 
or biochemical abnormalities were observed [10].
The clinical research facility of the Ifakara Health 
Institute in Bagamoyo, Tanzania, conducts clinical tri-
als evaluating efficacy of experimental malaria vaccines 
in the target population [11–13]. A controlled human 
malaria infection (CHMI) model has been successfully 
established since 2012 [14]. As part of these clinical trials, 
participants are closely monitored to identify any abnor-
mal clinical or laboratory parameters in order to evaluate 
vaccine safety and tolerability. Regularly, volunteers are 
screened for Plasmodium spp. parasites in blood using 
thick blood smear microscopy as well as quantitative pol-
ymerase chain reaction (qPCR). The volunteers described 
in this report participated in a study evaluating the safety 
and efficacy of immunization with  Sanaria® PfSPZ Vac-
cine composed of radiation attenuated, aseptic, purified, 
cryopreserved P. falciparum sporozoites (PfSPZ) [11, 
15–19] which was conducted between 2015 and 2016 
(clinicaltrials.gov: NCT02613520) [20]. The clinical cases 
of two young men infected with asexual blood stage P. 
malariae as diagnosed by qPCR are described. These 
volunteers were followed closely for 4 months during the 
clinical trial.
Case presentation
Two male residents of Bagamoyo, 20 and 22 years of age, 
were enrolled into the clinical trial based on predefined 
exclusion and inclusion criteria as outlined in the clinical 
trial protocol. A review of the medical history, physical 
examination, vital signs (pulse, blood pressure, and res-
piratory rate), and ECG did not reveal any abnormalities. 
At screening, the volunteers had negative serologies for 
human immunodeficiency virus (HIV), hepatitis B virus 
(HBV), and hepatitis C virus (HCV). A single stool sam-
ple collected at study enrolment was negative for intes-
tinal helminths and no Schistosoma haematobium eggs 
were detected in urine. No blood biochemistry abnor-
malities were detected, which included alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), 
total bilirubin (BIL), and creatinine (CRE). The urine 
analysis using a 13-parameter dipstick (Combina 13 
test strips, HUMAN Diagnostics, Germany) was nega-
tive at enrolment. A complete blood count (CBC) was 
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conducted at screening and showed normal haematologi-
cal parameters for volunteer 1, while volunteer 2 had ele-
vated eosinophil counts (1.19 × 103/µL compared to the 
pre-defined upper normal range of 0.78 × 103 cells/µL). 
During the 16 weeks of immunization (3 doses of PfSPZ 
Vaccine at 8-week intervals), the volunteers’ health sta-
tus was closely monitored. Every 8 weeks at pre-defined 
visits blood was drawn and any deviations from refer-
ence laboratory values were reported. Vital signs, body 
temperature and biochemistry remained within normal 
ranges when assessed four times during the follow up 
period. Haematological parameters which were tran-
siently outside normal ranges in both volunteers were 
regarded as not clinically significant (Tables 1, 2). Note-
worthy, for volunteer 2 the eosinophil counts remained 
consistently elevated until the end of the study (Fig.  1). 
Both volunteers tested once positive for low grade pro-
teinuria, during the study by urine dipstick (Tables 1, 2).  
0 100 200 300 400 500
0.0
0.5
1.0
1.5
days
Eo
si
no
ph
il
C
ou
nt
[c
el
ls
x
10
3 /
µL
] P. malariae treatment
Fig. 1 Elevated eosinophil counts for volunteer 2 over a time period 
of more than 400 days. Eosinophil counts of volunteer 2 covering all 
visits, from study enrolment to completion, are shown. The dashed 
line represents the upper limit of the normal range (0.78 × 103 cells/
µL)
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Fig. 2 qPCR data for the Plasmodium spp. screening and Plasmodium species identification assays. The upper panel shows the amplification curves 
for the Plasmodium spp. target of the screening assay. The lower panel shows the amplification for the four Plasmodium species-specific targets. All 
samples were run in triplicates and DNA from P. falciparum, P. malariae, P. ovale wallikeri, P. ovale curtisi and P. vivax were included as positive controls 
during the qPCR
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After concluding three PfSPZ Vaccine immunizations, 
and before vaccine efficacy was assessed by CHMI, the 
study protocol required screening of whole blood by 
qPCR to detect sub-microscopic malaria parasitaemia, 
so that these volunteers could be treated accordingly 
before participation in CHMI. During this routine visit, 
qPCR was conducted with fresh blood samples and it 
was discovered that two volunteers were infected with 
Plasmodium spp. parasites [21]. Based on P. malariae 
species-specific qPCR [22] and conventional nested PCR 
[23], P. malariae infections were confirmed. The presence 
of P. falciparum [24, 25], P. ovale spp. [26], and P. vivax 
[25] was excluded by qPCR and conventional PCR [23].
Treatment with 3 doses of artesunate/amodiaquine 
(200/540 mg) daily for 3 days was initiated, and complete 
parasite clearance was confirmed by qPCR 4  days later. 
Both volunteers then underwent CHMI and remained in 
the clinical trial until study completion. Within the fol-
lowing 296 days until the completion of the clinical trial, 
no recurrent (recrudescence or new infection) P. malar-
iae parasitaemia was observed. Both volunteers were 
negative for P. falciparum after the first CHMI, and both 
became positive for P. falciparum after a second CHMI at 
40 weeks after the last immunization and were success-
fully treated with artemether/lumefantrine.
Blood samples collected during the clinical trial and 
stored frozen were analysed retrospectively by qPCR 
to determine the time point of P. malariae infection. It 
turned out that both volunteers had P. malariae para-
sitaemia at enrolment into the clinical trial. Both vol-
unteers remained positive throughout the vaccination 
period. Plasmodium malariae parasites were detectable 
at four out of four clinical visits, namely at day 0, 53, 
113 and 128 of study and malaria treatment took place 
132 days after the first detection of the P. malariae infec-
tions (Fig. 2). Evaluation of four blood samples collected 
at the same days by thick blood smear microscopy and 
conducted by an experienced microscopist was reported 
as negative. Thick blood smear preparation and reading 
was performed according to our standard operating pro-
cedure followed during CHMI studies [14]. The negative 
microscopy results and the high Cq values (median of 
34.1 with a range of 31.6–37.7) obtained by the Plasmo-
dium spp. qPCR assay indicate that the parasitaemia lev-
els were low. When compared to qPCR based detection 
of P. falciparum 18S gene, these Cq values would corre-
spond to a parasitaemia between 1 and 10 P. malariae 
parasites per µL blood [27].
Discussion and conclusion
The two P. malariae cases presented here confirm the 
ability of this Plasmodium species to persist at low den-
sity in the human host for extended time periods without 
causing clinical symptoms or signs. Both were detected 
in clinically healthy, young men participating in a clini-
cal trial of PfSPZ Vaccine. No abnormalities in vital 
signs, alanine aminotransferase, aspartate aminotrans-
ferase, total bilirubin, and creatinine serum levels were 
detected. Except for a one-time low-level proteinuria, 
urine analysis parameters measured by dipstick remained 
within physiological ranges and there was no indica-
tion of impaired renal function in these two volunteers. 
Volunteer 2 did have mildly elevated eosinophil counts 
throughout the entire course of the clinical trial. These 
levels were not affected by the treatment of the P. malar-
iae infection and may have reflected an ongoing intesti-
nal helminth infection that was too low to be detected 
by a single stool examination. All other haematological 
abnormalities were of temporary nature and considered 
to be not clinically significant. Interestingly, the P. malar-
iae parasitaemia levels were not affected by the three 
rounds of PfSPZ Vaccine immunizations. This might be 
due the mode-of-action of the vaccine which is thought 
to act against the liver-stage of the parasite.
The data presented in this report demonstrates that 
study sites in malaria endemic regions conducting clini-
cal trials should develop on site malaria diagnostic infra-
structure, which includes the detection of low-density 
asexual blood stage parasitaemia and identification of 
different Plasmodium species. Eventually, if the goal of 
malaria elimination is pursued vigorously, the implemen-
tation of highly sensitive diagnostic methods to detect 
asymptomatic, low-density P. malariae infections need to 
be included into the malaria elimination agenda.
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5.1 Evaluation of the PfSPZ Vaccine in two different malaria pre-exposed populations  
 
An effective vaccine against malaria would contribute enormously to global health. The de-
velopment of vaccines against complex and chronic infectious diseases like HIV, tuberculosis 
and malaria has proven to be challenging [130]. It has become apparent that among the big-
gest challenge for successful vaccine development is the fact that different populations show 
variations in immune responses to the same vaccine [131]. Therefore, in order to prevent fail-
ure of an experimental vaccine, candidates should be evaluated early on during the develop-
ment process in the major target population – best by a human challenge model.  
The PfSPZ Vaccine, a malaria vaccine based on radiation-attenuated sporozoites, has proven 
to be safe and well tolerated in target populations including infants, children, adolescent, 
adults and people living with HIV infection. Compared to malaria-naïve US Americans 
[126], the VE of PfSPZ Vaccine was significantly lower in Tanzanian [124] and Malian vac-
cinees [94] using an identical immunization regimen. Among the US Americans the VE was 
92% (12/13 protected) assessed by homologous mosquito-bite CHMI, in Tanzania the VE 
was 20% (4/20 protected) against homologous CHMI using PfSPZ Challenge and in Mali the 
VE was found to be 29% in a field trial against heterologous natural P. falciparum infections. 
Even by increasing the dosage of RAS, the protection rates as seen in malaria-naïve volun-
teers were never achieved in the PfSPZ Vaccine trials in Tanzania and Equatorial Guinea. 
The same was observed for the PfSPZ-CVac approach, while the immunization with three 
doses of 5.12 × 104 sporozoites under chloroquine coverage was 100% effective (9/9 protect-
ed) in malaria naïve vaccinees, even higher doses of three times 1.0 × 105 did not nearly have 
comparable VE in Equatorial Guinea, where efficacy was calculated to be 57% (8/14 protect-
ed). 
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A generally weaker responsiveness to a number of vaccines in developing countries has been 
known for a quite a while [132]. Several vaccination studies have shown that children from 
Sub-Saharan Africa are less responsive to standard childhood vaccines than children from 
developed countries [133]. This was shown for vaccines against tuberculosis, typhoid fever, 
measles and polio vaccines (summarized in [133]). The underlying mechanisms are complex 
and multifactorial at best and the reason for this variation might be found in the host-
environment interaction [131]. In general, heterogeneity in vaccine responsiveness has been 
shown to be influenced by age [134], gender [135], genetics [136, 137], nutritional status 
[138] and has also been associated with the microbiome [139]. Co-infections with helminths, 
protozoans and viruses can result in decreased vaccine efficacy [133]. Especially, chronic 
immune activation, as induced by viral or helminth infections, has been associated with re-
duced immune responsiveness [140–142]. Deworming communities has shown to reduce the 
helminth-induced immune hypo-responsiveness against vaccines [143]. 
 
5.2 The use of CHMI for assessing vaccine efficacy 
 
The use of CHMI to assess vaccine efficacy in malaria pre-exposed individuals has been 
proven to provide protection data that fast tracks identification of best vaccine dosing and 
regimen. Compared to large field studies, CHMI studies allow to test various vaccine regi-
men and doses in relatively small groups in a shorter time frame. A simple way to demon-
strate how effective CHMI is in evaluating malaria vaccines, is to look at the data from the 
six clinical trials described in this thesis. Two different attenuation procedures (RAS and 
PfSPZ-CVac), various vaccination regimens, administering all immunization within 6 months 
to within 1 week, and 8 different doses of total RAS ranging from 6.75 x 105 to 8.1 x 106, 
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have been evaluated. All this was achieved in less than five years at two clinical trials sites 
with just 197 enrolled and vaccinated volunteers. In the same time, other clinical trial facili-
ties located in Kenya, Gabon and Mali also conducted CHMIs to evaluate the PfSPZ Vaccine 
and to understand host-pathogen interaction under defined conditions.  
CHMI studies are a valuable tool for dose finding and assessing immunogenicity, during the 
early phase of clinical development of vaccines, but by using relatively small numbers of 
volunteers the ability to predict effectiveness of a vaccine in a larger population might be 
limited. Clearly, CHMI can only be conducted in adult volunteers and the vaccine induced 
immune responses in infants and children might differ. An additional limitation is that only 
four P. falciparum strains are currently in use for CHMI studies [107], which does not neces-
sarily reflect the global range of genetic diversity of P. falciparum circulating in endemic 
regions. This is highly relevant since during the RTS,S/AS01 phase 3 trial, it was found that 
the vaccine effectiveness was impacted by the genetic diversity of the parasite [144]. Given 
these limitations, larger scale field trials assessing the effectiveness of vaccines in the target 
populations can hardly be replaced by CHMI studies. 
Besides testing the efficacy of vaccines, conducting CHMIs in developing countries offer 
also a great opportunity for capacity building and implementation of new techniques. We 
used the molecular malaria diagnosis platform for capacity building including training of per-
sonnel in Tanzania and Equatorial Guinea. Additionally, CHMIs also serve as a biobank for 
biological samples which can be used to evaluate and compare novel diagnostic methods us-
ing highly standardized blood samples with known parasite strains present. 
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5.3 The impact of naturally acquired immunity on vaccination and CHMI 
 
The principal features of NAI, the ability to control parasite density and disease, have been 
defined, but little is known about the underlying immune effector mechanisms [46]. Epide-
miological data show the widespread and persistence of parasitaemia in asymptomatic indi-
viduals and that natural exposure to sporozoites does not induce complete, sterile immunity 
[145] indicate that NAI is predominantly directed against the blood-stage of the parasite [46]. 
How could then NAI impact the vacation outcomes with RAS as we have seen in volunteers 
from endemic regions? One observation made during the BSPZV1 study, where higher levels 
of memory CD4 and CD8 T cells at baseline in the Tanzanian compared to the US volunteers 
were seen, could provide some explanation. Less available naïve cells for expansion during 
the vaccinations might explain the lower immunogenicity [124]. The interaction between 
NAI and vaccine take and responsiveness of PfSPZ Vaccine remains subject of debate and 
future research. 
The impact of NAI on parasite growth dynamics during CHMI has been described previous-
ly. The PMR, the fold change in number of parasites in the blood over one life cycle, can be 
calculated based on the qPCR-derived parasite densities measured during the pre-patent peri-
od [146]. Using CHMI to infect malaria-naïve volunteers found an average PMR of about 10 
[147], while if the same CHMI is conducted in volunteers living in malaria endemic regions -
PMRs are significantly lower and more variable [113, 116, 148, 149]. We used two different 
approaches to demonstrate the impact of recent malaria pre-exposure on the multiplication 
rate of P. falciparum parasites. We showed that recently cleared parasitaemia from an ongo-
ing P. falciparum single infection or P. falciparum and P. malariae co-infection leads to a 
significantly reduced PMR. And secondly, that the PMR is significantly reduced after a sec-
ond homologous CHMI conducted in the identical volunteer. This data indicates the devel-
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opment of parasite growth reducing immune effector mechanisms during a single episode of 
asexual blood stage infection. The biological specimens collected from these volunteers be-
fore, during and after CHMI will help to further identify and dissect these immune effector 
mechanisms. Additionally, the data presented here on interaction between HIV and P. falci-
parum demonstrate the ability of CHMI to provide the framework to study the impact of 
chronic co-infections on host-pathogen interaction.  
Chapter V - Discussion  223 
5.4 Development and implementation of tools for molecular malaria surveillance 
 
We used these vaccine trials to establish a molecular diagnostic platform on-site in two ma-
laria endemic countries. As a next step, we wanted to advance these techniques for use in the 
context of a broader approach – larger scale molecular surveillance of malaria. We addressed 
several key features, which in our opinion are critical to successfully run a molecular diag-
nostic platform. First, robust qPCR assays for quantification of Plasmodium spp. parasites 
should be used, which includes the establishment of a local supply chain for consumables and 
reagents. Second, a program for laboratory-based training and qualification of local personnel 
should be started early on. Lastly, user-friendly software solutions, e.g. ELIMU-MDx, will 
not only reduce time spent on data cleaning and analysis, but also increase quality and integ-
rity of qPCR data. 
P. falciparum strains carrying pfhrp2/3 deletions and evading detection by RDTs pose a 
threat to malaria control and elimination programs around the world [42]. Together with the 
emergence of artemisinin resistant strains, these parasites are a powerful example that molec-
ular surveillance systems need to be implemented in malaria control programs to monitor 
their potential expansion over time. A central part of molecular surveillance systems are nov-
el NAT-based assays enabling high-throughput screening of P. falciparum populations to 
identify isolates threatening malaria control efforts. As for the identification of pfhrp2/3 dele-
tions, the currently used methods, mostly based on nested PCR, are extremely time consum-
ing, and therefore impractical for screening of large number of samples, as required for a 
country-wide survey of pfhrp2/3 deletions. With growing availability of qPCR instruments in 
reference laboratories in Sub-Saharan countries, our novel assay could be used as a surveil-
lance tool to monitor over time the potential expansion of P. falciparum strains carrying 
pfhrp2/3 deletions. 
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Speciation of Plasmodium spp. parasites is another application of molecular diagnostic tools 
for surveillance of malaria. In Sub-Saharan Africa, P. malariae and P. ovale spp. are rarely 
detected by conventional diagnostic methods. The inability of detecting these parasites and 
with P. falciparum dominating the research agenda, has left the malaria research community 
with a knowledge gap concerning the health burden of chronic P. malariae or re-occurring 
and relapsing P. ovale spp. infections in an endemic context [23]. Most importantly, the ques-
tion on how P. malariae and P. ovale spp. interact with P. falciparum in co-infected individ-
uals can only be addressed if sensitive and specific diagnostic assays are used [23]. Several 
studies indicate that a mixed infection with P. malariae may reduce P. falciparum caused 
symptoms [150–152]. On the contrary, a study conducted in the Gambia observed more P. 
malariae clinical episodes during the dry season, when P. falciparum infections are less 
common, concluding that P. falciparum may reduce P. malariae infection related symptoms 
[153]. Understanding these interactions is of highest importance, if the introduction of spe-
cies-specific intervention tool, such as a P. falciparum vaccine, is considered. How are the 
infection dynamics and clinical features of P. malariae and P. ovale spp. infections impacted 
in a certain epidemiological context, if we specifically and exclusively target P. falciparum 
by a vaccine? 
Molecular malaria surveillance should be closely integrated into the existing health systems. 
We used two different platforms to evaluate NAT-based assays for malaria surveillance. 
First, we collaborated with the central blood bank in Malabo, Equatorial Guinea. The access 
to fresh and highly abundant blood makes blood banks a useful source of samples for disease 
surveillance. On the contrary, populations donating blood are often not very heterogenous 
and do not reflect the general population. Our second approach included the use of RDTs 
collected during the annual malaria indicator survey (MIS) on Biko Island, Equatorial Guinea 
during 2018. Using the small amount of blood found on RDTs is a convenient and cost-
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effective procedure which would reduce phlebotomy and blood collection to a minimum 
which is beneficial to the volunteer participation. Here, we addressed the steps needed to es-
tablish molecular disease surveillance program depending on the analysis of nucleic acids 
extracted from RDTs. During the MIS on Bioko Island in 2018, 13’505 people gave consent 
to the molecular analysis of their RDTs, which is currently ongoing. And with the extraction 
of nucleic acids from RDTs (ENAR) protocol, we developed a procedure that allows to ex-
tract nucleic acids from RDTs in a high-throughput manner. 
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More than one decade after a renewed scientific and political commitment to malaria eradica-
tion [154, 155], the WHO reports an alarming finding that no further significant reduction of 
global malaria cases was observed between 2015-2017 [12]. Despite these setbacks, in April 
2019, the first children in Malawi, Ghana and soon also in Kenya, were enrolled into a malar-
ia vaccine implementation program (MVIP), coordinated by WHO, to assess the feasibility of 
administering the required 4 doses of RTS,S /AS01 [79].  
Other vaccine candidates have reached different phases of clinical development. Among one 
of the most advanced vaccines is the PfSPZ Vaccine, which is based on the immunization 
with radiation-attenuated sporozoites. This vaccination approach has shown to be highly ef-
fective in malaria-naïve volunteers but failed to reproduce the same degree of protection in 
different malaria pre-exposed populations. The reason for lower protection in these vaccinees 
remains subject to further studies. As for now, optimization of the vaccine regimen in the 
target population might be the key to better vaccine efficacy. Increasing the total dosage of 
RAS did show some improvement in protection against homologous CHMI in Tanzanian 
volunteers. In Equatorial Guinea, a study comparing different regimens of PfSPZ Vaccine, 
focusing on short intervals between the immunizations, was recently completed and the data 
is currently analysed (EGSPZV3 study). Alternative attenuation procedures of the sporozoites 
also show promising results in human studies. Immunizations with sporozoites under chloro-
quine coverage did result in higher vaccine efficacy compared to immunization with RAS in 
a side-by-side comparison in Equatorial Guinean adults (manuscript in preparation). Genet-
ically attenuated parasites (GAP), which arrest their development during liver-stage due to 
targeted gene deletions, have recently transitioned into the early clinical phase [89]. No GAP 
has been tested for efficacy by CHMI or in an endemic setting for protection against field 
isolates so far.  
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In order to better identify mechanism of protection associated with PfSPZ vaccination, get-
ting access to liver biopsies for analysing liver-specific transcriptome and immunological 
changes upon vaccination would be desirable. Similar experiments were conducted success-
fully to study chronic hepatitis B infections [156]. At the Jenner Institute in Oxford, UK, liver 
cell aspirates have been taken from volunteers undergoing prime target vaccination ap-
proaches and the results will inform future research along these lines (unpublished) 
CHMI is increasingly used in malaria endemic regions, where it has been shown to be safe, 
including in vulnerable populations such as in immunocompromised people living with HIV. 
Vaccine efficacy can be assessed rapidly and in small groups directly in the target population. 
Based on our experience, one of the major inconveniences for the volunteers participating in 
CHMI is the time they have to spend at the clinical trial facility, which can take up to two 
weeks and also includes over-night stays. The same issue has also been raised by our col-
leagues in Kenya [123, 157]. By changing the primary outcome from TBS microscopy to 
qPCR positivity as proposed for CHMIs in non-endemic regions [118], the time spend in the 
clinical trial facility could be significantly decreased. This is especially important for popula-
tions where approximately 10% stay sub-microscopic for asexual blood stage parasitaemia 
and qPCR is detecting parasites on average 5.5 days earlier than microscopy. Not changing 
the primary endpoint of a CHMI to qPCR does unnecessarily increase the duration of CHMIs 
for studies assessing efficacy of pre-erythrocytic vaccines. Looking ahead, further develop-
ment of the CHMI facilities in Bagamoyo and Malabo should include the evaluation of other 
P. falciparum strains apart from PfNF54. Testing vaccine efficacy against different heterolo-
gous strains would be in line with recommendations of the US FDA [107]. Extending the 
CHMI platform to blood-stage challenge with non-falciparum Plasmodium species, as recent-
ly shown with P. malariae [102], would be desirable. This would provide insight into the 
interaction of different malaria species in co-infections. Also, the immune responses targeting 
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the different Plasmodium spp. species in the target population becomes amendable for in 
depth studies.  
As useful as CHMIs are during early phases of clinical development of a vaccine, it might not 
be suitable to replace large phase 3 field trials evaluating the effectiveness of PfSPZ Vaccine 
in the population. Currently, the planning for a phase 3 trial to evaluate PfSPZ Vaccine on 
Bioko Island is ongoing. The vaccine efficacy will be determined in a double-blind controlled 
study involving 700 placebos and 1400 vaccinees in the age category of 2 years to 45 years of 
age. After this study, a cluster randomized PfSPZ vaccine trial is planned that will inform 
about the development of herd immunity induced by PfSPZ Vaccine against malaria. The use 
of molecular diagnostic tools will be critical as the sensitivity of TBS microscopy or RDTs is 
not sufficient to identify the majority of P. falciparum infections in the Equato-Guinean pop-
ulation. It will be of greatest interest to see if failure in vaccine protection will be associated 
with certain P. falciparum genotypes. We propose to collect samples to conduct a sieve anal-
ysis in order to identify genotypes evading the PfSPZ Vaccine [144]. The molecular surveil-
lance during the phase 3 trial should be extended to other relevant pathogens which might act 
as confounder for vaccine responsiveness and vaccine induced protection. We have observed 
a high prevalence of filarial nematodes on Bioko Island, in particular Loa loa and Mansonella 
perstans, which are well known for their immunomodulatory properties impacting potentially 
negatively on vaccination outcomes [158–160].  
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Bioinformatics Usage of LINUX commands and tools for analysis of next-generation sequencing data. Sci-
entific programming for analysis and visualization of data using the R environment.  
Lab management Qualified in management of laboratories including quality control, supply chain management 
and supervision of technicians and students.   
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